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Abstract  
Pancreatic cancer is the 4th most aggressive cancer in the Western world. There are very 
little drugs available as chemotherapies for the treatment of pancreatic cancer. Of the ones 
used, most of them become eliminated by first pass metabolism before they reach their 
desired site of action. Nanoparticles which can work as drug delivery systems have huge 
potential for the treatment of different kinds of cancer such as pancreatic cancer. The 
qualities of silver nanoparticles applicable to human treatments are under investigation in 
assessing potential efficacy, laboratory and animal studies, toxicity, and costs.  Coating Iron 
oxide with silver nanoparticles can lead increase silver performance and it can del iver the 
silver nano particles and cancer drugs to the target cells.   
In this report, we focus on the design, synthesis, and characterization of hybrid iron oxide-
silver core-shell nanostructures (HNPs). The HNP were characterised by various techniques 
such as magnetic properties, particle size, zeta potential, inductively coupled plasma (ICP), 
ultraviolet light (UV) and transmission electron microscopy (TEM). The laser mediated 
heating confirmed that the HNPs possessed surface plasmon resonance and hence 
highlights the potential of new HNP capability in thermo-responsive drug delivery.  
 The drug conjugation, stability and releasing of HNP- BNIPDSpm and HNP-BNIPDSpm-PEG 
Thiol were assessed by FTIR, zeta potential and high performance liquid chromatography 
(HPLC).  HPLC results demonstrated new formulations have high physical and formulations 
stabilities. PEGylated formulations demonstrated greater release of drug in comparison with 
their unPEGylated counterparts. The drug release were assessed and optimised in biological 
media and aqueous environments. 
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The target peptide successfully conjugated in the novel drug formulations. In vitro drug 
uptake study also validated that hybrid formulations internalise and accumulate inside 
pancreatic cancer cells significantly higher than free drugs. The Cytotoxicity assays has 
shown the potential ability of BNIPDSpm novel formulations to accumulate and kill 
pancreatic cancer cells in comparison with free drugs, However there was not significant 
toxicity effect with naked HNP pancreatic cancer cells .  
 
Key words: Iron oxide-silver nanoparticles, BNIPDSpm, surface plasmon resonance (SPR),   
polyethylene glycol (PEG), pancreatic cancer, thermo-responsive drug delivery, cytotoxicity 
assays, target peptide 
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Introduction 
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1.1. Cancer 
Cancer is characterised as unusual cell division in an uncontrolled manner. Some cancers 
may ultimately move and grew into other tissues and spread throughout the body. Cell 
growth and division are normal in all type of tissues, so cancer can initiate anywhere in the 
human body (Wilde et al., 2012). 
 There are more than 200 different types of cancer. In all types of cancer, some of the 
body’s cells begin to divide without stopping and spread into surrounding tissues.  This may 
because of a growth called a tumour. The global cancer burden is evaluated to have risen to 
18.1 million new cases and 9.6 million deaths in 2018 (International Agency for Research on 
Cancer, 2018). One in 6 women and one in 5 men worldwide develop cancer during their 
lifetime, and one in 11 women and one in 8 men die from the disease. There are some 
factors which can have an effect on causing cancer, including population growth and 
increasing number of older people (International Agency for Research on Cancer, 2018). The 
most causes of cancer related deaths in the world are lung, liver, bowl, breast, prostate and 
pancreatic cancer (ACS, 2011).  
Risk factors relative to cancer are hereditary and can be classified as either preventable risk 
factors which include dietary habits (like high fat diet and alcohol), environmental factors 
(like ultraviolet radiation, chemical toxins and passive cigarette smoke inhalation) and non-
preventable such as aging (patients over 75 account for more than 30% of all patients 
developing cancer (Yancik et al., 2005). All these factors account for about 40% of cases in 
the United Kingdom (Surh et al., 2003; Yancik et al., 2005; Moiseeva et al., 2009; Cancer 
Research, 2016). 
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Pancreatic cancer 
 The pancreas is located within the abdomen surrounded by several other organs, major 
blood vessels and other tissue types (Zhi et al., 2014). Pancreatic cancer is still remaining as 
the 4th cause of death associated with cancer in the Western world (Jemal et al., 2007). 
Recently, CRUK have labelled pancreatic cancer as one of unmet need due to its poor 
patient survival rate and treatment progress in the last 40 years (Zhi et al., 2014).   
Pancreatic cancer mostly increases with increased age and it most commonly diagnosed in 
the 65-75 year age group (Lowenfels and Maisonneuve, 2006).  Every year, nearly 43,000 
individuals diagnosed with pancreatic cancer will die of this disease in the U.S. The majority 
of cases are identified in the late stages of the cancer, when the likely hood of treatments to 
cure or indeed manage the disease is severely limited (Jiang et al., 2019). 
Surgical resection is currently the only potentially curable option for pancreatic cancer 
patients. Even though there are advanced surgeries for cancer tumours’ resection, cancer 
recurrence is unavoidable in most patient and also relies on the patient being well enough 
for surgery which sadly is often not the case. Surgery often results in a median survival of 
approximately 11–15 months. Despite, the extraordinary advances have been occurred in 
chemotherapy and radiotherapy, death rates from pancreatic cancer has increased slightly 
in men and has levelled off in women (Jiang et al., 2019).  
Pancreatic cancer symptoms include pain in the upper or middle abdomen and back, 
jaundice, unexplained weight loss, loss of appetite and fatigue. Unfortunately, pancreatic 
cancer cannot be detected at early stages and most patients with localised disease have no 
detectable symptoms or signs. Therefore, it is not diagnosed until late stages, when cancer 
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has metastasised to other organs. This leads to poor prognosis and incidence equalling 
mortality (5 years survival rate) (Lowenfels and Maisonneuve, 2006).  
There are very few drugs available as chemotherapies for the treatment of pancreatic 
cancer. Of the ones used, most of them become eliminated by first pass metabolism before 
they reach their desired site of action. Therefore, it is obvious that an improved method is 
required in order to transfer these drugs to their target sites which will increase efficacy and 
therapeutic effect. Ineffective absorption or problems of systemic drug circulation resulting 
in unwanted side effects are the main problems related to the treatment of cancer using 
traditional drugs. Therefore, the main rationale of this work is to produce drug carriers 
capable of improving drug efficacy by transferring them directly to the site of action 
(Lowenfels and Maisonneuve, 2006). 
Pancreatic ductal adenocarcinoma (PDAC) 
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent epithelial and one of the 
most lethal malignancies which occur. It can present anywhere in the pancreas but is most 
common is the pancreatic head. The late detection can lead to poor prognosis, however this 
is dependent on whether the cancer is localised or metastases have occurred. Overall 
survival rate for 5-years is just 3–5%. Pathologic variables associated with prognosis include 
tumour size and grade (Gui et al., 2019). Many physical barriers may affect efficient PDAC 
drug delivery which results from numerous pathological features. These barriers are leaky 
and disorganised with non-functional vasculature (Farrell et al. 2009), characteristically 
dense stroma (Neesse et al., 2011) and deregulated cellular transport proteins (Farrell et al., 
2009). 
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PDAC influences more developed countries than other parts of the world with more than 
8000 cases diagnosed in the UK each year (Keane et al. 2014). It is now recognized that 
highly malignant and metastatic PDAC spreads from local precursor lesions called pancreatic 
intraepithelial neoplasia (PanIN). Molecular and pathological analys is has demonstrated an 
ordered series of genetic alterations during the progression of PanIN to PDAC. A general 
genetic analysis of 24 PDAC cases found an average of overexpression of 541 genes, which 
converge on 12 key cellular signalling pathways and 63 exotic alterations in this cohort (Song 
et al., 2019).  
Clinical research has only displayed slight progress in the median overall survival of patients 
in the past 20 years ago (Lockhart et al., 2005). Recent researches indicated that 
deregulated MicroRNAs (miRNAs) can play important role in PDAC development and 
progression by affecting multiple cellular processes, such as cell invasion, metas tasis, 
proliferation, survival, apoptosis and chemotherapeutic resistance of PDAC (Sassen et al., 
2008). 
Treatments for pancreatic cancer 
Surgical resection  
Pancreatic Cancer surgery is the only possible way to remove the cancer and prevent to 
spread between other body organs. Even though, surgery can be effective in cancer 
treatment, surgery is only beneficial for patients in the early stages of the disease and it only 
prove to be effective in a rate ranging from 3-4% up to 27% as the 5 years survival rate 
report said (Ferrone et al., 2012; Shrikhande et al., 2007).  
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Unfortunately, there is no specific symptom in the cancer early stages. This can make the 
cancer diagnoses and treatment very hard. Whipple's procedure is the name of the surgical 
procedure for treating pancreatic cancer (Sa et al., 2010; Kang et al., 2016). Most of the 
failures of the surgery treatment of pancreatic cancer lead to recurrent relapse of the 
disease after operation. This is because of lack of appropriate detection techniques and 
failure of metastatic cancer removal within the pancreas at time of diagnosis. In this case, 
adjuvants chemotherapies can be useful method for completing cancer elimination. 
Adjuvants chemotherapies for pancreatic cancer are usually gemcitabine, capecitabine, 
paclitaxel, 5-fluorouracil and cisplatin (Ferrone et al., 2012).  
Cancer chemotherapy 
Normal cells can grow and die in a controlled manner; however, cancerous cells keep 
growing without control. Chemotherapy works by killing the cancer, stopping them from 
dividing and reduce their growing speed. However, it can also harm healthy cells, which 
causes side effects. Depending on the sort and rate of chemotherapy, there are some side 
effects which may happen for patients. Some common side effects are fatigue, 
immunosuppression, nausea, vomiting, pain, and hair loss. Chemotherapy may be needed 
to be alone or with other treatments. The amount of chemotherapy is related to the level of 
cancer grows and the patients may get treatment every day, every week or every month 
(Nurgali et al., 2018). 
Dosing of chemotherapy 
Chemotherapeutic agents are mainly given in sequences to reduce the severity of side 
effects; the most of drug administration is normally several days  to weeks (Avendano & 
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Menendez, 2008). However, chemotherapy is limited by considerable cytotoxicity which 
often leads to suspension of treatment or variation from the optimal treatment protocol to 
ensure adoption (Chabner and Longo, 2011). The dose of cytotoxic agent has to be exactly 
calculated according to the rate of tumour cells progress, sickness start time and patient 
ability to cope which such treatments.  
Each chemotherapy regime can kill a certain percent of tumour cells and increasing dose of 
the agent will increase rate of cancer cell killing (Avendano & Menendez, 2008). However, 
high cytotoxic chemotherapy can lead to very bad side effects. Some of these side effects 
include gastrointestinal distress, alopecia, myelosuppression which can cause to blood 
cytopenia, immunosuppression and finally can induce a stroke-like syndrome that presents 
with transient neurological defects, for example alternating hemiparesis, aphasia, 
encephalopathy and seizures (Martino et al., 1984; Walker et al., 1986; Corrie et al., 2008). 
Gemcitabine 
Gemcitabine was the first drug used as chemotherapeutic agent for pancreatic cancer 
treatment (Figure 1). Gemcitabine is a nucleoside analogue that mimics physiological 
nucleosides in terms of uptake and metabolism and is incorporated into newly synthesised 
DNA resulting in synthesis inhibition finally it can stop the chain and inhibit from tumour 
build-up (Cunha et al., 2005). Gemcitabine has also been used for antiviral treatments aside 
from use in cancer therapy. 
Although studies on patients demonstrate that this drug is only effective in 23.8% of 
patients, chemotherapy with gemcitabine is the only choice for the patients who surgical 
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resection is unable to remove the tumour (Neoptolemos et al., 2010; O’Reilly et al., 2011; 
Neoptolemos JP et al., 2012; Tuveson & Neoptolemos, 2012; Vincent et al., 2011).  
 
Figure 1: The structure of gemcitabine. 
Capecitabine 
Capecitabine IUPAC's name is Pentyl [1-(3, 4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-
fluoro-2-oxo-1H-pyrimidin-4-yl] carba-mate (Figure 2). Capecitabine is a chemotherapy 
agent frequently used to treat solid cancers such as cancers, breast or pancreatic cancers 
(Akitake et al., 2011). 
 
Figure 2: The structure of Capecitabine. 
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Capecitabine is active as single agent, but can also can be mixed with other cytotoxic agents, 
such as cisplatin (Lordick, et al., 2014), Taxane (Naughton, 2010), Oxaliplatin and Irinotecan 
(Akitake et al., 2011). Capecitabine side effects are such as hair loss, fatigue, weakness, 
shortness of breath, headache (Okines, et al., 2009). Capecitabine and intermittent 5-FU are 
known for a low prevalence of cardiovascular toxicity. In comparison between both drugs, 
the capecitabine is associated with a lower rate of neutropenia; however hand-foot 
syndrome (HFS) occurs far more regularly (Petrelli et al., 2012). 
Paclitaxel 
Paclitaxel is an important member of the Taxane family of medications and without a doubt 
one of the most effective anti-cancer drugs of all time (Heinig et al., 2013). Paclitaxel is the 
first microtubule-stabilizing agent identified and considered to be the most significant 
advance in chemotherapy of the past two decades (Figure 3). It is considered as one of most 
useful antineoplastic agents with widespread activity in various cancers including, 
endometrial cancer, bladder cancer, breast cancer, non-small-cell lung cancer and cervical 
carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line 
treatment (Heinig et al., 2013). 
 
Figure 3: The structure of paclitaxel. 
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5-fluorouracil (5-FU) 
5-fluorouracil (5-FU) is a thymidylate synthase inhibitor (Figure 4). This enzyme has 
responsible for the synthesis of thymidine. Thymidine is a nucleoside and it is crucial for 
DNA replication (Mohamed & Safwat, 2016). 5-FU has been extensively used for several 
decades to treat a variety of tumours including stomach, cervix, oesophagus, colon, breast 
and pancreas (Ajani et al., 2008; Rubinson et al., 2015; Takahari et al., 2017).  
 
Figure 4: The structure of 5-fluorouracil (5-FU). 
The primary mechanism of action of 5-FU is inhibition of thymidylate synthase. Thymidine is 
the main factor for DNA replication (Longley et al., 2003). The ability of 5-FU to cross the 
blood brain barrier (BBB) may facilitate its central nervous system toxicity. 5-FU has second 
dangerous drug after anthracyclines. 5-FU Cardiac toxicity can manifest as chest pain, acute 
coronary syndrome/myocardial infarction, cardiac arrhythmias or rarely death (Chen et al., 
2014).  
There are some factors which can lead to drug cardiac toxicity and two main likely factors 
are ischemia due to coronary vasospasm and drug-related myocardial toxicity. So 
impairment of executive function is the main issue which can be achieved by using 5-FU 
(Snyder, 2015). 
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Cisplatin 
Cisplatin is a prototypic platinum chemotherapeutic agent and also first platinum which 
contain the anti-cancer drug. Cisplatin has four different mechanism for cancer removal 
include decreasing drug uptake, increasing DNA repair, defecting in apoptosis pathways, 
activation of pro-survival pathways and inhibition of pathways that promote cell death (Dai 
et al., 2016; Fang et al., 2017). Cisplatin structure includes a metallic coordination 
compound with two chlorine and two amine ligands in a cis conformation (Figure 5) (Dasari 
& Bernard Tchounwou, 2014).  
 
Figure 5: The structure of Cisplatin. 
Cisplatin is useful drug for some of cancers including neck, lung and ovarian cancers. It also 
can be mix with some of chemotherapeutic drugs and use for breast, prostate and 
pancreatic cancers treatment (Dasari & Tchounwou, 2014).   
Cisplatin must be activated by hydrolysis as it is chemically inert. In this case, chloride ions 
can replace with water molecules and make strong electrophile (Achkar, 2018). The amount 
of electrophile depending on the concentration difference of chloride ions between 
intracellular and extracellular milieu (approximately 2–10 mM, as compared to 
approximately 100mM in the extracellular space) (Michalke et al., 2010). The electrophilic 
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forms of cisplatin can make bound to endogenous nucleophiles, such as metallothioneins, 
reduced glutathione (GSH) and methionine (Galluzzi, 2014).  
Cisplatin interacts with nuclear DNA and mitochondria, which leads to the generation of 
inter- and intra-strand DNA crosslinks (Hu, 2018). This dativotes covalent binding forms DNA 
adducts which cause cancer cell DNA damage and block cell division which leads to 
apoptotic cell death (Dasari & Tchounwou, 2014). The studies demonstrate that the cancer 
cells can resistance against cisplatin treatment. There are many phytochemicals which are 
capable of reversing cisplatin resistance in various malignancies (Shahid et al., 2018). 
Naphthalimide and bisnaphthalimide based anticancer agents 
In the early 1970s, the team of Brana published the first series of 1, 8 naphthal imides 1a-d 
possessing good cytotoxicity towards HeLa and KB cancer cells (Figure 6). The compounds 
were prepared by simple condensation of 3-nitro-1, 8-naphthalic anhydride with the amine 
side chain. Later, more derivative of naphthalimides were synthesised by changing ring 
substituents, and side chain (Roldan et al., 1973; Brana et al., 1978; Brana et al., 2001).  
Studies demonstrate that the cytotoxicity of these compounds is very high as the presence 
of terminal amine functionality in the N-imide side chain.  Specific substituent types on the 
naphthalic ring also play important role in increasing the cytotoxicity; for example, 3-amino, 
3-nitro or 3-methoxy groups gave the best results. Activity was maximized when the amino 
group in side chain was two to three methylene groups from the 1, 8-naphthalimide unit. In 
addition, substitution at the C3 position of the naphthenic ring instead of C2 or C4 gave 
optimal results. According to the CPK model, the 3-nitro group lies in or nearer to then 
phthalic ring plane compared with a more sterically hindered nitro group at the C4 position 
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which rotates out of the plane (Paull and Nasr, 1984).This structure difference create 
stronger binding between binding of the3-nitro relative to the 4-nitro-1, 8-naphthalimide 
derivatives and DNA (National Cancer Institute, 1984). 
 
Figure 6: The structure of naphtha imides. 
Mitonafide and Amonafide (Figure 7) were selected from a library of naphthal imides and 
thoroughly studied (go through Phase I and Phase II) because of their potent cytotoxic 
action against a group of cell lines. Both compounds use their action by binding to DNA by 
intercalation and inhibit Topoisomerase enzyme II action while, other naphthalimides are 
unable to inhibit Topoisomerase enzyme II (Lundberg et al., 2011; Brana, 2001). 
 
Figure 7: Chemical structure of Mitonafide (1) and Amonafide (2).  
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Changing both the chromophore substituents (in the order NO2 > H > NH2 > CH3CONH) and 
the linker chain character (length and nature) can change biological activity of 
bisnaphthalimide compounds significantly. Derivatives of naphthalimides similar to 
Amonafide have been produced to increase the cytotoxic effects of the naphthalimides 
family. Bisnaphthalimides is one of these derivatives which have designed and synthesis to 
increase cytotoxic effect. This compound has stronger binding ability to DNA in comparison 
with the other naphthalimides derivatives (Brana et al., 2001). 
Elinafide (Figure 8), a bisnaphthalimide derivative selected for phase I and phase II study, 
has no substituents in the chromophore and has seven methylene groups in the linker chain. 
Recent studies show that Elinafide has the highest cytotoxic effect in compare with the 
other bisnaphthalimide derivatives. Even though Elinafide cytotoxic effects are too high, it 
can lead to raising the side effect and restricting anti-cancer effects (Brana et al., 2001). 
 
Figure 8: Chemical structure of Elinafide.  
One of the problems for bisnaphthalimide using is the poor solubility property of 
bisnaphthalimide. In this case, asymmetric bisnaphthalimide derivatives were synthesised to 
solve the problem, however, cytotoxicity of these compounds decreased without great 
improvement of aqueous solubility of the parent compound (Braña & Ramos, 2001). 
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Lin and colleagues could synthesis new compounds by using polyamines into the linker 
chain of bisnaphthalimides in order to increase their aqueous solubility and activity (Lin & 
Pavlov, 2000) and (Pavlov et al., 2001). 
Combination therapy 
Combination therapy is using multiple therapeutic agents with different mechanisms in 
combination for reducing the likelihood that resistant cancer cells will develop. In recent 
years, the combination therapy method has become the important strategy for cancer 
treatment. The varying pharmacokinetics of different drugs can lead to inconsistent drug 
uptake and suboptimal drug combination at the tumour sites and make them limit for 
cancer treatments. However, combination strategies in aim to maximize therapeutic efficacy 
is depend on the patient ability to cope this treatment, otherwise using combination 
therapy is impractical (Maiti et al., 2018). 
Knox and his colleagues have published a significant research about combination of 
gemcitabine with Capecitabine efficacy on biliary cancer in 2005. They researched on forty-
five patients were enrolled between July 2001 and January 2004. According to their 
research, “Eighty nine percent of patients had metastatic disease, 47% had gallbladder 
cancer and 43 percent had cholangiocarcinoma. The total objective response rate was 31%, 
with an additional 42% of patients with stable disease, for a disease control rate of 73%. The 
average of progression-free survival time was 7 months (95% CI, 4.6 to 11.8 months) and 
the average of total survival time was 14 months (95% CI, 7.3 months to not available)” 
(Knox et al., 2005). According to these data’s, the chemotherapy combination was generally 
well tolerated. Even though some of side effects such as thrombocytopenia, fatigue, 
transient neutropenia and hand-foot syndrome were commonly observed but the rate of 
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side effects was very lower in compare with using single cancer drug and consequently, they 
could easily manage it without discontinuing further treatment (Knox et al., 2005).  
1.2. Nanotechnology  
Nanotechnology is concerned with the development, manufacture and use of materials that 
have structures, particles, fibers or platelets smaller than 100 nm. Hornyak and his 
colleagues argue that “it is not just about size, it is about the unique physical, chemical, 
biological and optical properties that emerge naturally at the nanoscale and the ability to 
manipulate and engineer such effects.” Applications of nanotechnology are everywhere - it 
has helped make car bumpers lightweight, durable, and resilient; make fabrics resist 
wrinkling, staining, and body odour; improve shampoos, toothpaste, sunscreen, household 
cleaning products and food containers etc. (Hornyak et al., 2008).  
Nanotechnology accurately involves the making and application of biological, chemical and 
physical systems at scales ranging from single molecules or atoms to submicron dimensions, 
and also the integration of these resulting nanomaterials into larger systems. Scientists 
believe that nanotechnology has the potential to change and develop our perspectives 
about global issues and provide best resolve for future therapies. In the other words, 
nanotechnology has arisen as a multidisciplinary field, in which gaining a substantial 
understanding of the optical, electrical, mechanical and magnetic properties of 
nanostructures promises to deliver the next generation of functional materials with wide-
ranging applications. Nanostructures have huge abilities to be used as a best solution in 
environmental and technological challenges such as solar energy conversion, water 
treatment catalysis and medicines (Zadeh et al., 2019). 
17 
 
Nanotechnology in medicine 
Human health is one of the most important subjects in the most of science research. In 
recent years, scientists constantly have considered nanoparticles as unique materials in 
medicine and especially in cancer treatment. Even though using nanoparticles are incredibly 
increasing for cancer treatment and little clinical translation has been realised, it is still 
believed that nanoparticles are on the verge of a new era in the near future (Li et al., 2005). 
 Feynman is the person who was presented the concept of nanotechnology in his 1959 
lecture. By saying “There's plenty of room at the bottom”, defined the value of employing 
individual atoms using larger machines to creating smaller machines (Feynman, 1959).  
Nanoparticles are using in many different fields such as chemistry, engineering, biology and 
medicine. Nanoparticles are made by various physical and chemical methods such as 
photochemical (Li et al., 2005) chemical reduction (Wang et al., 2005) γ-radiation (Choi et 
al., 2005) and laser ablation (Tsuji et al., 2003). 
There are two ways for drugs loading in the nano particulate systems. These are via 
incorporation technique or incubation techniques. In the incorporation technique, drug 
encapsulation is often achieved at the period of nanoparticle construction but in the 
incubation technique, adsorbing of the drug onto the nanoparticle surface is often carried 
out after the nanoparticles have been prepared (Shu et al., 2014).  
Nano-drug delivery systems also have become a research hotspot in the field of drug 
delivery owing to the advantages of reduced drug toxicity and improved drug bioavailability. 
Be employing nano-drug delivery systems, drugs can be dissolved, adsorbed, and covalently 
bound to the surface of nanocarriers, or encapsulated and embedded inside nanocarriers. 
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Not only can this increase the solubility of the drug and improve its utilization in biological 
systems, it also targets the drug to the tumor site by exploiting the high permeability and 
retention effects of solid tumors, and by introducing surface modifications in the carrier. 
This helps avoid drug wastage by transportation to the normal tissues and enhances 
treatment safety (Kang et al., 2018). 
Nanoparticles can be comprised of organic or inorganic components. The organic 
nanoparticles consist of liposomes, amphiphilic polymers and dendrimers whilst the 
inorganic nanoparticles are often composed of metal oxides, gold and silver. Hybrid 
nanoparticles are constructed when two or more components are used to build more 
complex multifunctional systems conferring core-shell properties. The nano particles can be 
in different structure forms include micelles, vesicles, carbon nanotubes and metallic 
nanoparticles which are used for drug delivery systems (Islam & Miyazaki et al., 2010; 
Salameh et al., 2014). 
Research into NPs is in its infancy for pancreatic, liver, upper gastrointestinal and their use is 
becoming significantly popular as contrast media for radiological researches. On the other 
hands, more advanced technologies capable of active targeting are still in the first step of 
development for treatments in the clinics. Nanomedicines have many advantages for 
delivery, sensing and image-targeting agents (Andrén- Sandberg et al., 2012). 
Gregoria et al. prepared liposomes as drug carriers for the first time in 1974 (Gregoria et al. 
1974). This was first study in cancer therapy by nanomedicine. The engineered NPs 
structure, shape, size and chemical properties open a huge range of technical applications 
and novel approaches in medical research (Yang et al., 2009).  
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In recent years most researches in NPs are based on polymeric (Thompson et al., 2008), 
liposomes (Park et al., 2004), carbon nanotubes (Liu et al., 2007), quantum dots (Cai et al., 
2007), magnetic NPs (Thorek et al., 2006), gold NPs (Huang et al., 2011a) and silver NPs 
(Ferrari et al., 2005; Grodzinski et al., 2006).  
Polymeric and liposome NPs have been explored to encapsulate therapeutic agents in order 
to improve delivery efficiency, drug safety and increasing permeability of the cancerous 
tissues (Farokhzad and Langer, 2006; Moses et al., 2003). Carbon-based NPs have been used 
for photo thermal therapy (Kam et al., 2005) and drug delivery (Bekyarova et al., 2005; 
Bianco et al., 2005; Lin et al., 2004).  
Quantum dots have been exploited in biological finding and labelling because of their size 
dependent fluorescence properties (Bruchez et al., 1998; Chan et al., 1998; Lee, 2001). 
Magnetic NPs are suitable in magnetic hyperthermia therapy (Andra et al., 1999; Hilger et 
al., 2000; Kruse et al., 2014), MRI and cell sorting (Liberti et al., 2001; Lawaczeck et al., 1997; 
Meyers et al., 1963; Schleich et al., 2014) and drug delivery (Goodwin et al., 1999; Joubert, 
1997; Koppolu et al., 2012).  
Gold nanoparticles can enhance penetrability and retention (EPR) effect arising from the 
leaky vasculature and ineffective lymphatic drainage of the tumour tissue (Maeda et al., 
2000). In addition, the surface of gold nano particles can be changed and modified with 
active moieties such monoclonal antibodies, small molecules and peptides, to avoid from 
non-specific uptake, thus realizing tumour-specific targeting (Shakeri-Zadeh et al., 2010; Sun 
et al., 2014; Samadian et al., 2016). Silver nano-particles (AgNPs) are widely used in a range 
of consumer products as a result of their antimicrobial properties (Xu et al., 2015). 
20 
 
Stimuli-responsive nano-carriers 
Modifying of nanocarriers sensitive to exogenous or internal stimuli may indicate an 
attractive alternative to targeted drug delivery. The wide range of stimuli able to trigger the 
drug release at the right place and time, and the diversity of responsive materials that can 
be assembled in different architectures, allow great flexibility in the design of stimuli-
responsive system. Nanoscale stimuli-responsive devices may be sentient to particular 
endogenous stimuli, like lowered interstitial pH, a greater glutathione concentration or an 
enhanced level of certain enzymes such as matrix metalloproteinases (Mura et al., 2013).  
At the tissue level, one can take benefit of specific microenvironmental changes linked with 
neoplastic diseases (the treatment of which is the application of most of the research effort 
on stimuli-responsive nanocarriers) as well as pathological situations such as ischemia, 
inflammatory diseases or infections. At the cellular level, pH sensitivity can either trigger the 
release of the transported drug into late endosomes or lysosomes, or promote the escape 
of the nanocarriers from the lysosomes to the cell cytoplasm (Mura et al., 2013).  
The consensus is that both the structural heterogeneity of the biological targets and the 
limited accessibility of the target cells are detrimental for drug targeting (often because of a 
combination of an exaggerate desmoplastic reaction, an excessive interstitial pressure and a 
poor status of endothelial blood vessels). Extracorporeal physical stimuli can be also applied. 
 For example, the targeted delivery of pharmacologically active molecules  to a diseased area 
in the body can be magnetically guided by using ultrasmall iron oxide-based nanoparticles. 
Sustained drug release can also be achieved by thermo-, light- or ultrasound-sensitive 
nanoparticulate systems. Furthermore, the possibility of choosing between different routes 
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of administration (intravenous, oral, ocular or mucosal) is attractive (Mura et al., 2013). The 
thermosensitive liposomes, already in the clinical phase, are a good example. Consequently, 
immense progress in materials chemistry and drug delivery has led to the design of smart 
stimuli responsive concepts using well-engineered Nano systems (Mura et al., 2013).  
Metallic nanoparticles 
In 1857, Faraday first investigated the existence of metallic nano particles in solution. 
Metallic nano particle is nano sized metals with dimensions (length, width, thickness) within 
the size range of 1-100 nm. Nano materials can be prepared and adapted with huge 
different chemical structures and chemical functional groups. Metal nanoparticles include 
gold, palladium, copper, iron, zinc oxide, silver, selenium, platinum nanoparticles (Khande et 
al., 2016). 
Nano materials can bind with antibodies, drugs and ligands. These materials applied in wide 
range of areas such as biotechnology, therapeutic area, vehicles for gene and drug delivery 
(Harish Kumar et al., 2018). The advantages of metallic nanoparticles are diverse including 
the phenomenon possessed by some metallic nanoparticles (gold and silver) known as 
surface plasmon resonance (SPR). On the other hand, metallic nanoparticles have some 
disadvantages such as enhanced toxicity profiles, highly reactive nature, there can also be 
high chances of impurity from synthesis (Harish Kumar et al., 2018). 
Iron oxide metallic nanoparticles 
In 200 BC, Chinese people discovered iron oxide magnetism properties by using rocks 
containing iron oxide for religious purposes. The advance of Fe3O4-based compasses for 
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navigation occurred in Europe as early as 850 AD. Fe3O4 was one of the first mineral 
structures produced by Bragg in 1915 (Bragg et al., 1915).  
In the last decades, many different methods for the synthesis of iron oxide NPs have been 
published. Many reports have defined efficient green synthetic approaches to produce the 
biocompatible stable, shape controlled and monodispersed iron oxide NPs (Bharde et al., 
2008). Some of most applied methods include sono-chemical, micro emulsion, 
coprecipitation, hydrothermal synthesises and thermal decomposition (Cabrera et al., 
2008). 
 Additionally, there are some biological methods for preparing there NPs which can be 
useful as well. These methods include microorganism or bacterial synthesis (especially the 
Magneto tactic bacteria and iron reducing bacteria) (Bharde et al., 2008; Roh et al., 2006), 
electrochemical synthesis (Pascal et al., 1999) and laser pyrolysis techniques (Bomati Miguel 
et al., 2011). 
In recent years magnetic iron oxide NPs (MNPs) is the main subject of the researches 
because of they use for hyperthermia, imaging and many applications from utilising in the 
recovery of metal ions and dyes to drug delivery (Comoucka et al., 2010; Neuberger et al., 
2005). Studies have highlighted MNPs offer the benefit of utilising both EPR effect (passive 
targeting) whilst also allowing for a direct, externally guided delivery to the tumour (active 
targeting) (Arruebo et al., 2007). Iron oxide is used as a contrast agent in MRI scanners. 
Recently, scientists have focussed on coating magnetic nanoparticles with drugs, which can 
held the drug and deliver it to the desired site of action (Mejías et al., 2015; Dilnawaz et al., 
2011). 
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Iron oxide for magnetic resonance imaging (MRI) 
  Magnetic iron oxide nanoparticles (MNPs) are currently under research development to 
provide better diagnosis for a various range of diseases such as cancer (Ferrari et al., 2005), 
cardiovascular disease (Wickline et al., 2007) and neurological disease (Corot et al., 2004). 
Magnetic resonance imaging (MRI) is one of the major instruments used for clinical 
diagnosis due to its high soft tissue comparison, three-dimensional resolution (Ferrari et al., 
2005), depth penetration (Edelman, 1996) and ability to show contrast between healthy and 
diseased tissue (Wickline et al., 2007).   
Furthermore, MRI does not use ionizing radiation or radiotracers which can cause harmful 
side-effects. These days, magnetic iron oxide nanoparticles (MNPs) have become the in 
centre of attentions by scientists because of their great biomedical capability (Acar et al., 
2005). They have been used in targeted therapy, drug delivery and biological discovery by 
imaging (Corot et al., 2004).  
MNPs have large surface area in compared to their volume and low surface charge. MNPs 
cannot easily distribute in solution because of their magnetic property which causes of 
sedimentation of MNPs in solution. According to Neuberger, NPs can easily distributed in 
solution if coatings with polymers or other hydrophilic molecules are applied (Neuberger et 
al., 2005).  Magnetic nanoparticles can strongly adapted by various surface layers (Kalska 
Szostko et al., 2014). 
Interfacial reformation of the magnetic moment can lead to a rise in the magnetic hyperfine 
field and splitting of the MS spectra, which is in good agreement with data published for 
multilayers (Pan et al., 1996). Particular chemical surface rectification is useful for further 
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bonding of biological particles. Recent researches demonstrate that some metals such as 
gold, copper and silver can play important role for surface modification. The noble metals 
have interesting type of functionalization in comparison to the oxidised one. This property 
can distinguish them with other metals. The layer of metals nature can lead to an 
enhancement in the district of the compounds able to connect to magnetic nanoparticles 
with special emphasis on bio application (Vekas et al., 2006; Lu et al., 2010; Sanvicens et al., 
2015; Weller et al., 1996; O’Reilly et al., 2005).  
Khana and their colleagues have studied about increasing gemcitabine therapeutic efficacy 
in pancreatic cancer by using superparamagnetic iron oxide nanoparticles in 2019. They 
could synthesize and develop a superparamagnetic iron oxide nanoparticle (SPION) 
formulation of curcumin (SP-CUR) (Khana et al., 2019). This compound was characterized by 
different methods and confirmed that it’s not toxic, bioactive anti-cancer or bioactive anti-
inflammatory agents. The SP-CUR was played an important role in increasing drug delivery 
to the target cells (tumours). Moreover, their studies proved that Iron oxide could enhance 
gemcitabine (GEM) efficacy for reducing tumour growth and metastasis and pancreatic 
cancer treatment (Khana et al., 2019). 
Many nanoparticles, including superparamagnetic iron oxide nanoparticles (SPIONs) are 
using in different researches to delivery drugs to the desired site of action (tumour) or 
imaging. Vekas et al. could synthesise and preclinical evaluation of a multifunctional nano 
probe for dual MRI and optical imaging of pancreatic tumours. They synthesised a novel 
backbone cyclic core peptide targeting SSTR 1–5 with conjugating the Nano probe contains 
the magnetic ion cores for MRI and fluorescent dyes for fluorescence imaging and then they 
were anchored to FITC.PTR86 (Vekas et al., 2006). The Nano probe demonstrated no 
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detrimental effect on the cellular viability as confirmed by FACS data analysis of DAPI 
stained cells. They researched results demonstrated the improved accumulation of targeted 
Iron oxide Nano worms had better performance in compare with non-targeted nano worms 
in mice bearing subcutaneous human pancreatic ductal adenocarcinoma (PANC-1). 
Consequently, the resulted hybrid nano probe can be used as multimodal diagnostic agents 
for targeted imaging with commercially available PET-MRI scanners (Vekas et al., 2006). 
Gold nanoparticles 
In recent years significant progress in the design and application of numerous nanomaterials 
also improve and develop an understanding of the biomedical properties of nanoparticles 
for cancer treatment has occurred (Ferrari et al., 2005). In this area, gold nanoparticles 
(AuNPs) have recently emerged as promising agents. There are various types of AuNPs 
based on the physical properties, size and shape such as nano-rods, nano-shells, 
nanoparticles and nano-cages (Yang et al. 2015; Dreaden et al., 2012).  
AuNPs between 2 nm and 100 nm in diameter can be synthesised by wet chemical method, 
which is controlled reduction of an aqueous chloroauric acid (HAuCl4) solution with different 
reducing agents under varying conditions (Cai et al. 2008).  
Smaller Particle sizes have better chemical and physical properties, with interesting 
biomedical applications (Qian et al. 2008). AuNPs are useful for many different fields such as 
imaging (Zhang et al. 2009), cancer therapy (Jain et al. 2012), and drug delivery (Khan et al. 
2014). Brazzale, Canaparo and their colleagues have discovered important evidences about 
AuNPs capabilities in generate cytotoxic reactive oxygen species (ROS) upon light and 
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ultrasound irradiation. They proved that AuNPs can promote in photodynamic therapy (PDT) 
and sonodynamic therapy (SDT), respectively (Brazzale et al. 2016). 
Gold nanoparticles for cancer treatment 
The enhanced permeability and retention (EPR) effect is a controversial concept by which 
molecules of certain sizes (typically liposomes, nanoparticles, and macromolecular drugs) 
tend to accumulate in tumor tissue much more than they do in normal tissues . This is highly 
dependent upon cancer type as solid tumours are widely regarded as being difficult to 
penetrate. The surface of AuNPs can detect tumour-specific targeting easily as their 
functionalized are similar with active targeting moieties such as monoclonal antibodies, 
proteins, small molecules and peptides (Shakeri-Zadeh et al. 2010), (Shakeri-Zadeh et al. 
2010) and (Sun et al. 2014). 
 AuNPs have high surface area-to-volume ratio and versatile surface chemistry. These 
properties make them suitable option to use as nano carriers for drug delivery (Ghosh et al. 
2008). Moreover, AuNPs are qualified agents to be used as effective radio sensitizers for 
increasing cancer radiotherapy because gold nanoparticles have high atomic number to 
provide a larger X-ray absorption cross-section (Her et al. 2017).  
Recent studies have demonstrated that the photo thermal conversion capability of AuNPs 
make them significantly beneficial to contribute for hyperthermia in cancer therapy 
(Ghaznavi et al., 2018). Surface Plasmon Resonance (SPR) is a phenomenon that happens 
when polarized light hits a metal film at the interface of media with various refractive 
indices. This is resultant from the surface plasmon resonance of gold a unique property 
which makes it highly desirable in tumour ablation (Hong et al. 2018).  
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Blood endothelial cells are leaky at the tumour site, which let penetration of NPs to the 
tumour milieu. However, the lymphatic endothelial cells are tight at the cancer site, which 
cause retention of the NPs at cancer site and prevent their departure from the surrounding 
tumour cells. Gold nanoparticles are able to preferentially remain at the tumour site via 
enhanced permeability and retention (EPR) effect arising from the leaky vasculature and 
ineffective lymphatic drainage of the tumour tissue (Maeda et al. 2000). 
Biomedical application is the application of technology and engineering to living beings, 
especially the design and employment of medical equipment. Beik and colleagues studied 
on AuNPs in combinatorial cancer therapy strategies in 2019. They discovered that AuNPs 
could make a distinctive opportunity to combine various treatment modalities at the same 
time. Consequently, AuNPs have more applicability to cancer therapy in comparison with 
another nanostructure. “They provide a figure to show heat map the biomedical 
applications of some commonly used inorganic nanostructures. Red colour demonstrates 
that the respective nanostructure has not been reported to be applicable in a specific 
therapeutic modality. Bold blue colour indicates the extensive use of the respective 
nanostructure in a specific therapeutic modality” (Figure 9) (Beik et al., 2019). 
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Figure 9: Various Nano structures biomedical applications (Beik et al., 2019) 
Xu and colleagues fabricated dumbbell-like iron oxide-gold NPs and coupled with Herceptin 
and a platin complex. The platin-gold-iron oxide-Herceptin complex as a target-specific 
nanocarrier was capable to deliver platin into Her2-positive breast cancer cells (Sk-Br3) with 
strong therapeutic effects (Xu et al. 2009). Moreover, literature has revealed that the 
oxidised maghemite form preferentially binds gold compared with the magnetite form and 
is more stable and biocompatible form of iron oxide (Lyon et al. 2004). 
Silver Nanoparticles  
Silver nanoparticles (AgNPs) demonstrate highest level of usage at market in compare to 
other nanoparticles (Xiu et al., 2012). Almost 55.4% of the total nanomaterial- based 
consumer products are captured by AgNPs in the market (Wilson et al., 2011; Asghari et al., 
2012). Colloidal silver in the nano-scale has taken part in as the significant amount of 
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functional nano-antimicrobial in consumer products such as surgical coatings, dietary 
supplements, cosmetics, textiles, food packaging, medical implants, and water sterilized 
applications (Monteiro et al., 2009).  
The earlier researches verified that it is hard to achieve nanoparticles with size below 10 nm 
with high mono distribution and stability (Shirtcliffe and Nickel, 1999; Caswell, 2003). 
Therefore, there are significantly important to synthesis AgNPs in smaller size. It is also 
modified the stability and distribution of the particles in the system (Pal et al., 2007; 
Steinigeweg et al., 2003).  
 In most of the cases, borohydride-mediated reduction has been used for the synthesis of 
dispersible silver nanoparticles in wide range (Lin et al., 2003; Tan et al., 2003). However, 
NaBH4 is not good desirable in the production of large silver nanoparticles where other basic 
solvents are preferred (Yang et al., 2011). Another further weaker reducing agent is 
trisodium citrate (TSC) which contributes to manufacture of comparatively large silver 
nanoparticles.  However, it has a wider size distribution (Creighton et al., 1979). It is also 
significantly important to modify the shape of the nanoparticles for instance cubes, triangles 
and spherical nanoparticles are go supplemented with unwanted generation of rods (A. 
Pyatenko et al., 2007; Sharma et al., 2009). The recent studies demonstrated that applying 
either of sodium boro hydride (NaBH4) and trisodium citrate (TSC) can be enough effective 
to synthesize silver nanoparticles with size below 10 nm (Arvizo et al., 2012). 
Silver nano particles stability  
Konwarh et al. did significant research about silver stability. According their research, the 
mechanism of the AgNP formation is shown in Figure 10. They investigated that polyvinyl 
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acetate (PVA) and AgNPs mixture can lead to optical clarity which facilitates investigation of 
nanoparticles formation. In fact, PVA plays an important role in improving AgNPs stability 
because PVA prevents AgNPs from aggregation. Even though PVA concentration rising does 
not lead to the reduction of AgNP size, It is important to note that PVA as a protective agent 
plays a conclusive part in controlling the size distribution of AgNPs (Konwarh et al., 2009). 
 
Figure 10: Schematic of size controlled AgNPs synthesis employing the chemical reduction 
method (Ajitha et al., 2015). 
Silver nano particles antimicrobial properties 
Silver nanoparticles have been expended in different fields such as surface enhanced Raman 
scattering (SERS), biosensors, optoelectronics and antimicrobials (Sun et al., 2002; Bois et 
al., 2010; Dong et al. 2009).    
31 
 
Silver’s antimicrobial property has been extensively applied because of to its oligo dynamic 
action broad (Thiel et al., 2007), spectrum killing (Lok et al., 2006) and minor possible 
danger for growth of microbial resistance against it (Gunawan et al., 2011).  
Earlier studies have verified that AgNPs antimicrobial activity is dependent to the variation 
of size and shape, in consequence; smaller nanoparticles are better antimicrobial activity 
than greater nanoparticles (Morones et al., 2005). Different shape of the particle could 
produce different efficacy in different diseases, truncated-triangular nanoparticles appeared 
to be more effective for microbial killing. In comparison with different silver nanoparticles 
shapes, spherical nanoparticles have higher potential in antimicrobial activity (Agnihotri et 
al., 2013; Agnihotri et al., 2012; Mukherji et al., 2012).  
Recent studies have shown that silver nanoparticles have brilliant antimicrobial and antiviral 
properties in comparison with the other metal nanoparticles (Zhang and Wang, 2003; Claus 
et al., 1999; Compagnini et al., 1997; Elechiguerra et al., 2005). Silver has high surface to 
volume ratio, this property cause to increase their biomedical activities. Consequently, silver 
is relatively free of adverse effects so this metal originally used as an effective anti-microbial 
agent. Recent studies demonstrate that this property using electron microscopy, which has 
revealed size dependent interaction of AgNPs with bacteria (Morones et al., 2015). 
Ajitha and their colleges studied on Enhancing antimicrobial activity of silver nanoparticles 
with controlled particle size by pH variation in 2015. According to their studies “Silver 
nanoparticles of various sizes were synthesized through a simple reduction method at 
various pH values of the reaction solution (Ajitha et al., 2015). XRD results approved the 
decrement of crystallite size with the rise of pH. Morphological studies demonstrated the 
formation of spherical nanoparticles. The SPR peak is discovered to be shifted towards the 
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blue end with the increase of pH indicating the decrease in the particle size. A development 
in photoluminescence intensity was found with the increase of pH. Outcomes of 
antimicrobial studies demonstrated that the AgNPs efficiently inhibited different pathogenic 
organisms and reduced their viability in a pH-dependent manner”. Their work infers that the 
fine-tuning of synthesis parameters will enhance possibilities of desired Nano product tailor-
made for specific sensitive applications (Ajitha et al., 2015). 
Silver nano particles toxicity 
There are many ways of human exposure to AgNPs, including ingestion, dermalabsorption, 
inhalation and injection (Ahamed et al., 2010). Some of in vitro studies demonstarted AgNPs 
cytoxicities towards various types of human cells (Asharani et al., 2012; kitti et al., 2013; 
Foldbjerg et al., 2012; Gliga et al., 2014). However, the scientists have not found clear and 
acurate answer about the AgNPs toxicity mechanisms so far (Browning et al.,2013). 
This is very important to know that  how specific physicochemical properties, such as 
particle size and surface chemistry can affect on cell viability (Ahlberg et al., 2014; Comfort 
et al., 2014). There are some researches which have evaluated the amount of AgNPs toxic 
potential in different properties such as NP formulations (Boonkaew et al., 2014), different 
AgNPs sizes (Kim et al., 2012), the storage environment (Ahlberg et al., 2014) and the 
duration of exposure (Comfortetal., 2014)however there is not many researches about 
decreasing AgNPs cytoxicity by coating them with polymers (Sharma et al., 2009).  
Numerous polymers have also been used to coat AgNPs, such as polyvinyl pyrrolidone (PVP) 
(Haberl et al., 2013) and poly (ethylene glycol) (PEG) (Lópezetal, 2009; Nymark et al., 2013). 
Some of researches has reported that coating s ilver nano particles with the polymers can 
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decrease silver toxicity, promote stability and avoid aggregation (Tao et al., 2007; Lópezetal, 
2009).  
The few studies which have published the influence of coating on AgNPs toxicity stated 
conflicting information. It has been reported that the charged PVP coating improved the 
stability of AgNPs and decreased their toxicity (Zhang et al., 2014), while other studies 
reported that PVP-coated AgNPs could be highly cytotoxic to mammalian cells (Grosse et al., 
2013). 
Polyethylene glycol (PEG) have low molecular weight and able to neutralize the surface 
charge and lead to stabilize NPS through steric hindrance. PEG coating has been reported to 
decrease NP reactivity (Povoski et al., 2013), improve penetration through the mucus layer 
and decrease Silver toxicity (Lópezetal, 2009). These results has caused to  increase the 
interest in the use of this polymer for nanomedicine purposes(Suk et al., 2011; Tetley, 
2013).  
Silver nano particles for cancer treatment 
Silver nano particles (AgNPs) has shown potential cytotoxicity against various number of 
cancer cells such as cervical cancer HeLa cells (Jeyaraj et al., 2013), lung cancer A549 cells 
(Gengan  et al., 2013), Dalton’s lymphoma ascites tumour (Sariram et al., 2010), breast 
cancer MCF-7 cells (Jeyaraj, 2013) and colon cancer HT29 cells (Sanpui, 2011). 
Pharmaceutical application of nanomaterial is the most favourable way and also newest way 
for preparation of new biomedical sciences topic. nano formation of silver basically has 
significant characterises for suitable conductivity and outstanding therapeutic potential such 
as anti-inflammatory, antiplatelet, antimicrobial, antifungal, anti-angiogenesis and 
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anticancer activities and also chemical stability between different silver nanoparticles 
(AgNPs) (Austin et al., 2014; Vaidyanathan  et al., 2009; Dar et al., 2013; Tolaymat  et al., 
2010). 
Hsin et al. experiment was demonstrated in the mitochondrial pathway of apoptosis by 
AgNPs in NIH3T3 cells, which is mediated by a ROS- and JNK-dependent mechanism (Hsin, 
2008). Gurunathan et al. furthermore determined evidence for AgNPs able anti-angiogenic 
influence due to the activation of PI3K/Akt signaling pathways (Gurunathan et al., 2009).   
One of the important abilities of AgNPs is to act selectively to inhibit creation of HeLa cells 
by caspase-3-mediated which causes cell death and DNA damage (Jeyaraj and Rajesh, 2013). 
Still, none of the molecular triggers have been revealed any of the underlying biochemical 
mechanisms (DeLima and Seabra, 2012). However, the toxicity of AgNPs developed 
noticeable to be driven by the escape of silver ions. Although AgNPs has great cytotoxicity 
rate alongside NSCLC A549 cells, some of latest researches has been demonstrated that 
there are not cytotoxicity toward normal healthy peripheral lymphocytes (PLs) (Gengan et 
al., 2013). Greulich et al. stated that silver ions were more cytotoxic toward bacteria and 
human cells than AgNPs (Greulich et al., 2012).  
The AgNPs effects are not same as those of silver ions in inducing neurotoxicity through 
oxidative stress in rat cerebral astrocytes (Sun, 2016). Although, the recent researches have 
achieved the promising information’s in this case, the toxicity effects of AgNPs are proven 
but the underlying molecular mechanisms inside the human cells still are not fully 
recognised up to now. The cellular events were untangle in human glioblastoma cells (U251) 
and normal human lung fibroblast cells (IMR-90), and they displayed mitochondrial 
dysfunction and induction of reactive oxygen species (ROS), which cause turning off 
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chromosomal deviation and DNA damage, as the possible mechanisms (Asharani  et al., 
2009). 
Regarding to José study in vivo, Intramuscular organization of AgNPs critically raised mice 
survival at day 35 in L5178Y-R tumour-bearing mouse model (José et al., 2013).  
Sriram et al. studies designated that, the efficacy of biologically synthesized AgNPs have 
significant ability in anticancer therapy. In metastasis of cancer the initiate cancer call travel 
through the blood cycles and lymphatic system and create another new cancer somewhere 
else in the body. In consequence, AgNPs have a strong inhibitory activity on disease 
development, metastatic cancer cell and a potent restorative effect in a Dalton’s lymphoma 
ascites tumour-bearing mouse model (Sriram et al., 2010).  
Sanpui research demonstrated that "AgNPs showed a strong inhibitory effect on the growth 
of NSCLC cells (H1299) associated with their effects on bcl-2, caspase-3, and survivin. In a 
mouse H1299 xenograft tumour model, injection of mice with AgNPs potently suppressed 
the growth of H1299 tumours in SCID mice. AgNPs are better candidates for lung cancer 
chemoprevention than chemotherapy in vivo. Further researches should be carried out for 
the potential use of AgNPs in the treatment of NSCLCs" (Sanpui, 2011). 
Hybrid nanoparticles 
Hybrid nanoparticles have been reported in the literature consisting of metallic cores 
surrounded by additional coatings of another material. This could be polymeric based, lipid 
based or metallic based (Figure 11) (Chen et al., 2009). 
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Figure 11: Magnetic nanoparticles with various shells (Chen et al., 2009). 
Shells structured from noble metals do not allow degradation of the internal core 
particularly protecting them from physiological conditions like pH. They can also cause to 
better and longer stability of nanoparticles core in different solvents (Ang et al., 2014).  
Stabilization by thiol ligands of Au and Ag shell can influence optical properties what directly 
can be applied in sensing devices. Sperling et al. were carried out significant study on the 
surface modification, functionalization and bio conjugation of colloidal inorganic 
nanoparticles on 2010. According the research, “gold nanoparticles stabilized by various 
thiol ligands with or without functional organic groups demonstrate that optical properties 
of the thiol-stabilized gold nanoparticles strongly relate on the composition of the ligand 
shell. Such dependence is a result of the ligand shell’s direct influence on the electronic 
structure of the particle core” (Sperling et al., 2010). 
Iron oxide coated gold hybrid 
Magnetic nano particles (MNP’s) can be coated with materials such as silica, polymers, silver 
and gold. These materials can make the safe MNP’s safer. Iron oxide NPs coated with gold 
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are referred to as hybrid nanoparticle HNPs (Figure 12). Gold surfaces bind strongly with 
thiol (-SH) containing molecules via dative covalent linkages. This allows for ease of surface 
modification (Malekigorji et al., 2014). 
 
Figure 12: Schematic diagram of AuNPs surface charges (Malekigorji et al., 2014). 
Some studies have exploited this for the treatment of pancreatic cancer. Kumagai and his 
colleagues studied on enhanced in vivo magnetic resonance imaging of tumours by 
PEGylated iron oxide - gold core shell nanoparticles with prolonged blood circulation 
properties in 2010 (Kumagai et al., 2010). In this study, high‐density PEG coated iron oxide 
gold core shell nanoparticles with roughly 25 nm in diameter with a narrow distribution 
were synthesised as T2‐weighted magnetic resonance imaging (MRI) contrast agents for 
cancer imaging (Kumagai et al., 2010). Bio distribution tests in mice bearing a subcutaneous 
colon cancer model prepared with C26 murine colon adenocarcinoma cells demonstrated 
high gathering of the PEG‐AuIONs within the tumour mass and low nonspecific 
accumulation in the liver and spleen, resulting in high specificity to solid tumours. The 
research results demonstrated that PEG‐AuIONs are a promising MRI contrast agent for 
diagnosis of malignant tumours, including pancreatic cancer (Kumagai et al., 2010). 
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Iron oxide coated silver hybrid 
Iron oxide core- silver shell hybrid nanoparticles (HNPs) are of interest due to their 
multifunctional nature. Not only do these particles possess the magnetic benefits from the 
iron oxide but they also possess the antimicrobial properties as well as ease of 
functionalisation and heating ability of the colloidal silver (Sotiriou et al., 2010). Iron oxide 
core- silver shell hybrid structures add magnetic functionality to silver antimicrobial and 
anticancer properties (Jeyaraj et al., 2013). Iron oxide is one of the best drug carriers, 
moreover silver nanoparticles can be unique assist to the drug for destroying the tumour for 
cancer treatment.  
Coating Iron oxide with silver nanoparticles can lead increase silver performance and it can 
deliver the silver nano particles and cancer drugs to the target cells.  Targeted drug delivery 
is more advantageous than conventional drug therapy as in targeted drug delivery only a 
desirable area in the body is affected, which can minimise the side effects caused by 
conventional drug therapy. The purpose of drug chemotherapy is to transport a drug to the 
targeted area and treat the disease without affecting surrounding healthy tissue (Seil et al., 
2012). Recent researches demonstrate that anticancer and antibacterial efficiency of silver 
nanoparticles in Ag-Fe3O4 is stronger in compare with Ag-Fe2O3 heterodimers or plain Ag 
(Chen et al., 2013).  
Eugênia and their colleges carried out significant research on Compact Ag-Fe3O4 Core-shell 
Nanoparticles in 2014 (Eugênia et al., 2013). They design capable and efficient synthetic 
route to produce novel compact core-shell structures of silver surrounded by magnetite. It 
consists in a parallel silver seed production in the same reaction medium of the iron thermal 
decomposition without vacuum application in a temperature-paused ramp (Eugênia et al., 
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2013). The studies of the size, structure and magnetic properties of the multifunctional 
brick-like Ag-Fe3O4 NPs obtained reveal them as possible candidates for advanced medical 
purposes. They could discover that Ag-Fe3O4 NPs compact magnetite capping will help to 
increasing the biocompatibility as it helps to hinder the diffusion of silver ions to the 
surroundings (Eugênia et al., 2013). 
1.3. Aims 
To the best of my knowledge no research has focussed on the use of iron oxide and silver 
hybrid nanoparticles for cancer treatment. Following on from the success in Dr. Hoskins 
group with gold coated iron oxide in pancreatic cancer, I wanted to investigate whether 
switching the coating from gold to silver would result in a better delivery system. This is 
based on the assumption that silver has increased plasmonic properties compared with gold 
and may result in for efficient heat triggered delivery. To test this theory, we aimed 
conjugated novel bispnaphthalimido drug compounds electrostatically onto the surface of 
our fabricated particles and study their physical, chemical and biological properties in order 
to assess their potential as new therapies in pancreatic cancer treatment.  
The hybrid iron oxide-silver nanoparticles research is consisting of different parts include 
synthesis and characterisation of HNPs. Firstly, the hybrid nanoparticles will be synthesised 
and characterised using inductively coupled plasma-optical emission spectroscopy 
(ICP/OES), fourier transform infrared spectroscopy (FTIR), transmission electron microscopy 
(TEM), UV/Visible spectroscopy and photon correlation spectroscopy and zeta potential 
measurement. Moreover, laser irradiation assess for thermos responsive drug delivery. In 
the second part drug loading (bisnaphthalimide based drugs), drug releasing assess and 
optimise and also HNP physical and chemical stability assess in various conditions. 
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Consequently, new formulations design and assess in vitro conditions. Third part is biological 
investigations of the novel formulations. In this part the hybrid nano particles cytotoxicity 
measure and compare with the drug and new formulations by MTT and trypan blue assays. 
In vitro cellular uptake of formulation comparison between only the drug and the new 
formulations will be conducted. 
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Chapter Two 
Synthesis and 
characterisation of 
iron oxide-silver           
core-shell hybrid 
nanoparticles 
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2.1. Introduction 
Silver nanoparticles (AgNPs) are capable to be used in various technologies such as 
nanoscale electronics (Yang, 2010), imaging (Lee et al., 2006), catalysis (Christopher et al., 
2008) and surface enhanced raman scattering (Baik et al., 2009). In recent years, silver 
nanoparticles are in centre of attention for many studies such as anticancer and anti-
angiogenic agents in retinal endothelial cells  (Sriram et al., 2010).  
It is a well-known fact that silver ions and silver-based compounds are highly toxic to 
microorganisms which include major species of bacteria. This aspect of silver makes it an 
excellent choice for multiple roles in the medical field. Silver is generally used in the nitrate  
form to induce antimicrobial effect, but when silver nanoparticles are used, there is a huge 
increase in the surface area available for the microbe to be exposed to.  
AgNPs demonstrated significant toxicity properties in various human cells such as human 
brain cells (U251) (AshaRani et al., 2009), endothelial cells (Kalishwaralal et al., 2010), 
human lung fibroblast cells (IMR-90) and MDA-MB-231 human breast cancer cells 
(Gurunathan et al., 2013). Silver nanoparticles have the ability to anchor to the cancer 
intraceluular bacterial wall and subsequently penetrate it, thereby causing structural 
changes in the cell membrane like the permeability of the cell membrane and death of the 
cell. There is formation of ‘pits’ on the cell surface, and there is accumulation of the 
nanoparticles on the cell surface (Sondi et al., 2004). The formation of free radicals by the 
silver nanoparticles may be considered to be another mechanism by which the cancer cells 
die. There have been electron spin resonance spectroscopy studies that suggested that 
there is formation of free radicals by the silver nanoparticles when in contact with the 
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bacteria, and these free radicals have the ability to damage the cell membrane and make it 
porous which can ultimately lead to cell death (Danilcauk et al., 2006) 
There are some different methods for synthesising of silver nano particles with various sizes 
(Jau-RungChiou et al., 2013; Agnihotr et al., 2012). Agnihotr synthesised silver nanoparticles 
with various sizes such as 5 nm, 7 nm, 10 nm, 15 nm, 20 nm, 30 nm, 50 nm, 63 nm, 85 nm 
and 100 nm (Agnihotr et al.2012). Silver nanoparticles were synthesized by using sodium 
borohydride (NaBH4) as a primary reducing agent and trisodium citrate (TSC). Both of agents 
have grate potential to act as secondary reducing agent and the stabilizing agent. The 
reduction processes were accomplished in two stages thermal treatment involves 60 °C and 
90 °C. The best pH of the solution was identified to be pH 10.5 using certain amount of 
sodium hydroxide (Agnihotr et al., 2012). 
Controlled synthesis of nanoparticles was established on the co-reduction approach using a 
two stage thermal treatment (Figure 13) (Agnihotr et al., 2012). The initial reduction was 
accomplished using NaBH4 at 60 °C (stage I). In this stage the large number of silver 
nanoparticles starts to be produced. At this stage, the reduction of silver cations leads to 
creation of new silver nuclei. Silver nanoparticles formed at the initial stage consequently 
participated in the growth process. In stage II the temperature should rise to be 90 °C. In 
this stage, TSC-mediated reduction of unspent Ag ions occurred. On the other hands, TSC 
presented with NaBH4 during the initial stage. At the lower temperature dominating in stage 
I, TCS play important role in preventing silver nanoparticles agglomeration. An adequate 
NaBH4 to TSC ratio was acute to control the nucleation and progressing procedure in the 
two stage co-reduction approach (Agnihotr et al., 2012).  
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Figure 13: Different stages in synthesis of silver nanoparticles (Agnihotr et al., 2012). 
Agnihotr and their colleague studies demonstrated that NaBH4 is main factor for achieving 
silver nanoparticle smaller sizes. The AgNPs with range of 60- 100 nm can easily accumulate 
and TSC was the most important reducing agent for preventing silver nanoparticles 
agglomeration (Agnihotr et al., 2012). The silver nano particles were characterized by UV-
Vis, TEM, XRD, zeta potential analyser. Consequently, the experiments shown that even 
though all AgNPs were found to be highly toxic to the bacterial strains, their antibacterial 
efficacy sharply increased with lowering particle size. This effect was considerably increased 
as the size of nanoparticles moved to the 5 nm range. AgNPs demonstrated 5nm size was 
the fastest bactericidal activity in compare to 7 nm and 10 nm (Agnihotria et al., 2012). 
The work in this chapter follows the synthetic route plans by Agnihotr and colleagues for the 
production of AgNPs for application in antibacterial and anti-cancer therapy (Agnihotria, et 
al., 2012).  
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Magnetic iron oxide NPs (MNPs) has significant potential in the recovery of metal ions and 
drug delivery systems (Comoucka et al., 2010; Neuberger et al., 2005). Coating iron oxide 
with silver nanoparticles can be an important step in cancer treatment. Iron oxide has 
shown great potential as a drug carrier, however covering this magnetic core in a  silver shell 
can present unique multifunctional properties permitting for image guidance as well as 
triggered heating (Sotiriou et al., 2010). 
There are a few strategies reported for the synthesis and fabrication of iron oxide – silver 
nanoparticles such as facile one-pot green method (Jau-RungChiou et al., 2013) and 
precipitation-deposition method (Sangili et al., 2019). Jau-RungChiou and colleagues 
reported the one-pot green synthesis of silver/iron oxide compound nanoparticles for           
4-nitrophenol reduction in 2013 (Jau-RungChiou et al., 2013). They could successfully 
synthesize silver/iron oxide compound nanoparticles  via a facile one-pot green method by 
the use of L-arginine. The green synthesis route is a noble way for synthesis metal nano 
particles by using harmless alternative bio compatible molecules such as vitamin B2, 
proteins, starch, amino acids, coffee and tea, d-glucose, peptides, cellulose, soybeans and 
extract as stabilizing and reducing agents (Nadagouda et al., 2008). 
Chiou and colleagues studies demonstrated that when ferrous chloride was used for the 
synthesis of iron oxide nanoparticles, silver chloride was designed instead of metallic silver 
in the followed silver coating (Chiou et al., 2013). However, for synthesising iron oxide they 
used ferrous sulphate. The experimental data showed that, the action rate increased with 
escalating the reaction temperature. Therefore, the best temperature for synthesising was 
70°C according to the research. The silver weight was 8.53% of total product and with a 
pH=10. The particle size for the final product was about 13.8 nm. It displayed acceptable 
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catalytic activity for the reduction 4-aminophenol from 4-nitrophenol by using sodium 
borohydride. The reduction reaction followed the pseudo-first-order kinetics. In addition, 
this product had quite good stability. In their research there was not considerable activity 
loss was happened after reuse for five cycles (Chiou et al., 2013). 
Sangili and colleagues worked on synthesis of silver nanoparticles decorated on core-shell 
structured tannic acid (TA)-coated iron oxide nano spheres (Sangilia et al., 2019). In first 
step, they synthesised TA-Fe3O4-AgNPs monohybrid. In this case, Fe3O4 nano spheres were 
organised by the solvo thermal method.  
The average particle size for iron oxide was about 250 nm. The second step was coating 
Fe3O4 nano spheres by using a thin layer of carbon cell with TA as a carbon source via 
hydrothermal method. Hydroxyl and kenotic group play important role in immobilizing the 
catalytic active species (Sangilia et al., 2019). As the matter of fact, hydroxyl and kenotic 
compounds possess functional groups on the surface of the Fe3O4 nano sphere. In last step, 
Ag ions were added to the product and the ions were adsorbed by the hydroxyl/ ketonic 
group of TA present on the Fe3O4. Consequently, TA can act as an excellent stabilizer and 
green reducing agent to convert Ag ions to AgNPs (Sangilia et al., 2019).  
Joshi et al. investigated the silver and gold nanoclusters have very similar optical properties 
(Joshi et al., 2015). Silver and gold nanocluster's also have so similar crystal structure us ing 
X-ray diffraction. In this case, it would be possible to use synthesis of Fe3O4-Au core-shell 
HNPs for silver nanoparticles as well (Joshi et al., 2015). 
Barnett and colleagues studied on the synthesis of Fe3O4-Au core-shell HNPs with the core 
diameter of 70 nm, using a polymer intermediate ((poly (ethylenimine) (PEI)) (Barnett et al., 
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2013a). These particles finally were PEGylated with PEG-thiol through dative covalent 
bonding between the gold shell of the NPs and the thiol groups (-SH) on the polymer 
(Barnett et al., 2013a). Particles were characterised by the size of particles, Fourier 
transform infrared spectroscopy (FTIR), zeta potential, transmission electron microscopy 
(TEM) and T2 reflexivity. Moreover, The HNP heating potentials were checked to proof any 
physical degradation might happen since first measurement during 6 months (Barnett et al., 
2013a). HNPs were suspended in 3 different contains such as deionised water, the dialysis 
membrane and conical flasks containing 200 mL RPMI cell culture media (in sink condition). 
Media was pH modified from pH 7.2 and 4.5 to mimic blood and lysosomal physiological 
conditions.  
The hybrid formulation was investigated for Fe and Au content by inductively coupled 
plasma-optical emission spectroscopy (ICP-OES). The metal concentration in HNP 
formulation was measured and ICP results demonstrated 3:1 ratio for Fe: Au (wt:wt). FTIR 
spectroscopy was shown the presence of characteristic the PEG coating peaks attributed. 
After six months, there were not any surface alteration and particle size modification which 
was confirmed by ICP and TEM, for the formulation. Zeta potential measurements test 
results also indicated that the gold shell did not degrade during the stability test. The ΔT 
values (change in temperature) achieved upon laser irradiation shown to be stable after six 
months, evaluated to the initial study (Barnett et al., 2013a). 
This work describes the synthesis and characterisation of silver coated iron oxide HNPs 
based on the techniques Barnett and colleagues reported for HNP assembly (Barnett et al., 
2013a). This method is able to synthesis magnetic nanoparticles and also capable coat the 
Iron oxide by AgNPs. As Iron oxide and AgNPs have negative surface charge so it would be 
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hard to stabilize coating, moreover, the iron oxide surface is to smooth. In this case, using 
PEI is so applied method as it had negative surface charge and the difference between the 
surfaces charges can steak the AgNPs strongly to the Fe3O4 coated with using PEI. 
Characterisation of the HNPs will be carried out using a number of analytical and microscopy 
techniques, photon correlation spectroscopy and zeta potential measurement, ICP-OES, 
UV/Visible spectroscopy, photon correlation spectroscopy, laser irradiation and 
transmission electron microscope (TEM). These methods are described below in relation to 
our work.  
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) 
Inductively coupled plasma optical emission spectroscopy (ICP-OES) method has been used 
over the past three decades for various applications and particularly in the quantification of 
metal in nanoparticle synthesis (Parham et al., 2009). This technique is ordinarily used in 
inorganic chemistry to quantify metallic element in systems such as metals concentration 
measurement in hybrid nanoparticles (Warra and Jimoh, 2011).  
A schematic diagram of ICP- OES can be seen in Figure 14 (Boss and Fredeen, 1997). 
Fundamentally by injecting the samples into the ICP, the formation of solid samples 
modified to the liquid state and subsequently this material digest in the acids which mainly 
are hydrochloric and nitric acid. However, the gas and liquid state samples can be injected 
straight into the instrument (Mermet, 2005). In next step, the solution injected as a fine 
aerosol by combining it with a stream of argon gas which acting as a nebulizer (Todolí & 
Mermet, 2006). This aerosol is transferred with argon plasma of around 7000 °C to excite 
the outer electrons of the metals within the sample. After excited state, atoms will rest to 
the ground state through the emission of a photon, which have particular energy level. This 
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energy can be identified via the quantised energy level structure for the atoms or ions. 
Therefore, the wavelength of the photons determines the elements from which they 
originated. Finally, the concentration of element in the sample was calculated by 
considering the photons total numbers (Hou and Jones, 2000).  
The work reported in this chapter will use ICP to confirm the ratio concentration of iron and 
silver in the novel hybrid nanoparticles.  
 
Figure 14: Schematic diagram of ICP-OES (Farias and Smichowski, 1999). 
UV/Visible spectroscopy 
Ultraviolet and visible (UV/Vis) spectroscopy is the main common analytical technique used 
to assess the absorbance of visible light and ultraviolet radiation of materials, usually 
organic compounds with conjugation and transition metals (Dean et al., 2002c).  
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UV/Vis is a valuable tool in most scientific research, to demonstrated metal or ligand binding 
and the stability of compounds and reaction kinetics (Mohamed et al., 2012; Alison and 
Bruce, 2010). The spectral variety is between 190 nm to 800 nm (Brian, 2002). When light is 
adsorbed after passing through the sample, outer electrons are pushed to higher states. 
This is because the electrons energy levels increase by electromagnetic radiation. The 
electrons are kept tightly in single bonds, making them hard to excite but the electrons take 
in double and triple bonds are kept less strong and can be exited even more. UV/Vis 
spectrometer includes of an appropriate wavelengths radiation source, tools for isolating 
light to a single wavelength (monochromator and optical geometry), a sample container for 
set up the test sample and convert them to the light beam and lastly a sensor to assess the 
light intensity (Figure 15). 
 
Figure 15: Simplified UV-vis diagram (Bordoloi, 2017) 
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Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is a useful technique for detecting the surface of 
materials with more details based on shape and size. TEM has been used to image 
nanomaterials, measuring of particle and/or grain size, size distribution, and morphology. In 
this technique, a beam of electrons with high energy is allowed to pass through a very thin 
layer of specimen which causing scattered by the internal structures (Joyce et al., 2015) 
(Figure 16). 
TEM like other microscopic techniques is used for observing the surface of materials at a 
detail too high for the naked eye. Conventional optical microscopes use a series of lenses to 
magnify the images of materials to a size visible with the naked eye. However these lenses 
diffract visible light and are limited by the Abbe diffraction limit, which is the point where a 
microscope cannot distinguish two objects close to each other. The condition of images 
depends on the contrast of the sample relative to the background. The samples were made 
by drying NPs on a copper grid, which is coated with a thin layer of carbon. Chemicals with 
high electron densities such as carbon nanotubes, metals (copper, silver, gold and etc.) and 
metal oxides (iron, titanium and silica oxides), polymer NPs and quantum dots can be easily 
imaged compared with amorphous carbon. Consequently, TEM can be useful technique for 
observing size and shapes of nanoparticles in each step of synthesising (Douglas B, 2002). 
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Figure 16: Schematic diagram of TEM (Wikimedia Website). 
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Photon correlation spectroscopy 
Photon correlation spectroscopy (PCS) is based on the dynamic light scattering of a laser 
beam of a certain wavelength by particles or macro-molecules in a liquid medium. PCS 
known as dynamic light scattering (DLS) and this technique was developed by Robert Pecora 
in 1964 (Pecora, 1985). A schematic diagram of PCS can be seen in Figure 17. 
 
Figure 17: Schematic diagram of PCS (Lee et al., 2016). 
PCS is used to identify macromolecule and nanoparticle size in solution. This technology is 
non-destructive and non-invasive. When small particles are exposed to the incoming light, 
the light will scatter in all directions. If the light supply coherent and monochromatic laser 
by moving particle and their speed level, PSC can detect dispersion intensity randomly in the 
solutions (Lee et al., 2016) 
Large particles move more slowly in a liquid than smaller particles, speed of motion is used 
to measure by the PSC (Figure 18). The existed small particles in the liquid expose in PSC 
light, so the dispersion intensity of scattering light measure by the detector.  
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 The dynamic data of the particles is originated by an auto-correlation of the intensity trace 
recorded all over the procedure (Sibilia, 1996).  
 
Figure 18: Particles size effect on the particles movement (Sibilia, 1996). 
Zeta potential measurement 
Zeta potential is a parameter that measures the electric potential energy of nanoparticles at 
their surface and compared with the charge of the particle-liquid interface and also 
standard technique to understand the stability of colloidal dispersions (Ruiz-Cabello et al. 
2014).  
When the potential is small, influence changings can be more than the revulsion and the 
light spreading may break simply. Colloids with higher zeta potential (negative or positive) 
are more and better electrically stabilised than colloids with low zeta potentials. For 
molecules and particles that are small enough, a high zeta potential will grant stability, i.e., 
the solution or diffusion will resist aggregation. Patel and Agrawal classified the zeta 
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potentials by stabilities, according their research the zeta potential  between ±0-10 mV, 10-
20 mV, 20-30 mV and 30+ mV are considered “highly unstable”, “relatively stable”, 
“moderately stable”, and “highly stable” respectively (Patel & Agrawal 2011). These 
particles will aggregate more, which leads to low stability. In contrast, high surface charge 
represents strong repulsive forces between particles, resulting less aggregation, and higher 
stability (Bhatta et al. 2016). 
Laser irradiation 
Laser irritation is putting the materials under fast and restricted energy for creating 
situation of electronic and thermodynamic non equilibrium. When a laser is irradiated to a 
sample surface, the surface reflects a ratio of the energy and also absorbs the rest of that. 
The reflection depends on the material and the laser wavelength (Zhigilei et al., 2009). The 
adsorbed energy is transmitted from optical photons to electrons and subsequently to the 
lattice, resulting diffusion of the energy into the material (Liu, 2005). The laser‐induced heat 
can be localized in the materials and lead to heat generation by the material. Metal oxides 
are of significant interest for Biological applications. Investigation of the localized heating 
effect due to the laser irradiation on the particle is required to prevent unwanted thermal 
effects (Palneedi et al., 2018). 
There are numerous researches about the metal nanoparticles thermal effects when 
exposued under laser irradiation. Tsuji et al. investigated morphological changes from 
spherical silver nanoparticles to cubes after laser irradiation in acetone–water solutions. 
According to the research, the shape changes of spherical AgNPs observed in acetone–water 
mixed solutions after they were laser-irradiated and left for 1–14 days. Results of 
observations of Ag NPs after preparation confirmed that AgNPs formation occurred 
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automatically after laser ablation and laser irradiation. The silver nanoparticle changes lead 
to increasing thermal properties and it can be useful for destroying cancer cells . Moreover, 
results suggest that acetone and ethanol would act only as stabilizing reagents. Instead, 
water plays an important role in atom transfer (Tsuji et al., 2018). 
Aims and objectives  
The aim of this study is to synthesise hybrid iron oxide-silver core-shell NPs and characterise 
them in order to ensure the correct structures were fabricated. After synthesising the hybrid 
nanoparticles, they will be characterised for their surface charge, size, shape, concentration 
and the capability of HNPs to heat after laser irradiation.  
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2.2. Materials and methods 
Materials used 
Table1. Materials used in synthesis and characterisation of HNPs. 
Materials Suppliers 
Potassium nitrate Sigma-Aldrich Co., UK 
Sodium Borohydride ACROS Organics Co., 
Ethanol Sigma-Aldrich Co., UK 
Trisodium Citrate Sigma-Aldrich Co., UK 
Copper grid Agar Scientific Co., UK 
Iron III Sulphate Hydrate ACROS Organics Co., USA 
Chloroform Sigma-Aldrich Co., UK 
Silver Nitrate Sigma-Aldrich Co., UK 
Nitric Acid Sigma-Aldrich Co., UK 
Hydroxyl amine Sigma-Aldrich Co., UK 
Poly(ethyleneimine) (PEI) (ave. Mw=750 kDa) Sigma-Aldrich Co., UK 
Chloroauric acid Sigma-Aldrich Co., UK 
Hydrochloric acid Sigma-Aldrich Co., UK 
Poly(ethyleneimine) (PEI) (ave. Mw=2 kDa) Sigma-Aldrich Co., UK 
Sodium hydroxide Fisher Scientific Co., UK 
Sulphuric acid Sigma-Aldrich Co., UK 
Copper grid Agar Scientific Co., UK 
Iron and Gold standard for ICP Fluka analytical 
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Methods 
The synthesis and characterization of iron oxide and coating that with PEI and silver was 
inspired by Barnett et al. research in 2013 and also Goon and colleagues in 2009, which 
involved using a ‘‘polymer cushion’ of PEI between the magnetic iron core and the outer 
gold shell which called indirect gold coating (Goon et al., 2009; Barnett et al., 2013). Iron 
oxide core was synthesised through coprecipitation method (Sugimoto et al., 1980).  
Synthesis of iron oxide core 
Sodium hydroxide (NaOH, 1.03 g) and 1.82 g potassium nitrate (KNO3) were dissolved in 
180mL deionised water at 90 °C under nitrogen (N2) for 1 h. Iron (III) Sulphate heptahydrate 
(FeSo4.H2O, 3.89 g) was dissolved in 20 mL, 0.01 M sulphuric acid (H2SO4). The mixtures 
were added to the reaction with stirring for 24 h at 90 °C under N2. After 12 h, the reaction 
was cooled in ice and the particles were magnetically separated from solution. The 
supernatant was removed after using a strong permanent magnet on the outside of a glass 
vial containing the iron oxide NPs to separate the magnetic material from the solvent. This 
magnetic fraction was washed 6 times and suspended in deionized water. Then particles 
were kept in 15 mL deionized water and after 1 week was characterised by zeta potential 
measurement and photon correlation spectroscopy and transmission electron microscopy 
for measuring and identifying the particle size and potential surface charge. 
Polymer coating of iron oxide nanoparticles  
The iron oxide nanaoparticles (5 mL) was added to 20 mL poly (ethylenimine) (PEI, MW 
750,000) (5 mg mL-1, pH=9) (C2H5N) and sonicated for 2 h. The particles were washed 6 
times with deionised water and were magnetically separated from solution with magnet. 
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The final particles re-suspended in 5 mL deionized water. The surface charge of the particles 
was monitored via zeta potential measurement.  
Synthesis of colloidal silver seed nanoparticles 
The synthesis of AgNPs was according co-reduction method employing two different 
reductants (i.e., NaBH4 and TSC) (Agnihotria et al., 2012).  In this case, 0.007 g sodium 
borohydride (NaBH4) was added to 0.110 g trisodium citrate (TSC) in 100 mL deionised 
water. The mixture was mixed and heated to 60 ◦C for 0.5 h in the dark coated Erlenmeyer 
with maximum stirring to ensure a homogenous solution. 0.016 g silver nitrate solution was 
added drop wise to the mixture and subsequently, after adding silver nitrate the 
temperature was raised to 90 °C and pH of the solution was adjusted to pH 10.5 with using 
0.1 M NaOH (0.04 g) for 20 min until a change of colour was evident.  
The nanoparticles were cooled at room temperature to removing any unreacted starting 
material and also the bigger sized silver nano particulates.  AgNPs suspensions were 
centrifuged (16128 RCF) for 15 min 3 times. After each centrifuge, 50 mL of top part of test 
tube was taken and 50 mL deionised water was added to tube. Finally, the AgNPs were kept 
at 4 °C. The AgNPs were characterised by zeta potential measurement and photon 
correlation spectroscopy and transmission electron microscopy for measuring and 
identifying the particle size and potential surface charge. 
Polymer coating Fe3O4-PEI-AgNPs 
Colloidal silver (50 mL) was added to 5 mL Fe3O4 – PEI and stirring for 2 h at room 
temperature. The magnetic particles were magnetically separated from solution and 
washed 6 times with deionised water. Deionised water (5 mL) was added to the mixture. By 
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coating Fe3O4 – PEI by AgNPs the surface charge must shift from the positive value toward 
the negative charge due to the presence of AgNPs coating. In this case, the hybrid 
nanoparticles were characterised by zeta potential measurement and photon correlation 
spectroscopy and transmission electron microscopy for measuring and identifying the 
particle size and potential surface charge and also the shape of hybrid nanoparticles which 
must not be smooth surface due presenting AgNPs.  
Silver seeds coating of iron oxide nanoparticles-PEI 
Fe3O4 – PEI –AgNPs (5 mL) were stabilised by stirring in a solution of 5 mL of 1 mg mL
-1 PEI 
(MW 2000) for 20 min. The particles were washed extensively with deionised water 6 times 
and re-suspended in 5 mL deionised water. By coating HNPs by polymer the surface charge 
must shift from the negative value which has achieved from last step toward the positive 
charge due to the presence of PEI coating again. 
Silver coating process  
Sodium hydroxide (NaOH, 100 mL, 0.01 M) was mixed with the particle solution at 60 °C. In 
order to achieve a complete shell silver was reduced onto the particle surface. To do this 
0.5 mL of 1% AgNO3 was added followed by hydroxyl amine (NH2OH·HCl, 0.75 mL, 0.2 M). 
Two consecutive iterative reductions were carried out by addition of 1% AgNO3 (0.5 mL) and 
0.2 M NH2OH·HCl (0.25 mL) with 10 min intervals for four times.  
The final particle solution was stirred for 0.5 h then the product was washed at least five 
times by water and separated by magnetic. Final product was added by 5 mL of water and 
left for 1 week in case of confirming the product stability (Figure 19). The final product was 
characterized by zeta potential for potential surface charge, UV/Vis spectroscopy upon the 
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complete coating, photon correlation spectroscopy and transmission electron microscopy 
for measuring and identifying the particle size, ICP for the ratio between silver and Iron in 
the final product and also Laser irradiation in case of checking the HNPs thermos 
capabilities.   
 
Figure 19: Schematic diagram of silver coating process. 
Characterisation of hybrid nanoparticles  
Photon correlation spectroscopy and zeta potential measurement  
Hydrodynamic diameters and zeta potential measurements were carried out using a photon 
correlation spectrometer (PCS, Zetasizer nano-ZS, Malvern Instruments, UK). The amounts 
of particle size and zeta potential changes were investigated from first to last steps of iron 
oxide coatings. 
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Inductively Coupled Plasma - Optical Emission Spectroscopy (ICP-OES)  
For determining the concentration of metal content in the HNPs, inductively coupled 
plasma-optical emission spectroscopy (ICP-OES, Optima 7000V DV, PerkinElmer, 
Wokingham, UK) was used. Before the HNP analysis; samples were dissolved using an acid 
digestion procedure (1:10 sample: acid). This digestion is carried out using a concentrated 
solution of hydrochloric acid: nitric acid (1:1) at 100 °C. Samples then diluted with deionised 
water (1:10) to be ready for analysis (Barnett et al., 2012). Before testing the samples, a 
calibration was run using iron and silver standard solutions 0.05 – 10 ppm (R2 = 0.9999). The 
concentration of HNPs used for all experiments indicates the concentration of Fe.  Finally, 
the final sample concentrations were calculated by using standard curves data’s by using the 
Microsoft Excel software package. 
Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is the one of the most powerful and popular 
technique to characterize nanoparticles (Wang et al., 1999). TEM was used to visualize the 
particles. TEM grids were coated with chloroform and the grids were left to be dry for 1 day.  
Samples were pipetted onto formvar coated copper grids (2μL) and dried under a heat lamp 
for 4 h. The grids were directly imaged using a JEOL JEM-1230 microscope with Analysis 
software (JEOL, Japan). 
Ultraviolet- visible spectroscopy (UV/VIS) 
The samples include iron oxide NPs, Silver seeds and HNPs in deionised water was were 
aliquoted into quartz cuvettes and their absorbance monitored on Ultraviolet- visible 
spectroscopy (UV-VIS) system and scanned between 200 – 800 nm (Agilent Technologies, 
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Cary 60). All measurements were run in triplicate at room temperature (25 °C) and recorded 
as average values. 
Laser Irradiation 
The ability of the HNPs to act as localised nano-heaters was determined using laser 
irradiation. Agar (2 g) was diluted in 100 mL water and heated up to 60oC until the mixture 
changed to the clear solution. The gel (0.076 mm diameter, T-type, PFA coated, Omega, UK) 
has been used in various studies as a mimic for biological tissues (Curtis et al. 2015).       
We used the gel to provide the conditions like tumour environment for indicating the        
HNP heating capability. The particles were suspended in 2 % agar at both 25 μgmL-1 and            
50 μgmL-1. The dispersed HNPs in agar were allowed to cool to form gels in 35 mm diameter 
plastic petri dishes. Samples were exposed to pulsed laser beam (10 ns, 1 W, 6 Hz) emitted 
by a solid state laser system (Ng: YAG pulsed 1064 nm). It is assumed that laser irradiation at 
1064 nm should cause localised heating of the HNPs without heating of biological tissues.  
Moreover, laser systems using 1064 nm pulsed sources are widely used both in the cosmetic 
industry for tattoo removal and hair removal and also in clinical settings for ophthalmic 
treatment (Tanaka et al., 2011). In first step, simple gel was equilibrated to 37oC to mimic 
body temperature by oven. The gels were then exposed to wave laser beam for 30 s and the 
temperature monitored using an Optris PI640 Thermal Imaging Camera (Optris, Germany). 
The data was recorded on Optris PI Connect software (Optris, Germany). The temperature 
changes for HNP was suspended in 2 % agar at both 25 μgmL-1 and 50 μgmL-1 were 
compared to control gels with no HNPs present and the thermal changes were calculated 
within the Microsoft Excel software package (ΔT = (Tfinal– Tinitial) − ΔT control).  
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For measuring the heat dissipation the samples were exposed to laser irradiation at 1064nm 
using a ML- LASER-YB5 Q-switched Nd:YAG Laser Treatment System (WeiFang MingLiang 
Electronics Company Ltd, China).  Heat dissipation analysis away from the laser culmination 
point was measured and analysed for 0s, 10s, 20s and 30s. In this case the thermal imaging 
camera (Optris PI640) was positioned 5 cm away from the gel and focussed on the 
irradiation site. The laser culmination point possessed at the highest temperature and the 
heat in the gel at set distances (1, 2, 3, … 10 mm) from this were recorded in order to give 
an indication of how localised the heating would be in vivo.   
2.3. Results 
The iron oxide cores and subsequent PEI coating were successfully achieved as per the 
literature and confirmed with PCS, zeta potential measurement and TEM. TEM imaging 
represented a precise view of the Fe3O4 shape and size, which was 80 nm (n = 20, SD = ± 
4.88) (Figure 20). The TEM micrograph demonstrated the smaller particle sizes in compare 
with photon correlation spectroscopy (PCS). This phenomenon is possible due to the very 
small fraction of the sample represent in TEM image. On the other hands, a number of 
factors have a great influence on the hydrodynamic diameter of the particles measured by 
dynamic light scattering such as polymer shells, hydration layer or other stabilisers, which 
lead the particles size to be seen larger by PSC (Heinz et al., 2014). 
Basically PSC has been used in each step of coating to demonstrate the size changes in each 
level. The particle size was decreased from Iron oxide to HNP in each step of synthesis and it 
could be due to decreasing particle agrigation. 
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Figure 20: Size and shape estimations of Fe3O4 nanoparticles analysed by TEM. 
The Iron oxide had negative surface charge of -22.67 ± 0.96 mV which due to the surface 
sulphate associations from the synthetic procedure (Hoskins et al., 2012a). The surface 
charge potential was changed to + 46.40 ± 0.68 mV when iron oxide core coated with PEI 
and the main reason is the presence of the positively charged primary amine groups in the 
PEI backbone (Table 2). 
Table2. Hydrodynamic Radius, polydispersity index and zeta potential analysis for 1 mg mL-1 
aqueous polymer solutions n=3, ave (SD). 
Particle Hydrodynamic Radius 
nm ± SD 
Polydispersity 
Index ± SD 
Zeta Potential 
mV ± SD 
Fe3O4 846.97± 0.21 0.30±0.05 - 22.67±0.96 
Fe3O4-PEI 590.77±59.01 0.31±0.06 + 46.40±0.68 
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Synthesis of silver nanoparticles and silver coating characterisation 
One major difficulty faced in this work was the repeatable synthesis of silver seed 
nanoparticles for attachment onto the Fe3O4-PEI which act as anchor points for subsequent 
coating. Silver nanoparticles have high surface area which might be lead to poor colloidal 
stability and aggregation in solution (Wu et al., 2010).  
Hence, the method development took a long time to complete. Multiple attempts at 
synthesis were hindered mainly by the aggregation of the silver seeds, whereby, particle 
sizes at approximately 30 nm were formed. This was far above the size required for seeding 
onto the Fe3O4-PEI. Moreover just a little number of AgNPs was attached on the Fe3O4-PEI 
surface after washing the particles.  
The main concern regarding the particle size was in order to make the ‘seeds’ small enough 
to attach onto the Fe3O4-PEI for subsequent coating. If the particles were too large the final 
silver coat would be very thick, studies have shown for gold hybrid NPs that the thinner the 
coat the better plasmonic properties observed (Barnett et al., 2012). Hence, a smaller seed 
particle size was desirable but this was very difficult to achieve in reality and a lot of method 
development was required at this stage. Previous researches demonstrated that they could 
achieve gold nanoparticles by 2 – 5nm size; however the lowest size of silver nanoparticles 
was around 25 – 30 nm by using this method (Barnett et al., 2012). Table 4 demonstrated 
some of attempts for synthesising silver nanoparticles which were failed in different dates 
by PCS. In this case some of factors like temperature or mixing substances time were 
changed but it did not have significant change in the silver particle size (Table 3).  
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Table3. Failed attempts in synthesising silver nanoparticles by PCS. 
Different Batches  Hydrodynamic Radius 
nm ± SD 
Polydispersity 
Index ± SD 
Zeta Potential 
mV ± SD 
Batch 1 25.56± 3.58 0.25±0.15 - 13.6±14.58 
Batch 2 36.61±5.55 0.35±0.18 - 25.69±0.93 
Batch 3 24.6±1.25 0.21±0.05 - 1.68±1.52 
Batch 4 12.57±26.81 0.25±0.62 + 1.19±0.37 
Batch 5 12.68±1.65 0.32±0.25 - 3.58±1.55 
Batch 6 66.02± 0.56 0.31±0.20 - 1.58±1.89 
Batch 7 11.09±2.08 0.28±1.77 +11±4.81 
Batch 8 39.15±3.55 0.32±2.11 - 60.57±2.58 
Batch 9 10.57±8.20 0.12±4.81 + 1.19±0.37 
Batch 10 13.55±1.74 0.33±1.17 - 41.77±0.91 
Batch 11 80.17± 3.10 0.39±4.10 - 20.20±12.71 
 
The other concern was about silver stability. In other studies, silver nanoparticles were 
synthesised around 8 nm in diameter, even though, silver was not stable and the particle 
were aggregated after couple of weeks (Kholoud & Abou, 2010). When we tried this 
methodology the silver seeds were highly unstable aggregated after couple of weeks. TEM 
results demonstrated the aggregated silver nano particles with bigger sizes than PSC results 
for silver nano particle size after 8 weeks from synthesising (Figure 21A and 21B).  
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Figure 21A and 21B: TEM micrographs of aggregated silver seeds.  
This stability issues was not really an issue for this work as the seed particles could be 
synthesised and then immobilised onto the Fe3O4 surface for subsequent coating. However, 
The TEM demonstrated that the lower numbers of silver nanoparticles were attached on 
Fe3O4-PEI surface charge by using this method as well (Figure 22A and 22B) (Kholoud & 
Abou, 2010). 
  
Figure 22A and 22B: Failed TEM result for attached AgNPs on Fe3O4-PEI. 
 
69 
 
The optimal synthesis of AgNPs in this work was carried out as Agnihotr and colleagues 
described (Agnihotria, et al. 2012). The method involves the synthesis of AgNPs with 
different size and demonstrated that AgNPs with 5 -10 nm was using co-reduction method 
employing two different reductants (i.e., NaBH4 and TSC) (Agnihotria, et al., 2012).   
Once the silver colloid methodology was deduced the HNP synthesis was easily achieved as 
evidenced by PCS, zeta potential measurement, ICP and TEM as described in the sections 
below. The change in physical appearance can be seen in Figure 23. 
 
Figure 23: Colour changes from Fe3O4 to Fe3O4-PEI-AgNPs. 
ICP allowed for the measurement of elements of Fe and Ag presented within the HNPs and 
their ratios in order to quantify their concentration and ratios (Malekigorji et al, 2017). 
Water blanks were analysed against the calibration curves to ensure all false positives were 
removed. In first step standard solutions were created for standard carve and the 
formulation of y = ax ± b were used to find the final concentration for silver and iron. The 
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maintained regression linearity (R2) was 0.99 over the calibration range of 0 – 10 µg L-1 in 
single particle analysis mode (Barnett et al., 2013a) and (Hoskins et al., 2012b) (Figure 24).  
 
Figure 24: ICP standard curve. 
The second major difficulty faced in this work was the repeatable synthesis of silver coating 
process. For the silver coating, some ICP data demonstrated that the ratio of iron to silver 
was much greater than 3:1 in the HNP. The ICP result wasn’t same as previous researches 
(Barnett et al., 2013a; Hoskins et al., 2012b) (Table 4). In this case the silver coating process 
method was repeated to achieve ratio of 3:1 for Fe and Au. This ratio was desirable as  the 
data agrees with the TEM images, whereby a coating of similar thickness was obtained for 
both particles in this ratio. The ICP test was repeated 6 times for 3 different batches of HNPs 
showing that the standard deviations and means are reliable and the synthesis protocol is 
reproducible. 
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Table4. Failed attempts in synthesising HNP by ICP. 
Batches Silver Concentration (mg mL-1 ± SD) Iron Concentration (mg mL-1 ± SD) 
Batch 1 0.29±13.63 54.93±1.36 
Batch 2 0 0.28±0.94 68.69±0.88 
Batch 3 0.45±2.51 254.17±0.73 
Batch 4 0.13±9.91 24.59±22.47 
Batch 5 0.93±0.57 98.32±21.50 
Batch 6 0.61±3.22 14.83±0.66 
Batch 7 0.26±3.27 68.10±0.81 
Batch 8 0.27±1.02 43.53±0.40 
Batch 9 0.29±1.88 54.93±0.72 
 
According to the three different batches ICP results, the average iron concentration was 
2.865± 3.18 mg mL-1 and silver concentration was 0.733 ± 2.44 mg mL-1. 
The ICP data demonstrates that iron oxide core was successfully coated with silver forming 
the HNPs with a ratio between Fe and Ag of 3:1. ICP analysis for Fe and Ag was run 6 times 
for 3 different batches of HNPs showing that the standard deviations and means are reliable 
and the synthesis protocol is reproducible. 
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Photon correlation spectroscopy and zeta potential measurement 
The hydrodynamic radius of Fe3O4 core and HNP was 846.97 ±0.21 nm and 100.29 ± 0.91 nm 
respectively, which determined by photon correlation spectroscopy (Figure 25).  
 
Figure 25: Particle size from F3O4 to HNP and AgNPs. 
For iron oxide to HNP, a large diameter was obtained due to the inherent magnetic 
properties of the iron oxide cores. Silver nanoparticle did not have magnetic properties. The 
particle size for AgNPs were synthesised with 8.1 nm± 1.07 nm. The particle size was shift to 
smaller size as the coatings in each step decreased the aggregation of the particles.  
The reactions were monitored using zeta potential measurements. The zeta surface 
potential also was shown the amount of changes from Fe3O4 to HNP (Figure 26).  
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Figure 26: Surface charge from F3O4 to HNP and AgNPs 
The Fe3O4 had negative surface charge of -22.67 ± 0.96 mV which due to the surface 
sulphate associations from the synthetic procedure (Hoskins et al., 2012a). The surface 
charge potential was changed to + 46.40 ± 0.68 mV when iron oxide core coated with PEI 
and the main reason is the presence of the positively charged primary amine groups in the 
PEI backbone (Table 2). The silver nanoparticles surface charge was -58.17 ± 0.68 mV 
because of the negatively charged silver atoms and this negativity amount was reduced to    
-12.63 ± 1.02mV when the AgNPs were added to Fe3O4-PEI. As the data shows, the surface 
charge was changed to +11.63 ± 0.68 mV after coating Fe3O4-PEI-AgNPs with PEI, and finally 
the HNP product possessed a surface charge of -3.05 mV ± 0.29 mV (Figure 26). The surface 
charge potential changes indicated that the HNPs were successfully synthesised. 
The poly dispersity index (PDI) of particles demonstrated that they possess homogeneous 
distribution within the formulation as PDI from Fe3O4 to Fe3O4-PEI-Ag seeds-PEI were 0.3 to 
0.381 respectively and also the PDI was 0.4 for final product. This increase could be due to 
the presence of small fraction of free silver seeds in formulation leading to more 
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polydispersity samples; these could easily be removed by centrifugation or magnetic 
separation (Table 5). 
Table 5. Hydrodynamic Radius, polydispersity index and zeta potential analysis for 1 mg mL-1 
aqueous polymer solutions n=3, ave (SD). 
Particle Hydrodynamic Radius 
nm ± SD 
Polydispersity 
Index ± SD 
Zeta Potential 
mV ± SD 
Fe3O4-PEI-Ag seeds 623.13±64.07 0.37±0.04 - 12.63±1.02 
Fe3O4-PEI-Ag seeds-PEI 348.57±87.87 0.38±0.08 + 11.63±0.68 
HNP 100.29±0.91 0.40±0.01 - 3.05±0.29 
 
Transmission electron microscopy imaging (TEM) 
The TEM micrograph represented a precise view of the Fe3O4 (Figure 20) (refer to page 65), 
AgNPs (Figure 27), Fe3O4-PEI-AgNPs (Figure 28A) and HNP (Figure 28B), sizes and shapes. 
Silver nanoparticles (Figure 27) were represented the size of 5 nm. The shapes 
demonstrated that AgNPs were not aggregated after 6 weeks from synthesising.  
 
Figure 27: Size and shape estimations of silver nano-seeds analysed by TEM 
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Figure 28A was demonstrated the TEM image of the fully coated Fe3O4-PEI coated with Ag 
seeds displayed unique shape and different from the iron oxide core and the size is 85 nm    
(n = 20, SD = ± 3.29) and finally we could get the particle size with 90 nm (n = 20, SD = ± 
3.90) for the HNPs (Figure 28B). 
  
Figure 28: TEM micrographs of A) Fe3O4-Auseed and B) HNPs. 
Ultraviolet- visible spectroscopy (UV-VIS) 
The use of Ultraviolet- visible spectroscopy (UV-VIS) is one method to identify the presence 
of an absorbing species in solution. UV-Vis is based on the Beer–Lambert law. This law state 
that the absorbance of a solution is directly related to the concentration of the absorbing 
molecules in the solution (Bouguer, 1729). UV-visible spectroscopy was carried out to 
achieve absorption spectra of the particles (Figure 29) in order to determine the wavelength 
at which maximum absorbance occurred (λmax). This value is indicative of the wavelength 
which is required for maximum efficiency of laser mediated heating at the surface plasmon 
resonance of the particles. 
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Figure 29: UV/Vis spectra of Fe3O4, Fe3O4-PEI, Ag seed, Fe3O4-PEI-Ag seeds and HNP. 
According to the UV chart there is no plasmon resonance appears for Fe3O4 and Fe3O4-PEI 
because of lack of presence of silver in these particles. Ag seeds have λmax of 400 nm. 
Fundamentally, when UV light is applied to the AgNPs, polarization of free electrons occurs 
which can lead to a charge separation. Consequently, the surface plasmon resonance (SPR) 
persuades a strong absorption of the applied light which can be measured by using a UV/Vis 
spectrometer (Xiaohua and Mostafa, 2010). The Fe3O4-PEI-Ag seeds indicate λmax shift to 450 
nm which might be due to the interaction between solute and solvent or Ag shell and PEI 
polymer. The λmax of 490 nm was observed for HNP. According to the previous researches 
the different NPs size and shape can effect on light absorption range (John et al., 2013; 
Hainfeld et al., 2014). The λmax shift is confirmation that the HNPs were successfully 
synthesised. However, the value of 490 nm was somewhat lower than expected. The peak 
although very broad did not appear to spread into the region of 1064 nm which was the 
wavelength of the laser system used for subsequent heating studies. Ideally a laser around 
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490 nm may result in better heating of the particles. However caution is advised as this sits 
below the biological near infrared window whereby tissue is not damaged. At 490 nm laser 
irradiation would likely result in tissue ablation which is not the focus of this s tudy. 
Absorbance is measured in absorbance units (Au), which relate to transmittance as seen in 
figure 29. A silver nano particle has less than 1.0 Au and the other nano particles have 1.5 – 
2.6 Au. In fact, higher concentrations at the other particles (In comparison with silver 
nanoparticle) can lead to decreasing transmittance inherently. It can lead to have higher 
absorbance units in comparison with silver nanoparticle.   
Laser irradiation  
Despite the low λmax value, the laser irradiation studies were carried out in order to evaluate 
whether using a laser of 1064 nm (known to be safe for use in cosmetics) could induce 
localised heating in the HNPs. The rationale was that thermo-responsive drug delivery 
would result in localised drug release resulting in localised tumour damage with minimum 
damage to the surrounding normal tissues. The hybrid nanoparticles with different 
concentrations (25 μgmL-1 and 50 μgmL-1) were dispersed within the agar phantom. This 
particular agar phantom was used as it mimics the stiffness and physiology of human tissue 
(Tanaka et al., 2011). The particles were initially equilibrated to body temperature before 
being irradiated (Ng: YAG pulsed 1064 nm, 1000 V, 6 Hz) at oven. The change in 
temperature was monitored both inside beam and outside beam using an infrared camera.  
Initially, the experiment was set up for 60 s irradiation, however, it was observed that the 
agar phantom began to melted and rip inside laser beam point when the temperature 
exceeded 47 – 50 °C. Therefore, in order to be confident that the measurements taken were 
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not subject to phase change in the agar the experiment was conducted over 30 s duration to 
overcome this issue. 
The amount of temperature change for simple agar (control) was maximum 2.3 °C. All data’s 
have subtracted from the control temp. All tests were carried out for three different batches 
of 25 μgmL-1 and 50 μgmL-1 of the HNPs in 37 °C for 30 s. Figure 30 demonstrates the laser 
irradiation for 25 μgmL-1 and 50 μgmL-1 HNPs in 37 °C for 30 s (subtracted from the control 
temperature). 
 
Figure 30:  Laser Irradiations for 25 μgmL-1 and 50 μgmL-1 HNPs dispersed in 2 % agar gel in 
37 °C for 30 s. 
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When the samples exposed to laser irradiation, the 25μgmL-1 HNP has sharp increased (4 oC) 
in first 5 s. The temperature went up to more than 7 oC in 25 s. The temperature appeared 
to plateau towards 30 s. At concentrations 25 μgmL-1 HNP temperature was increased to 
44.5 °C ± 0.35 at 37 °C for 30 s (p >0.05). According to the data there were minimal 
deviations which occurred between different batches of 25 μgmL-1 HNP = p >0.05 or 50 
μgmL-1 HNP = p >0.05. However, the results demonstrate that there are significant changes 
between times, concentration between different HNPs in compare with the control              
(p <0.05). 
At concentrations 50 μgmL-1 HNP temperatures increased to 48 °C ± 0.56 in after 25 s              
(p >0.05) The data demonstrates high increasing temperature in first 5 sec followed by a 
more discrete rise up to 15 s, after which a plateau was observed.  
According to the data, the steepest rise in temperature increase occurred consistently 
within the first 5 s of irradiation. The temperature went up for 5.8 oC at 25 μgmL-1 HNP and 
9.2 oC at 50 μgmL-1 after 10 s (p <0.05). The temperature in the 25 μgmL-1 sample increased 
7 oC and 11 oC in the 50 μgmL-1 after 25 s and the temperature were stable during 30 s (p 
>0.05). A similar trend was observed across the irradiation duration. Consequently it could 
be concluded that the extend of temperature change is dependant less on time of 
irradiation, given that most samples heated within the first 10 s and also increased 
concentration does result in increased temperature rises, though the extent of which may 
not be significant for application. 
The heat dissipation analysis away from the laser culmination point was measured and 
analysed for 0, 10, 20 and 30 s. It was assumed that since the HNPs were spherical that heat 
distribution was equal at all points of the spheres exterior resulting in a uniform halo like 
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effect (Curtis et al., 2015). In this case, the laser culmination point possessed the highest 
temperature and the heat in the gel at set distances from this were recorded in order to 
give an indication of how localised the heating would be in vivo. Figure 31 indicated the 
temperature changes of the different HNP concentration on the agar across the 10mm. 
 
Figure 31: The heat dissipation between 25 μgmL-1 HNP and 50 μgmL-1 HNP (n=3, ±SD). 
According to the chart, at 25 μgmL-1 HNP there is not heating effect occurred in 8 mm from 
the laser irradiation site in 0 s. Moreover when 25μgmL-1 HNP exposed in laser irradiation 
for 10 s, heat dropped from 43oC and there is not heating effect in 10 mm. At same HNP 
concentration, there are small heating effect in 10 mm distance from laser irradiation and 
the temperature were 0.3 oC and 1 oC higher than body temperature in 20 and 30 s 
respectively (p >0.05). 
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At 50 μgmL-1 HNPs there are still experiencing heating effects at 10 mm distance. The graph 
showed that in 1 mm distance from laser irradiation the temperatures were 43.5oC, 46oC, 
47.3 oC and 47.5 oC in 0 s, 10 s, 20 s and 30 s respectively. The temperatures were dropped 
to 38.5 oC, 40 oC, 41 oC and 41.2 oC in 0 s, 10 s, 20 s and 30 s, respectively (p <0.05). 
According to the chart the heating distribution was too wide and it can damage to surround 
healthy tissue. 
According to the graph even though the increasing concentration can raise the heating 
generation ability, it can spread heating more and it cause to damage to the surrounding 
cells from laser point. Generally, these data’s can proof that the HNPs can be useful for 
thermal applications such as for ablation or thermal responsive switches for drug delivery. 
However, the heating spreads was better performance in lower concentration and it can 
cause to lower damage to surround healthy tissue. 
2.4. Discussion 
The results demonstrated that the hybrid iron oxide-silver nanoparticles were successfully 
synthesised. As discussed in the results section the synthesis of the silver colloids was the 
rate limiting step for this whole study with the method development taking up to 1.5 years. 
Eventually, the Agnihotr and colleague method was identified as the optimal synthetic route 
for synthesis silver nanoparticles in 5 nm size. This method helps to connect silver seeds on 
the Iron oxide smooth surface and also increase the silver properties to act as strong anti -
cancer agent (Agnihotria, et al., 2012). The iron oxide synthesis and coated with PEI by using 
Barnett et al. research in 2013 and also Goon and colleagues in 2009 methods.  
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Generally, the colour was changed in each step of iron oxide coating according to the Figure 
23 which can be indicated the chemical reaction in each step. In each step of synthesising 
the sample were characterised by photon correlation spectroscopy and zeta potential 
measurement. The particle sizes were measured in each step for checking and confirming 
the nanoparticle size. The surface charge constantly shifted between positive and negative 
surface charges between iron, silver and PEI during coating as expected and in agreement 
with the Barnett and Malekigorji gold-iron oxide HNP studies (Barnett et al., 2013; 
Malekigorji et al., 2014). 
The iron oxide surface charge was - 22.67 ±0.96 mV and by coating iron oxide with PEI the 
surface charge shift to + 46.40 ± 0.68 mV. The silver seeds and the surface charge when it 
coated on the Fe3O4 - 12.63 ±1.02 mV and then by coating silver seed by PEI the surface charge 
shift to positive again (+ 11.63 ±0.68 mV). The silver coating process in final step leads to shift 
the surface charge to - 3.05 ±0.29 mV. The changing zeta surface charge demonstrates that 
the surface charge changes make the stronger bonds and better between different layers. 
Patel and Agrawal classified the zeta potentials by stabilities . According to their work a zeta 
potential (Patel & Agrawal, 2011) (Table 6). 
Table 6. Nanoparticle stability Classification according to the surface charge level. 
Surface Charge Stability 
±0 mV Highly Unstable 
From -10 mV to +10 mV Relatively Stable 
From -20 mV to +20 mV Moderately Stable 
≤ -30 mV to +30+ mV ≥ Highly Stable 
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Therefore, the HNPs developed can be considered to be highly stable. Moreover, 
nanoparticles with high surface charge indicate strong repulsive forces between particles, 
resulting less aggregation, and higher stability (Bhattacharjee, 2016). 
The TEM images indicated that the silver seeds were successfully anchored onto the surface 
of the Fe3O4-PEI and also that subsequent coating had been achieved. The TEM micrograph 
demonstrated the smaller particle sizes in compare with photon correlation spectroscopy 
(PCS). This phenomenon is possible due to the very small fraction of the sample represent in 
TEM image. On the other hand, a number of factors have a great influence on the 
hydrodynamic diameter of the particles measured by dynamic light scattering such as 
polymer shells, hydration layer or other stabilisers, which lead the particles size to be seen 
larger (Heinz et al., 2014). In comparison with naked iron oxide, polymer coated iron oxide 
NPs tend to be smaller and more uniform; this result correlates well with the aim of using 
the polymer layer as stabiliser (Heinz et al., 2014). Increase of the solution stability leads to 
decrease of particle agglomeration and size. However, iron oxide NPs agglomerates and 
form large clusters due to the hydrophobic interactions between the NPs because of its 
large surface area-to-volume ratio and hydrophobic surfaces properties (Wei et al., 2012).  
UV/Visible spectroscopy was carried out in order to identify the presence of colloidal silver 
in HNP. The λmax, measured via UV/Visible spectroscopy, the λmax shift occurred from λmax of 
400 nm for silver NPs, λmax of 450 nm for Fe3O4-PEI-Ag seeds and finally λmax of 490 nm for 
HNP. There was not observed plasmon resonance for Fe3O4 and Fe3O4-PEI (Figure 29). The 
UV results demonstrate that silver iron oxide HNP was successfully coated. 
The ratio between iron and silver were identified by using ICP. The ratio demonstrated the 
silver and iron existing ratio in the HNP is 1: 3.1 respectively. In general, previous studies 
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have shown that the ratio of iron oxide in HNPs formulations was 4-fold of gold (Malekigorji 
et al., 2017; Curtis et al., 2015). 
There has not published any article about thermal effects of iron oxide-silver (HNPs) so far. 
However, there are few investigations which have been performed for the thermal effects 
of iron oxide-gold HNPs (Hirsch et al., 2003). Hirsch et al. transferred their novel HNPs into a 
tumour tissue in mice, which was exposed to laser irradiation (820 nm, 4 Wcm-2, 5 mm spot 
diameter) for around 6 min. The result demonstrated that irradiation of this novel particles 
inside the tumours raised the temperature to 37.4 °C after 4 - 6 min irradiation. Hirsch 
reported that this temperature increase was above the threshold temperature at which 
irreversible tissue damage occurs (Hirsch et al., 2003).  
Malekigorji et al. studied on gold-iron oxide HNP thermal ability in 2014 (Malekigorji et al., 
2014). They compared heat changes between 50 μgmL-1 and 100 μgmL-1 for gold-iron oxide 
HNP were dispersed in agar gel and irradiated with continuous wave laser (Ng:YAG pulsed 
1064 nm, 1000 V, 6 Hz) in room temperature and 37 °C  for 60 s. According to their work at 
concentrations of 50 μgmL-1 at room temperature and 37 °C, ΔT was 5.57 °C ± 1.43 and at 
100 μgmL-1, ΔT was 7.70 °C ± 0.80 which were significantly higher than the temperature 
increase achieved outside the beam (p < 0.05). They also observed a small time dependant 
rise in temperature upon longer laser exposure, which was not significant (p > 0.05). The 
experiment was repeated at 37 °C and around the same ΔT was achieved for samples at this 
temperature (p < 0.05) (Malekigorji et al., 2014).  
In comparison with the previous research, the silver-iron oxide HNPs demonstrates 
significantly greater thermal capability in lower concentrations (25 μgmL-1). Here, at 
concentrations of 25 μgmL-1, ΔT was 7 °C ± 0.35 and at 50 μgmL-1, ΔT was 11 °C ± 0.56 at        
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37 °C in 30 s (p <0.05.). The charts clearly demonstrated that there is not differ between 2 
points in any concentrations or times. At 25 μgmL-1 and 50 μgmL-1, the heat dissipation 
changes were not significant for 0 -2 mm but the changes were dropped significantly from 2 
to 10mm. There interestingly, the study had to be curtailed after only 30 s due to agar 
melting, again highlighting the great efficiency of laser induced heating. The SPR optimal 
wavelength of the particles was 500 nm and our HNPs observed heat generation up to 11°C 
at 50 μgmL-1 and dissipation up to 10 mm away from radiation site for 25 μgmL-1 (0 s and      
10 s). Consequently HNPs may also be useful in tumour ablation however due care is 
required in order to minimize heat dissipation to healthy tissues. 
This excellent heating ability was somewhat unexpected due to the λmax of the silver HNPs 
being so low and the broad peak disappearing before the 1064 nm of the laser. However, 
our UV-Vis instrument only recorded absorbance 300 - 700 nm. Nevertheless, the laser 
irradiation data demonstrated that the HNPs have capability in increasing temperature 
which may be exploited in thermally-triggered drug release. 
All the data also showed that maximum heating occurred after 10 s. Interestingly, this was 
also observed in Malekigorji’s work where the sharp temperature rise was followed by a 
plateau. In this case, the temperature rise was sufficient theoretically to induce drug release 
according to her study. In the next chapter this will be explored further. It is pertinent to 
note that Malekigorji only irradiated her tumours in vivo for 20 s (Malekigorji et al., 2014). 
Therefore the data collected in this study over 30s is still very relevant for application.  
In next chapter the pancreatic cancer drug (bis (naphthalimidopropyl)spermine (BNIPDSpm)) 
will conjugate onto the HNP surface. In concentration of 25 μgmL-1 at 37 °C, the 
temperature of the particles increased up to 44.5 °C and in concentration of 50 μgmL-1 at        
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37 °C, the temperature of the particles increased up to 48°C, which is enough for our 
therapeutic agent to be released inside the tumour cells (will be described in Chapter 
Three).  
Some of drugs linkers such as BNIPDSpm derivetives can frequently contain of long chains or 
polymers, which may exist in some distance from the particle surface. The heat distribution 
from the HNP needs to be such that the thermally labile linker experiences the temperature 
rise for payload release, otherwise the system would be impractical. Additionally, the 
heating effects must be manageable, in that the thermal rise must be adequate for drug 
release but not for cellular stress or damage (Curtis et al., 2015). Consequently lower 
concentration would be more suitable for these purposes. Not only the heating generation 
was not significant different with higher concentration, but the heat effect did not occur or 
with a small increase (1 oC) after 10 mm for 25 μgmL-1.It can decrease possibility of 
surrounding tissues.  
2.5. Conclusion 
Novel iron oxide-silver core-shell HNPs have been successfully synthesised and 
characterised by using different techniques such as ICP, PCS, TEM and UV-Vis. The results 
have shown the HNP which has coated with silver is 90 nm. The laser mediated heating 
confirmed that the HNPs possessed surface plasmon resonance and hence highlights the 
potential of new HNP capability in thermo-responsive drug delivery. 
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Chapter Three 
Drug conjugations and 
characterisation of new 
formulations 
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3.1. Introduction 
Nanoparticles (NPs) are colloidal particles with core diameter between 10- 100 nm. NPs can 
be unstable and easily react with active substances and change their structure to reach a 
relatively stable state in some cases. High reactivity and small particle size of NPs can lead to 
make them unstable and also the main reason of the aggregation (Xu et al., 2018). The main 
factors which influence NP aggregation are the presence of electrolytes, temperature, pH, 
ionic strength, type of NPs, duration and of storage and the zeta potential. Increasing NPs 
stability is main solution for preventing from NPs high reactivity and aggregation (Bhadra et 
al., 2002; Jokerst et al., 2011). 
 A common method of stabilizing NPs is the utilization of the electrostatic repulsion among 
NPs, which are modified with charged ligands such as citrate (Dong et al., 2007) and 
triphenyl phosphine (Pan et al., 2007) or using amphiphilic polymers such as polyethylene 
glycol (Thiol-PEG) (Wang and Nie, 2008).  
Polyethylene glycol thiol (SH-PEG)  
SH-PEG is most widely applied in various studies due to its good solubility, biocompatibility 
and also its antifouling properties (Dreaden et al., 2009; Liu et al., 2007; Simpson et al., 
2012) and (Jiang et al. 2002). Many studies have shown that conjugating PEG on surface of 
NPs has significant effect on the particle stability and sensitivity of NPs (Durgadas et al., 
2010) and circulation times (Maus et al., 2010). In order to conjugate PEG onto gold or silver 
nanoparticles a thiol (-SH) functionality is required to form a dative covalent bond between 
the metallic surface and PEG residue; hence SH-PEG is commonly used. Many researchers 
have used PEGylated NPs for increasing drug targeting and as biosensors under physiological 
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conditions. These PEG-Thiol effects on delivery systems have many advantages including 
prolonging the blood circulation time as well as mimicking biological molecules and hence 
allowing the NPs to evade macrophage capture and clearance (Dreaden et al., 2010). The 
Thiol-PEG also can encapsulate anticancer drug and control drug release (Maus et al., 2010). 
Wang et al. studied the effect on the performance of PEG-modified gold nanoparticles 
(AuNPs) (Wang et al., 2013). According to Wang and colleagues studies, PEG plays important 
roles in improving the AuNP system. These roles include: use as an antifouling spacer arm 
between the functional ligands and gold surface, as a steric stabilizer for AuNPs under 
complicated conditions, for screening the charge on the AuNPsto avoid unexpected effects 
between sodium citrate and other electrolytes which implies that the PEG capping densities 
crucial to the saturation amount of functional ligands on AuNPs (Figure 32) (Wang et al., 
2013). 
 
Figure 32: Structure of thiol-PEG-modified AuNPs (Wang et al., 2013). 
Silver colloids are usually chemically stable against auto-aggregation which is essential for 
materials in antibacterial and anticancer medicine. However, silver nanoparticles have high 
90 
 
surface area which leads to poor colloidal stability and aggregation in solution. Stabilizing 
and capping agents such as polymers have been used in the synthesis process of AgNPs to 
overcome this instability (Wu et al., 2010; Maccuspie, 2011; Prathna et al., 2011; Tejamaya 
et al., 2012). Polymers are applied to form an outer shell coating to the silver cores or a 
carrier to loading AgNPs on their surface and providing a steric barrier to aggregation. 
Moreover, the types of polymers have some effect on the size, shape and properties of 
AgNPs (Batista et al., 2018; Hu et al., 2012; Krklješ et al., 2007; Mallick et al., 2004; Wu et al., 
2010). 
Mengda et al. studied the effect of SH-PEG on the AgNPs stability and antimicrobial 
properties (Mengda et al., 2018). According the research, silver-polyethylene glycol (Ag-
PEG) nanoparticles were synthesized with the thiol-functionalized polyethylene glycol (SH-
PEA) as the coating, reducing and stabilizing agent. Moreover, the results of antibacterial 
activities demonstrated that the Ag-PEG nanoparticles exhibited strong antibacterial activity 
against Staphylococcus aureus, Escherichia coli and Bacillus subtilis. The results of 
cytotoxicity showed the Janus Ag-PEG nanoparticles had lower toxicity for healthy cells than 
the multi-core shell nanoparticles (Mengda et al., 2018). 
Naphthalimide derivatives 
Brana and Ramos synthesized the 1,8-naphthalimide derivatives in 2001 (Brana and Ramos, 
2001). According to their research, “naphthalimide derivatives can connect to DNA by 
intercalation of the chromophore and two of them, mitonafide and amonafide, were used in 
clinical trials. The therapeutic properties of these drugs can improve by designing new bis 
intercalating agents. In this case, elinafide, demonstrated powerful activities against solid 
tumors” (Brana and Ramos, 2001). 
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Quaquebeke et al. assessed effect of new naphthalimides as anti-cancer against for breast 
cancer MCF-7, pancreatic cancer (BxPC-3) and colon cancer HCT15 Cell Lines in 2007 
(Quaquebeke et al., 2007). They synthesised naphthalimides with modified linker alkyl chain 
with 2, 3 and 4 carbons and the terminal groups include amino, imino, pyrrole, nitrobenzene 
and ureas. These compounds were assessed against breast cancer MCF-7, colon cancer HCT-
15 and pancreatic cancer BxPC-3 cell lines. The new compounds demonstrated very good 
GI50 values towards MCF-7, HCT-15, and BxPC-3 cancer cell lines. By changing the alkyl 
chain length in 1,8-naphthalimido derivatives they could  increase anticancer activity against 
different type of cancer cells (Quaquebeke et al., 2007). 
Clinical reports displayed that adding free amine group amonafide can switch it to N-acetyl 
derivative. Mateusz et al. added groups such as amides, ureas, thio-amides, amines, and 
imines to make new compound to increase the activity and to prevent the metabolism that 
provoke the hematotoxicity (Mateusz et al., 2018). The greatest effective complex 
demonstrated amines group have higher tolerated dose compare with amonafide and did 
not cause hematotoxicity in mice at doses that displayed strong antitumour results. Even 
though, 5-fold compound weaker intercalating power than amonafide, it is able to restrain 
its strand-passage activity (Mateusz et al., 2018). 
Naphthalimide derivatives signify as a class of DNA-binding agents. These agents have been 
broadly studied as antitumor agents (Paull et al., 1984) like some of the naphthalimide 
derivatives, such as bisnafide, amonafide and elinafide (Figure 33) (National Cancer 
Institute, 1984). Elinafide and bisnafide were formed by a polyamine linker and two 
naphthalimide groups. Naphthalimide derivatives have ability to bind with the DNA and 
anticancer activity of the intercalation (Marshall et al., 1994). Amonafide has entered phase 
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II clinical trials. Amonafide showed activity towards breast and prostate cancer (Isabella et 
al., 1995). Amonafide acts as a Topo II poison by perturbing the cleavage-relegation 
equilibrium, which consequences in store of DNA-Topo II covalent adducts (Nishio et al., 
1983). Blocking the relegation step after DNA cleavage makes of double-strand breaks. 
Despite its activity, Amonafide is no longer in clinical trials  because of unexpected toxicity 
begun by one of its metabolite, N-acetyl-amonafide (Felder et al., 1987). 
 
Figure 33: Representative naphthalimide derivatives in clinical trial (National Cancer 
Institute, 1984). 
Bis-naphthalimido compounds can attach to DNA double helix via the major groove (Bailly et 
al., 1995) The cytotoxicity of these compounds are much greater than higher monomeric 
compounds. Bis-naphthalimido compounds can be extremely insoluble in aqueous solutions 
depending on their linker. Many attempts were carried out for increasing their solubility and 
decreasing cytotoxicity activity. Eight bis-naphthalimido compounds were modified with 
adding one or two nitrogen atoms in the linker chain (Brana et al., 1996). The Bis-
naphthalimido modified could simply react the corresponding alkyltetraamine with 1,8- 
naphthalic anhydride (Brana et al., 1996). 
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Naphthalimide-based anti-tumour drugs may cause serious side effects, including dose 
limiting toxicity and central neurotoxicity. In order to develop their efficacy and decrease 
the side effects, naphthalimide derivatives, adapted with imide substituents, fused aromatic 
rings and various side chains (Tabor, 1984). Recently, the studies have been published in 
design of novel drugs for sequence-specific binding of naphthalimides to DNA (Tomczyk et 
al., 2018). The trisubstituted naphthalimide derivatives can bind telomeric G-quadruplexes 
with extraordinary anti proliferation activity against different cell lines  (Barron et al., 2010). 
The substituents at naphthalimide skeleton and linkers play crucial roles in determining the 
cytotoxic activity, photophysical properties and sequence selectivity of bisnaphthalimides 
derivatives (Filosa et al., 2009).  
In 2000, Thoo Lin and colleagues synthesised of bis-naphthalimidopropyl polyamine 
derivatives, which contain 2, 3 and 4 nitrogen atoms in the linker chain (Thoo Lin et al., 
2000). They increased the aqueous solubility of bis-naphthalimido compounds with adding 
more heteroatoms (N-alkylation reaction) in the linker chain (Thoo Lin et al., 2000; Paul et 
al., 2000). The new bis-naphthalimidopropyl polyamine derivatives was involve oxa-
putrescine (BNIPOPut), bis-naphthalimido- propyl putrescine (BNIPPut), 
Bis(naphthalimidopropyl) spermidine (BNIPSpd) and Bis(naphthalimidopropyl)spermine 
(BNIPSpm). The general intermediate for the synthesis of BNIPPut, BNIPSpd, BNIPSpm and 
BNIPOPut is toluene- nesulfonyloxypropylnaphthalimide (Figure 34) (Dance et al., 2004). 
This was formulated by first reacting 1,8-naphthalic anhydride with aminopro- panol to give 
N-(3-hydroxypropyl) naphthalimide which upon reaction with tosyl chloride in 60% yield 
(Dance et al., 2004). Thoo Lin et al. discovered that using four times excess of tosyl chloride 
in a small volume of solvent could make best situation to achieve a maximum yield. On the 
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other hands (e.g., with equimolar or 2 molar quantities of tosyl chloride), a combination of 2 
and 3, N-(3-chloropro pyl)naphthalimide is constantly formed so reducing the overall yield 
of the reaction and also, renders purification very complex (Figure 34) (Dance et al., 2004). 
 
Figure 34: The steps of bis-naphthalimidopropyl polyamine derivatives preparation (Dance 
et al., 2004). 
According to the Dance et al. studies “To obtain bis-naphthalimides such as oxa-putrescine 
(BNIPOPut), bis-naphthalimido- propyl putrescine (BNIPPut), Bis (naphthalimidopropyl) 
spermidine (BNIPSpd) and Bis(naphthalimidopropyl) spermine (BNIPSpm) (Figure 35), 
polyamines (4,5,6 and 7) were covered with 2,4,5-trimethylsulphonyl chloride (Mts-Cl) in 
pyridine followed by their N-alkylation with compound 2 to yield the fully protected 
bisnaphthalimido compounds which, on subsequent deprotection with hydrobromic 
acid/glacial acetic acid in dichloromethane. The BNIPPut, BNIPSpd, BNIPSpm and BNIPO 
were made as their hydrobromide salts” (Dance et al., 2004). Their research was 
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demonstrated that BNIPSpd and BNIPSpm have stronger bind to DNA and have more 
potential to contribute to their cytotoxic action than the other compounds. Consequently 
BNIPSpd and BNIPSpm were better basis for their further development as anticancer drugs  
(Dance et al., 2004). 
 
Figure 35: BNIPPut, BNIPOPut, BNIPSpd and BNIPSpm formulations (Dance et al., 2004). 
National Cancer Institute (NCI) compered cytotoxic properties of BNIPSpd and BNIPSpm 
against 60 standard human cell lines derived from nine different tumours including breast 
cancer. BNIPSpd and BNIPSpm were indicated to be very active against all panels of cell 
lines, with mean IC50 values (drug concentration that causes 50% growth inhibition) ranging 
from 0.25 to 7.43mM and demonstrating considerable selectivity depending on the panel 
and cell line tested (Thoo Lin et al., 2000). 
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Malekigorji et al. researched the interaction between bisnaphthalamide derivatives and 
novel HNPs with using gold nanoparticles for pancreatic cancer treatment.  
The impact of conjugation ability, stability and drug release pattern of hybrid formulations 
were assessed in their study. The bisnaphthalamide derivatives were compared between 
bisnaphthalimido 1,12-diaminododecane (BNIPd), bisnaphthalimidopropyl spermine 
(BNIPDSpm), bis naphthamimidopropyl -3,3-butane-1,4-diyl, bis sulfanediyl, bispropan-1-
amine (BNIPds) and bisnaphthalimido-1,20-diaminoicosane (BNIDi). Their researches 
illustrated that BNIDi was not able to conjugate with HNP because this compound did not 
have amine group, resulted in weak electrostatic interactions between the drug and 
particle. So the amine group could be main reason to conjugate the bisnaphthalamide 
derivatives to the HNP. Moreover BNIPd to BNIPDSpm had stronger interaction of drug-NPs 
cause of 4 amine group’s existence in the structures . BNIPDSpm (with four amine groups) 
displayed highest loading capacity, fastest release and greatest stability on the surface of 
HNP between the other bisnaphthalamide derivatives. According to their research, 
PEGylated formulations mostly revealed greater release of drug in comparison with their 
unPEGylated counterparts (Malekigorji et al., 2017). 
Malekigorji et al. found that BNIPDSpm was the best option in their Fe304-Au system. 
Therefore, this is the drug of choice for conjugation with the silver HNPs synthesised in the 
previous chapter (Malekigorji et al., 2017). Additionally, previous SH-PEG was also seen to 
be advantageous and therefore this will be included onto the HNP surface in combination 
with the drug molecules (Mengda et al., 2017).  
In this chapter, the interaction between BNIPDSpm and BNIPDSpm- PEG Thiol on novel 
HNPs with using silver nanoparticles was compared together. After formulation they also 
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were characterised by different analytic instruments such as  photon correlation 
spectroscopy (PSC), fourier transform infrared spectroscopy (FTIR), inductively coupled 
plasma optical emission spectroscopy (ICP-oes) and reverse phase high performance liquid 
chromatography (RP-HPLC). 
Fourier Transform Infrared spectroscopy (FT-IR) 
The Fourier Transform Infrared Spectroscopy (FTIR) can rapidly deduce a chemical finger 
print with high sensitivity & specificity, in a fast and non-destructive manner (Alvarez-
Ordóñez et al. 2011).  
When molecules are exposed to infra-red radiation the atoms attract particular frequencies 
and vibrate (Williams & Fleming. 2007). On a typical infra-red (IR) spectrum the frequency is 
demonstrated in wavenumbers 400-4000 cm-1, which is the reserve of frequency 
(1/frequency) in cm-1. The percentage transmission of identifiable wavenumbers offers a 
strong indication to the functional groups (Williams & Fleming, 2007).  
The samples expose on IR and absorbance of the infrared light’s energy at various 
wavelengths. FTIR analysis measures the range of wavelengths in the infrared region that 
are absorbed by a material. This technique is a quick and cost effective method for 
identifying unknown particles, residues, films or fibres.  FTIR can also assess levels of 
oxidation in some polymers or degrees of cure in other polymers as well as surface 
contamination or additives in materials (Andersen et al., 2016). Figure 36 demonstrates the 
schematic diagram of an FTIR spectroscopy (Dost & İdeli, 2012). 
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Figure 36: Schematic diagram of a FTIR spectrometer (Dost & İdeli, 2012). 
High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) is a great technique for separation and 
analysis of components within a mixture. HPLC can be utilised to analyse complex mixtures 
of molecules based on distribution between stationary and mobile phases  (Neue, 2007; 
Dean et al., 2002c; Jared et al., 2015). HPLC basically used for separations and purifications 
in various areas including biotechnology, polymer, food industries, environment and 
pharmaceuticals (Hema et al., 2009). Figure 37 illustrates a schematic diagram of an HPLC 
system (Czaplicki, 2012).  
99 
 
 
Figure 37: Schematic diagram of High Performance Liquid Chromatographer (HPLC) 
(Czaplicki, 2012). 
After injecting the fixed amount of sample, the sample will incorporate in the mobile phase 
and pass through the column at a fixed flow rate. The column is packed with stationary 
phase (usually silica). The sample adsorbs onto the stationary phase dependant on its 
chemical characteristics and this will alter its retention time. Once the sample is eluted it is 
detected via fluorescence spectroscopy, UV/Vis spectroscopy, mass spectrometry or 
electrochemical detectors. The whole system is connected to a built-in computer interface 
control (Dost & İdeli, 2012; Khare et al., 2016; Ansari & Häubl, 2016; Campos et al., 2016). 
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Chromatographic separation can be classified into number modes such as size exclusion 
(SE), ion exchange (IE) and reversed-phase (RP) according to the size, polarity and charge of 
the molecules (Chi-San. 1995; Haddad and Jackson. 1990). Reversed-phase (RP) can 
separate all substances in various compounds (Snyder et al., 2010). Separation mechanism 
based on the hydrophobic binding of the solute molecule in the mobile phase (polar) to the 
immobilised hydrophobic stationary phase such as inorganic polymers  with large surface 
areas, carbon  and silica gel (Rubinson, 2000). 
Retention time is the particular time taken for passing of a particular mixture component 
through the column. Various factors can effect on the retention time such as polarity of the 
column adsorbent. In normal-phase HPLC systems, columns containing polar adsorbents will 
have a higher affinity for polar components in a separation mixture. So, these polar 
components move slower during column and the lead to increasing retention time. On the 
other hands, non-polar solvent travel through the column quicker and cause to shortens 
their retention time. Moreover, longer columns cause to increase the retention time, as the 
distance components must travel before reaching the end will increase (Campos, 2016). 
Aims and objectives 
The aim of this chapter is to study the ability of BNIPDSpm and BNIPDSpm-PEG to conjugate 
onto the surface of the silver HNPs produced in Chapter 2. In previous chapter the HNP 
thermal ability were assessed and in this chapter. Laser irradiation, will result in quick drug 
release from the particles. Then the free drug can enter cells`  nucleus and interact with DNA 
for anticancer effect.  We will check drug release in different temperatures. In this case, the 
release pattern of the formulations inside the pancreatic cancer cells, before and after laser 
irradiation can be predicted. The nano-formulation will be characterised by PCS, ICP-OES, 
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FTIR and RP-HPLC. The amount of drug loading and releasing of novel formulation will be 
assessed at varied temperature and pH and quantified using RP-HPLC. The stability of 
formulation and physical stability will be tested at different temperatures and forms 
(dispersed in water or freeze dried) by RP-HPLC and ICP respectively for 4 weeks. 
3.2. Materials and methods 
Materials used for this chapter 
Table7. Materials used in Drug conjugations, synthesis and characterisation of new 
formulations   
Materials Suppliers 
PRMI Medium 1640(1X) Thermo Fisher, UK 
HPLC Grade acetonitrile Sigma-Aldrich Co., UK 
Octane sulfonic acid Sigma-Aldrich Co., UK 
Sodium acetate ACROS Organics Co., USA 
HPLC Grade hydrochloric acid Sigma-Aldrich Co., UK 
HPLC Grade dimethyl sulfoxide Sigma-Aldrich Co., UK 
Hybrid nanoparticles (HNPs) Synthesised in Chapter Two 
Nitric acid Fisher Scientific, UK 
Hydrochloric acid Fisher Scientific, UK 
Thiolated poly ethylene glycol (PEG-thiol) Sigma-Aldrich Co., UK 
Bis(naphthalimidopropyl)spermine 
(BNIPDSpm) 
Provided by Keele Nanopharmaceutics 
Group 
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Methods 
Drug conjugation 
HNPs solutions (1 mg mL-1) were mixed with the drugs in the ratio (HNP: Drug) 1:1, 1:5, 1:10, 
5:1 and 10:1 respectively. The solutions were stirred for 3 h at room temperature. Finally 
the solution was magnetically separated and highly washing with deionised water for three 
times.  
The particles were separated from the supernatant (waste solution) after drug conjugation 
by using a strong permanent magnet on the outside of a glass vial containing the 
formulation. One mL of the waste solution (in water) was diluted with 1 mL of DMSO and 
drug concentrations were analysed via HPLC. All measurements were run in triplicate and 
recorded as average values. 
PEG-thiol was added simultaneously into the drug-HNP reaction at 25 mg, 50 mg and 100 
mg of powdered polymer (based on the concentration used in the literature for PEG-thiol) 
was added with the solution respectively (Barnett et al., 2013a; Barnett et al., 2013b). The 
particles were washed after 3 h as previously described. It was assumed that PEG will coat 
the surface of HNPs completely if it was added before the drug, thus no free surface would 
be available for the drug attachment (Barnett et al., 2013a; Barnett et al., 2013b).  
Drug quantification 
RP-HPLC (Prominence, DEGASSER, LC20AD, SHIMADZU) with a fluorescence detector at 234 
nm (Excitation) and 394 nm (Emission) (Jasco, PU-980, Japan; column C18 (2), 150×4.60 mm 
5 micron, flow rate: 1 mLmin-1, injection volume: 20 μL) were used for identifying amount of 
drug loading and releasing of HNP- BNIPDSpm and HNPs- BNIPDSpm-PEG-Thiol. In this case, 
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to improve the retention, the buffer used in HPLC mobile phase was made by adding 1.64 g 
sodium acetate and 0.432 g octane sulfonic acid in 200 mL of deionised water. After 
dissolving the materials in water, the pH of the solution was decreased to 4.5 by the 
addition of hydrochloric acid (2 mL). Finally, acetonitrile were added to the solution with 
ratio of 70:30, respectively. For dissolving BNIPDSpm without sonication DMSO added to the 
solution before injecting to HPLC. The amount of attached drug was assessed from the 
amount of free drug in waste solution and distinguished via HPLC.  
Characterisation of novel formulations 
Zeta potential measurement 
Zeta potential measurements of novel formulations were assessed using a photon 
correlation spectrometer (PCS, Zetasizer nano-ZS, Malvern Instruments, UK) as described in 
Chapter Two (Section 2.2.2.7.1). 
Fourier Transform Infrared Spectroscopy (FT-IR) 
HNP, HNP- BNIPDSpm and HNPs- BNIPDSpm-PEG-Thiol with highest drug loading 
concentrations (5 mL) were freeze dried using a Heto Power Dry LL3000, Thermo-Fisher UK. 
The freeze dried samples were analysed on the FTIR using a diamond tipped attenuated 
total reflectance attachment (Nicolet iS5 with iD5 ATR, Thermo-Fisher UK) over 600 scans. 
In vitro drug release study 
In vitro drug release study in aqueous environments 
HNP-drug or HNP-Drug-PEG solution (2 mL) were place into dialysis membrane (12-14 KDa) 
and the membrane were placed and stirred into conical flask containing 200 mL of deionised 
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water or RPMI media at varied pH (pH 7.2, pH 4.6 and pH 3.6)  and temperatures (37˚C, 
44˚C, 50˚C & 60˚C). Different samples (1 mL) were taken from the exterior solution at 
selected time points (0.017 h, 0.084 h, 0.17 h, 0.33 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 24 h, 48 h and 
72 h).  All extracted samples were diluted with 1 mL of Dimethyl sulfoxide (DMSO) and drug 
concentrations were analysed via HPLC.  
Stability study 
Formulations Chemical Stability study 
HNP-BNIPDSpm and HNP- BNIPDSpm-PEG (1 mL, drug = 0.5 mg mL-1) was kept at room 
temperature or 4˚C over 5 weeks. The concentration of released drug in samples was 
monitored each week by magnetic separation and RP-HPLC of the supernatant. Additionally 
each formulation with the same mentioned concentration was freeze dried. The powder 
formulations were kept at room temperature or 4 ˚C and each week the powder 
formulations reconstituted in deionised water and the concentration of released drug 
analysed via HPLC in the supernatant after magnetic separation. All samples were sonicated 
with a sonic bath before the separation of particles from the supernatant. All measurements 
were run in triplicate and recorded as average values. 
Stability of HNPs in physiological conditions 
Previous researches were carried out for testing HNP stability in physiological conditions 
(Hoskins et al., 2012b). For physical stability, 2mL HNP (100 μgmL-1) were pipetted into 
dialysis membrane (12-14 KDa) and then placed in 200 mL RPMI (Life Technologies, UK). The 
samples were taken from stirred particles during 1 h, 4 h, 24 h, 48 h, 72h, 168 h, 336 h, 504 
h and 672 h. The media was pH changed to pH 7.2 and 4.5 to mimic blood and lysosomal 
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physiological conditions respectively. The physical stability of novel formulations was carried 
out using ICP-OES spectrometer for analysing for amount of Iron in the solution. Iron 
content in solution was calculated in respect to a calibration as described in Chapter Two 
(section 2.3.1). 
3.3. Results 
Drug conjugation 
BNIPDSpm was analysed by HPLC. The fellow rate adjusted in 1 mLmin-1 and fluorescence 
detector at Excitation 234 nm and Emission 394 wavelengths. A calibration was run using 
drug solutions dissolved in 50: 50 H2O: DMSO with the concentration of 31.25 -1000μgmL-1 
(R2 = 0.999) (Figure 38).  
 
Figure 38: Calibration graph of BNIPDSpm for drug loading. 
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The drug had sharp peak which observed between 9-10 min (Figure 39). 
  
 
Figure 39: RP-HPLC analysis of 100 μgmL-1 BNIPDSpm (dissolved in DMSO/H2O (50:50 v/v)). 
The drug conjugation were assessed in different ratios between HNP and the drug according 
to the Figure 40. 
 
Figure 40: Drug conjugations in different ratios of HNP and BNIPDSpm. 
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According to the Figure 40, BNIPDSpm conjugated into HNP with 80-90% in different ratios. 
The existence of 4 positive charged amine groups in BNIPDSpm structure can lead to strong 
electrostatic interactions between the drug and HNP with negative surface charge. Figure 40 
demonstrated that the ratio of 1:10 HNP: BNIPDSpm has the highest percentage of drug 
conjugation among other concentrations. In this ratio 81.72 mg  ± 1.03 (out of 90 mg) of the 
drug conjugated into the HNP (9 mL, 1 mg mL-1) (Table 8). The percentage of drug 
conjugation was 90.88 %± 1.03 which means that 1mg mL-1 HNP (Fe) conjugated 9 mg mL-1 
of the drug in optimum ratio. 
Table 8. Actual weight of drug conjugations in different ratios. Experiments were performed 
three times, and data were expressed as mean ± standard errors (n=3, ave ± SD). 
Different Ratios (mg.mL-1 ) Drug conjugated (out of 90 mg)  
1:10 HNP:BNIPDSpm 81.72 mg ± 1.03 
1:5 HNP:BNIPDSpm 78.31 mg ± 1.17 
1:1 HNP:BNIPDSpm 74.69 mg ± 0.27 
5:1 HNP:BNIPDSpm 72.93 mg ± 1.06 
10:1 HNP:BNIPDSpm 71.10 mg ± 1.93 
 
Different ratios PEG-Thiol was added to the optimum ratio HNP-Drug (1:10 respectively). 
These ratios were including 1:10:1 HNP:BNIPDSpm:PEG-Thiol, 1:10:5 HNP:BNIPDSpm:PEG-
Thiol and 1:10:10 HNP:BNIPDSpm:PEG-Thiol. The drug conjugation was according to the 
Figure 41. 
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Figure 41: Drug conjugations in different ratios of PEG-Thiol. 
According to the Figure 41, ratio of 1:10:10 HNP:BNIPDSpm:PEG-Thiol has the highest 
percentage of drug loading in compare with the other ratios. In this ratio 84.78 mg ± 0.83 of 
the drug (out of 90 mg) was attached into the HNP (9 mL, 1mg mL-1) (Table 9). The 
percentage of drug conjugation was 94.21 %± 0.83 which mean 1mg mL-1 HNP (Fe) was 
conjugated 9.42 mg mL-1 of the drug in optimum ratio (Table 9). 
Table 9. Drug loading in different ratios of PEG-Thiol. Experiments were performed three 
times, and data were expressed as mean ± standard errors (n=3, ave ± SD). 
Different Ratios (mg.mL-1 ) Drug conjugated (out of 90 mg) 
1:10:1 HNP:BNIPDSpm:PEG-Thiol 81.91 ± 0.78 
1:10:5 HNP:BNIPDSpm:PEG-Thiol 83.29 ± 0.03 
1:10:10 HNP:BNIPDSpm:PEG-Thiol 84.78 ± 0.83 
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Characterisation of novel formulations 
Zeta potential measurement of novel formulations 
HNP, BNIPDSpm-HNP and BNIPDSpm-HNP-PEG were characterised by photon correlation 
spectroscopy (PCS) (Table 10). 
Table 10. Zeta potential index of particles measured at 1 mg mL-1 (concentration of 
conjugated drug) in deionised water (n=3, Ave ± SD). 
Particle Zeta Potential (mV ± SD) 
HNP -3.05± 0.29 
BNIPDSpm-HNP +32.51± 0.35 
BNIPDSpm-HNP-PEG +18.77± 0.41 
The data showed that the ‘naked’ HNPs possessed a negative surface charge (-3.05 ± 0.29 
mV) before conjugating with the drug. This is probably due to the slight electronegativity of  
silver surfaces in the colloidal form. BNIPDSpm possessed 4 amine groups so the surface 
charge shifted to positive (+32.51 ±0.35 mV) after drug conjugation. The surface charge for 
BNIPDSpm-HNP-PEG was positive but lower than BNIPDSpm-HNP (+18.77±0.41 mV), 
indicating further modification of PEG. This could be due to the -OH groups in the PEG 
chains possessing a slight negativity, thus reducing the net surface charge. The decrease of 
zeta potential confirms the PEG binding. 
Fourier transforms infrared spectroscopy of formulations 
FTIR were carried out for HNP, BNIPDSpm-HNP and BNIPDSpm-HNP-PEG to confirm whether 
the drugs/PEG had conjugated onto the HNPs. Before conjugation the drug, the ‘naked’ 
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HNPs were characterised (Figure 42). As seen in the spectra, no substantive peaks were 
observed, as expected. 
 
Figure 42: FTIR spectra of HNP, between 1000-4000 cm−1. 
The attachment of BNIPDSpm with HNP and HNP-PEG was confirmed by FTIR spectra (Figure 
43A and 43B). The series of characteristic IR bands for both formulations are summarised in 
detail in Tables 11. Bands 1098 cm−1 in BNIPDSpm-HNP and 1124 cm−1 BNIPDSpm-HNP-PEG 
approved the presence of aromatic in-plane C-H bending. Bands 1573 cm-1 and 1580 cm-1 
presented aromatic C=C stretching in BNIPDSpm-HNP and BNIPDSpm-HNP-PEG respectively. 
C=O (Stretching) bands appeared in 1684 cm-1 in BNIPDSpm-HNP and 1641 cm-1 in 
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BNIPDSpm-HNP-PEG. Bands in 2910 cm-1 and 2989 cm-1 area approved existence of C-H 
(Stretching) in BNIPDSpm-HNP-PEG AND BNIPDSpm-HNP-PEG respectively. Other bigger 
Peak observed at 1341 cm−1 (C–H bending; −CH2 and −CH3) confirm the presence of bound 
PEG within BNIPDSpm -HNP- PEG formulation (Figures 43A and 43B). 
Table 11. Assignment of FTIR spectra for BNIPDSpm-HNP and BNIPDSpm-HNP-PEG. 
Samples IR bands (cm−1) Description 
BNIPDSpm-HNP 1098 
1573 
1684 
2910 
Aromatic in-plane C-H (bending) 
Aromatic C=C stretching 
C=O (Stretching) 
C-H (Stretching) 
BNIPDSpm-HNP-PEG 1124 
1580 
1641 
2989 
Aromatic in-plane C-H (bending) 
Aromatic C=C stretching 
C=O (Stretching) 
C-H (Stretching) 
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Figure 43: FTIR spectra of A) BNIPDSpm-HNP and B) BNIPDSpm-HNP-PEG, between 1000 -
4000 cm−1. 
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Stability tests 
After optimizing the formulations, the formulations were kept in a dark airtight container at 
room temperature and under refrigeration (4 °C). Moreover the samples were assessed with 
2 different states include freeze dried ‘cakes’ (reconstituted with water and sonicated)  and 
liquid state for up to 5 weeks (Figures 44 and 45). Both forms (dried and disperse) were 
sonicated before stability measurement. 
 
Figure 44: Stability test for BNIPDSpm-HNP at 20 ᵒC and 4 ᵒC in the form of dispersed in 
water and freeze dried, over the period of 5 weeks (n=3, ave ± SD). 
 
Figure 45: Stability test for BNIPDSpm-HNP-PEG at 20 ᵒC and 4 ᵒC in the form of dispersed in 
water and freeze dried, over the period of 5 weeks (n=3, ave ± SD). 
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Figures 44 and 45 demonstrated that formulation state and temperature are two important 
factors in the stability of HNP. The results were shown that solid state is more stable than 
liquid state it might be due to the presence of water in in aqueous formulations, which can 
raise the risk of drug release from the nano-carriers. Moreover decreasing temperature can 
increase the stability. In comparison between 20 ᵒC and 4 ᵒC, the test result illustrated the 
new formulations were more stable in 4 ᵒC than 20 ᵒC. Infact, reducing temperature leads to 
less drug detachment and protects the integrity of the electrostatic bonds and due to the 
stronger electrostatic binding on the HNP surface. Consequently, the new formulations 
were completely stable in 4 ᵒC and solid state. According to Figures 44 and 45, the test 
results demonstrated better result for BNIPDSpm-HNP-PEG than BNIPDSpm-HNP. 
BNIPDSpm-HNP-PEG was reduced lower % drug conjugation during 5 weeks than 
BNIPDSpm-HNP. The drug stability for BNIPDSpm-HNP was around 80% - 88% and the 
stability for BNIPDSpm-HNP-PEG was slightly more and around 87 % - 90 %. 
In vitro drug release study 
The release of the drugs from the optimal formulations were investigated in aqueous 
environment and culturing media at various temperatures and pH via HPLC. A calibration of 
the free drug dissolved in DMSO/H2O (50:50) (R
2 = 0.999) were carried in deionised water 
(Figures 46). The peak areas for various samples were compared to calibration. All samples 
were carried out for three times.  
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Figure 46: Calibration graphs of BNIPDSpm for drug release in deionised water. 
In vitro drug release study in aqueous environments in various temperatures 
BNIPDSpm-HNP and BNIPDSpm-HNP-PEG were assessed in terms of the amount of drug 
release in 20 ˚C, 37 ˚C, 44 ˚C, 50 ˚C and 60 ˚C in deionised water (Figures 47A and 47B)                   
(p> 0.05). BNIPDSpm release for both formulations measured over 72 h showed a biphasic 
release profile due to an initial burst, which is followed by a constant release. According to 
the HPLC results, drug release in first 4 h was greater that after 4 h. It can be due to 4 amine 
group in the drug and number of amine groups which can conjugate on HNP surface.  
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Figure 47: Drug release study of A) BNIPDSpm-HNP and B) BNIPDSpm-HNP-PEG in 20 ˚C,     
37 ˚C, 44 ˚C, 50 ˚C and 60 ˚C in deionised water (p < 0.05). Experiments were performed 
three times, and data were expressed as mean ± standard errors (n=3, ave ± SD).  
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In 20˚C the drug was released 9.69 % ± 0.12 in the first 10 minutes for BNIPDSpm-HNP and 
also 11.73% ± 0.92 in first 10 minutes for BNIPDSpm-HNP-PEG. The drug releasing was 
increased sharply over 3 h and then slightly increased over 72 h. At 72 h, the drug was 
released 35.41% ± 0.95 in 20˚C for BNIPDSpm-HNP and also 40.91% ± 1.65 in 20˚C for 
BNIPDSpm-HNP-PEG. This low drug release over 72 h could be due to the strong 
electrostatic interactions between the drug and particles, as BNIPDSpm have four amines 
groups within its structure. However the drug releasing result for BNIPDSpm-HNP-PEG was 
better than BNIPDSpm-HNP in all temperatures. In the absence of PEG, BNIPDSpm and HNP 
might have stronger interactions as flattened at the surface of the particles because of the 
abundance of free space. In the presence of PEG, drug might have challenge with the 
polymer for the particles surface. 
The graphs demonstrated that increasing temperature will increase drug realising. In this 
case in 60 ˚C, the drug was released 59.22% ± 0.66 over 72 h for BNIPDSpm-HNP and also 
78.31% ± 0.91 for BNIPDSpm-HNP-PEG over 72 h for. 
In vitro drug release study in aqueous environments in various pH. 
The drug release was assessed for BNIPDSpm-HNP and BNIPDSpm-HNP-PEG in 20 ˚C, 37 ˚C, 
44 ˚C, 50 ˚C and 60 ˚C at pH=4.6 and pH=3.6 in deionised water (Figures 48 and 49).  
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Figure 48: Drug release study of A) BNIPDSpm-HNP and B) BNIPDSpm-HNP-PEG in 20 ˚C,     
30 ˚C, 40 ˚C, 50 ˚C and 60 ˚C at pH=4.6 (p < 0.05). Experiments were performed three times, 
and data were expressed as mean ± standard errors (n=3, ave ± SD).  
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According to Figure 48 the drug release were compared between BNIPDSpm-HNP and 
BNIPDSpm-HNP-PEG PEG in 20 ˚C, 30 ˚C, 40 ˚C, 50 ˚C and 60 ˚C at pH=4.6 (p < 0.05). The 
graphs demonstrated that the drug releasing were increased in pH=4.6 in compare the 
previous data’s.  Also the drug release results for BNIPDSpm-HNP-PEG was more than 
BNIPDSpm-HNP in same situation. 
The drug release for BNIPDSpm-HNP and BNIPDSpm-HNP-PEG in 20 ˚C, 37 ˚C, 44 ˚C, 50 ˚C 
and 60 ˚C at pH=3.6 were as below graphs  as well (Figure 49). 
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Figure 49: Drug release study of A) BNIPDSpm-HNP and B) BNIPDSpm-HNP-PEG in 20 ˚C,     
30 ˚C, 40 ˚C, 50 ˚C and 60 ˚C at pH=3.6 (p < 0.05). Experiments were performed three times, 
and data were expressed as mean ± standard errors (n=3, ave ± SD). 
The graphs demonstrated that the drug release rate of BNIPDSpm from PEGylayed 
formulation is significantly higher than the release from unPEGylated formulation (p < 0.05). 
Moreover reducing pH considerably increased the release rate of drug from both 
formulations as electrostatic interactions can be broken faster in lower pH (p < 0.05).  The 
data’s were shown that in first 4h the drug release rate were significantly higher than after 
that. In BNIPDSpm-HNP-PEG the drug completely released after 75 h at 60 oC and drug 
release was higher than lower temperatures (p <0.05). 
As we discussed in chapter 2 (achieved by laser irradiation), we assessed the drug release in 
different pH and temperatures. The results demonstrated that release of BNIPDSpm from 
the particles in 44 ˚C was greater/faster at lower pH and PEGylated formulation always 
possessed more release compared to the unPEGylated formulation. In pH=3.6 almost 73% ± 
1.22 of the drug was released after 75 h. By considering these data we suggest that when 
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the BNIPDSpm-HNP-PEG particles cross the pancreatic cancer cell membrane and 
accumulate inside the lysosome (pH=3.6), at 44 ˚C (achieved by laser irradiation), about 
46.72 %± 0.97 of drug will be released in the first 1 h (p < 0.05). BNIPDSpm drug release 
pattern was investigated at 44 oC, as this is the optimum temperature generated by HNPs 
upon the laser irradiation, described in Chapter Two (Section 2.3.5). 
In vitro drug release in biological media 
The drug release were analysed in in culture media at pH= 7.5, pH=4.6 and pH=3.6 at 20 ˚C, 
37 ˚C and 44 ˚C and 50 ˚C up to 312 h to mimic cytoplasm (pHi =7.42), endosome and 
lysosome environment in pancreatic cancer cells, respectively (Preissler and Williams, 1981)  
as below graphs. A calibration of the free drug dissolved in DMSO/H2O (50:50) (R
2 = 0.999) 
were carried in RPMI (Figures 50). The peak areas for various samples were compared to 
calibration. All samples were carried out for three times. 
 
Figure 50: Calibration graphs of BNIPDSpm for drug release in RPMI 
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According to Figure 51, in 20 ˚C, 30-40 % of release from BNIPSDpm-HNP and BNIPDSpm-
HNP-PEG respectively occurred in pH=3.6, 4.6 and 7.5 before 4 h. 
 
Figure 51: Drug release BNIPDSpm-HNP and BNIPDSpm-HNP-PEG in 20˚C at pH=7.5, pH=4.6 
and pH=3.6 (p < 0.05). Experiments were performed three times, and data were expressed 
as mean ± standard errors (n=3, ave ± SD). 
The drug release was increased with decreasing pH because the lower pH was broken the 
electrostatic interactions in NPs and can separate the drug from NPs amine groups. 
Moreover the drug release in formulation with PEG was higher rate in compare with the 
formulation without PEG as surface charge results demonstrated that BNIPDSpm-HNP-PEG 
has lower surface charge so the electrostatic interactions can break easier in compare with 
BNIPSDpm-HNP. 
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Figure 52: Drug release BNIPDSpm-HNP and BNIPDSpm-HNP-PEG in 37˚C at pH=7.5, pH=4.6 
and pH=3.6 (p < 0.05). Experiments were performed three times, and data were expressed 
as mean ± standard errors (n=3, ave ± SD). 
In 37 ˚C more drug release was occurred in compare with 20 ˚C. BNIPDSpm-HNP-PEG at pH=3.6 
had highest rate of drug releasing. In this pH 20% ± 2.05 of drug release was occurred in first 
0.5h and the drug release arrived to the 40% ± 0.715 in first 4 h. The drug release sharply 
increased in first 4 h and then the rate of increasing was slightly went up until 312h 
(p<0.05). The best drug release rate was for BNIPDSpm-HNP-PEG in pH=3.6. In this 
formulation 78% ± 1.92 of drug was release before 312 h.  
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Figure 53: Drug release BNIPDSpm-HNP and BNIPDSpm-HNP-PEG in 44˚C at pH=7.5, pH=4.6 
and pH=3.6 (p < 0.05). Experiments were performed three times, and data were expressed 
as mean ± standard errors (n=3, ave ± SD). 
The same pattern was observed in 44 ˚C, and again the higher release occurred in lower pH 
(Figure 53). The release from PEGylated formulation was significantly higher than its 
unPEGylated counterpart (p < 0.05). In first 10 minutes 11.30% ± 1.72, 20.31% ± 3.74 and 
25% ± 1.74 of drug release from unPEGylated in pH=7.5, pH= 4.6 and pH=3.6 respectively. In 
first 10 minutes 18.12% ± 1.90, 22.23% ± 1.71 and 30.26% ± 2.94 of drug release from 
PEGylated formulation in pH=7.5, pH= 4.6 and pH=3.6 respectively. Half of the drug (0.5 mg) 
released from BNIPSDpm-HNP-PEG in pH=7.5, pH= 4.6 and pH=3.6 in 3 h, 1 h and 0.5 h, 
while these amount of drug released from unPEGylated was in 4 h , 3 h and 2 h with the 
same pH mentioned above, respectively (p < 0.05). In 168h almost 100% of drug was release 
in BNIPDSpm-HNP-PEG in pH=3.6 (Figure 53). 
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Figure 54: Drug release BNIPDSpm-HNP and BNIPDSpm-HNP-PEG in 50˚C at pH=7.5, pH=4.6 
and pH=3.6 (p < 0.05). Experiments were performed three times, and data were expressed 
as mean ± standard errors (n=3, ave ± SD). 
At 50 ˚C, 50 % release from BNIPSDpm-HNP in pH=7.5, pH=4.6 and pH=3.6 occurred in 3 h, 1 
h and 0.5 h, while this amount of drug released from PEGylated formulations in 2 h , 0.5 h 
and 0.33 h with the same pH mentioned above, respectively (Figure 54). These data suggest 
that decreasing pH significantly enhanced the release rate of drug from both formulations   
(p <0.05). Moreover, release rate of BNIPDSpm from PEGylayed formulation is higher than 
the release from unPEGylated formulation (p < 0.05) (Figure 54). After 168 h the drug 
completely released from both formulations at 50 oC in pH=3.6.  
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Stability of HNPs in physiological conditions 
The ICP results represented the chemical stability of HNP and HNP-PEG at pH=7.5, pH=4.6 
(Figure 55). 
 
Figure 55: Physical stability of HNP (Fe) and HNP-PEG (Fe) at pH=7.5, pH=4.6 (p < 0.05). 
Experiments were performed three times, and data were expressed as mean ± standard 
errors (n=3, ave ± SD). 
The results were compared with the initial amount of Fe weight at the first of experiment 
which was 100 μgmL-1. At pH 7.2 a maximum of 0.032% ± 0.52 of the iron concentration was 
observed in the media for the HNP and 0.030% ± 1.35 of iron were released for HNP-PEG in 
same pH. The graph demonstrated that the results for HNP was slightly more than HNP-PEG 
as the matter of fact the HNP-PEG was more stable than HNP however the results was not 
significantly different (p > 0.05). At pH 4.6, particle degradation was bigger than pH 7.5       
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(p < 0.05). At pH 4.6 an initial burst release of iron (0.034% ± 1.25) was observed in the first 
24 h for HNP followed by a slow incline over the duration to a maximum of 0.065%± 1.37 
and 0.066%± 0.77 for HNP and HNP- PEG respectively (p > 0.05). The increased degradation 
compared with at higher pH can be attributed to the iron core being slowly dissolved in 
acidic environments (Hoskins et al., 2012b). 
3.4. Discussion 
In previous studies, the ability of conjugation of different bisnaphthalamide based drugs 
onto their surface via electrostatic interactions or covalent bonds  onto the surface of HNPs 
with gold nanoparticles were assessed and compared (Malekigorji et al., 2017). In that 
research the conjugation ability of BNIDi, BNIPd, BNIPds and BNIPDSpm were compared 
together (Malekigorji et al., 2017). According their test results by FTIR spectra the BNIDi 
could not be conjugated to the surface of HNPs (even with the highest loading 
concentration). BNIDi does not have amine group in the structure and amine group is very 
important and critical for making electrostatic interaction between the drug and HNPs 
(Malekigorji et al., 2017). The BNIPd formulations were not stable and most of attached 
drug on the HNP were released easily in initial minutes. In fact, the low number of amine 
group made BNIPd formulation unsuitable for drug delivery system (Malekigorji et al., 
2017). On the other hands, due to the low release rate of BNIPds from formulations in 
different pH and temperatures, BNIPds could not be good option for conjugating the drug 
on HNP surface (Malekigorji et al., 2017). Consequently the best drug loading, releasing and 
stability was BNIPDSpm-HNP due to the BNIPDSpm molecule possessing the greatest 
number of amine groups (four amines) compared with other drugs . The amine group is a 
crucial factor for electrostatic interaction to the surface of HNPs, as two central amines in 
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bisnaphthalmide chain seem to have more affinity to the gold surface (Malekigorji et al., 
2017). 
In the other research Barnett and co-works proved that the thiol-containing pendant group 
can raise the connection of HNPs by dative covalent bonding (Barnett et al., 2013b). The 
PEG-Thiol effects were assessed on delivery systems by Dreaden and colleagues and the test 
results confirmed that PEG-Thiol can circulate in the blood for a long time and can avoid the 
killing by mononuclear macrophages (Dreaden et al., 2010). The Thiol-PEG also can 
encapsulate anticancer drug and control drug release (Maus et al., 2010).   
In first step, different ratio of HNP and the drug were mixed together and the solution was 
stirred for 3 h at room temperature (20 oC). After separating the solution and highly washing 
with deionised water for three times, the amount drug loading were assessed by HPLC. The 
results demonstrated that the ratio of 1: 10 HNP: BNIPDSpm had the highest level of drug 
loading which was 90.88%± 1.03. In fact, 1mg.mL-1 HNP (Fe) was conjugated 9 mg.mL-1 of 
the drug in optimum ratio. In next step, various ratios of powdered polymer (based on the 
concentration used in the literature for PEG-thiol) were added with the solution 
respectively. The particles were washed after 3 h as previously described. It was assumed 
that PEG will coat the surface of HNPs completely if it was added before the drug, thus no 
free surface would be available for the drug attachment (Barnett et al., 2013a; Barnett et 
al., 2013b). The percentage of drug conjugation was 94.21%± 0.83 which mean 1mg.mL -1 
HNP (Fe) was conjugated 9.42 mg.mL-1 of the drug in optimum ratio (1:10:10 
HNP:BNIPDSpm:PEG-Thiol) (Table 9). 
HNP possess a negative surface charge (-3.05 ± 0.29 mV) before conjugating with the drug. 
BNIPDSpm have 4 amine groups so the surface charge were shifted to positive (+32.51 ± 
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0.35 mV) when the drug were conjugated to the HNP. The previous researches 
demonstrated that the presence of amine groups increased the surface charge of the 
particles (Kardys et al., 2013). The surface charge for BNIPDSpm-HNP-PEG was positive but 
lower than BNIPDSpm-HNP (+18.77 ± 0.41 mV), indicating further modification of PEG. This 
could be due to PEG chains shielding surface charge of silver coating. The decrease of zeta 
potential confirms also the binding of thiol groups on silver surface. Thiol group and PEG 
shifted the zeta potential toward negative values (Ku et al., 2010). 
FTIR were carried out for HNP, BNIPDSpm-HNP and BNIPDSpm-HNP-PEG to approve the 
conjugation of drugs onto the HNPs. The presences of peaks for C-H (3442 cm-1), N-H 
stretching (2930 cm-1) and N-H bending (1651 cm-1) proved the presence of PEI in HNP. The 
FTIR Bands demonstrated the presence of aromatic in-plane C-H bending, aromatic C=C 
stretching, C=O (Stretching) bands and C-H (Stretching) which presented the existence of 
BNIPDSpm-HNP and BNIPDSpm-HNP-PEG respectively. On the other hands, bigger peak 
observed at 1341 cm−1 (C–H bending; −CH2 and −CH3) confirm the presence of bound PEG 
within BNIPDSpm -HNP- PEG formulation (Figures 43 A and 43 B). 
HPLC results were shown that formulation state and temperature are two important factors 
in the stability of HNP. The results were shown that solid state is more stable than liquid 
state it might be due to the presence of water in in aqueous formulations, which can raise 
the risk of drug release from the nano-carriers. Moreover decreasing temperature can 
increase the stability. In comparison between 20 ᵒC and 4 ᵒC, the test result illustrated the 
new formulations were more stable in 4 ᵒC than 20 ᵒC. Infect, reducing temperature leads to 
less drug detachment and protects the integrity of the electrostatic bonds and presumably 
due to the stronger electrostatic binding on the HNP surface.  
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After finding amount of drug loading by HNPs and HNPs-PEG-Thiol, the amount of drug 
release were assessed as well. The method followed previous reports revealed linear 
correlation model between In vitro drug release in water and in vivo absorption (Bose and 
Wui, 2013; Cardot et al., 2007). Barnett et al. were placed the HNP in dialysis membrane 
and the volume of dialysis fluid was in excess to mimic the ‘sink’ conditions experienced 
after injection into the blood stream (Barnett et al., 2013a). Drug release study for 
formulations was achieved at different temperatures (37 ˚C, 44 ˚C, 50 ˚C & 60 ˚C) in 
deionised water and RPMI. This test was carried out to mimic the temperature change upon 
the laser irradiation. Jelveh and Chithrani used this method to check the release of drug 
from gold NPs after laser irradiation (Jelveh and Chithrani, 2011). The drug releasing were 
carried out in pH=4.6 and pH=3.6 in deionised water and PRMI to simulate endosome and 
lysosome environment as well. In this case the pH was adjusted by using concentrated 
hydrochloric acid (20 M).  
BNIPDSpm-HNP and BNIPDSpm-HNP-PEG were assessed in terms of the amount of drug 
release in 20 ˚C, 37 ˚C, 44 ˚C, 50 ˚C and 60 ˚C (Figures 47A and 47B) (p < 0.05). BNIPDSpm 
release for both formulations measured over 72 h showed a biphasic release profile due to 
an initial burst, which is followed by a constant release. In 20 ˚C the drug was released 
9.69% ± 0.12 in first 10 minutes for BNIPDSpm-HNP and also 11.73% ± 0.92 in first 10 
minutes for BNIPDSpm-HNP-PEG. The drug releasing was increased sharply over 3 h for all 
temperatures and then slightly increased over 72 h. This low drug release over 72h could be 
due to the strong electrostatic interactions between the drug and particles, as BNIPDSpm 
have four amines groups within its structure. However the drug releasing result for 
BNIPDSpm-HNP-PEG was better than BNIPDSpm-HNP in all temperatures. In the absence of 
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PEG, BNIPDSpm and HNP might have stronger interactions as flattened at the surface of the 
particles because of the abundance of free space. In the presence of PEG, drug might have 
challenge with the polymer for the particles surface. 
The graphs demonstrated that increasing temperature will increase drug realising. In this 
case in 60 ˚C, the drug was released 59.22% ± 0.66 over 72 h for BNIPDSpm-HNP and also 
78.31% ± 0.91 for BNIPDSpm-HNP-PEG over 72 h. Moreover reducing pH considerably 
increased the release rate of drug from both formulations as electrostatic interactions can 
be broken faster in lower pH (p < 0.05). In fact, lower pH was broken the electrostatic 
interactions in NPs and can separate the drug from NPs amine groups. The data’s were 
shown that in first 4 h the drug release rate were significantly higher than after that             
(p <0.05). 
The drug release were analysed in in culture media at pH= 7.5, pH=4.6 and pH=3.6 at 20 ˚C, 
37 ˚C and 44 ˚C and 50 ˚C up to 312 h to mimic cytoplasm (pH =7.42), endosome and 
lysosome environment in pancreatic cancer cells, respectively. The drug release was 
increased with increasing temperature and decreasing pH because the electrostatic 
interactions in NPs were broken and can separate the drug from NPs amine groups. 
Moreover, drug release in BNIPDSpm-HNP-PEG was significantly higher than BNIPDSpm-
HNP in culture media.  
As we discussed in chapter 2 (achieved by laser irradiation), we assessed the drug release in 
different pH in 44 ˚C and 37 ˚C. In this case, the release pattern of the formulations inside 
the pancreatic cancer cells, before and after laser irradiation can be predicted. In body 
temperature, 64% ± 1.92 of drug was release for BNIPDSpm-HNP-PEG at pH=3.6 before 312 
h. Moreover, in 44 oC, 100% of drug was release in BNIPDSpm-HNP-PEG at pH=3.6 after    
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168 h (p < 0.05). Therefore, it is assumed that after accumulation of the NPs in endosome 
and lysosome, the low environmental pH and increasing the temperature through laser 
irradiation, will result in quick drug release from the particles. Then the free drug can enter 
cells` nucleus and interact with DNA for anticancer effect.  
In cancer therapy, many drugs such as small molecule chemotherapeutic agents, siRNA, 
DNA and proteins have to be delivered by a carrier and released into the particular cellular 
compartments, which is usually cytoplasm or nucleus of cancer cells. Intracellular 
environment-responsive NPs, which possess high extracellular stability while rapidly 
releasing their cargo inside cancer cells have been enormously investigated for improving 
cancer therapy (Park et al., 2006). The HNP and HNP-PEG physical stability was assessed in 
cell culture media during 4 weeks at pH=7.2 and pH=4.6. At pH 7.2 a maximum of 0.032% ± 
0.52 of the iron concentration was observed in the media for the HNP and 0.030% ± 1.35 of 
Iron were released for HNP-PEG in same situation. The graph demonstrated that the results 
for HNP was slightly more than HNP-PEG as the matter of fact the HNP-PEG was more stable 
than HNP however the results was not significantly different (p > 0.05). At pH 4.6, particle 
degradation was bigger than pH 7.2 (p < 0.05). At pH 4.6 an initial burst release of iron 
(0.034% ± 1.25) was observed in the first 24 h for HNP followed by a slow incline over the 
duration to a maximum of 0.065%± 1.37 and 0.066%± 0.77 for HNP and HNP- PEG 
respectively. 
3.5. Conclusion 
BNIPDSpm was loaded on the HNP surface with high rate in optimum ratio. The drug loading 
were assessed and confirmed by FTIR and also changing surface charges in HNP, HNP- 
BNIPDSpm and HNP-BNIPDSpm-PEG. The HPLC and ICP demonstrated that HNP and HNP-
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PEG have high physical and formulation stabilities. Drug release study of BNIPDSpm 
formulations demonstrated that quicker release was occured by increasing the temperature 
and reducing the pH in water and culture media (close to the pH of intracellular organelles). 
Moreover, PEGylated formulations mostly revealed greater release of drug in comparison 
with their unPEGylated counterparts. 
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Chapter Four 
Drug loading and release 
from linker targeted 
formulation 
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4.1. Introduction 
Arginine-glycine-aspartic acid (RGD) peptides 
Targeting drugs to tumour cells is a significant way to improve existing cancer therapies. 
Directing therapeutic agents like such as toxins, viruses for gene therapy, enzymes for 
prodrug therapy chemo- or radiotherapeutic drugs can increase the ability of anticancer 
drugs and to reduce side effects (DeNardo, 1998). In the 1970s, it was reported that 
arginine–glycine–aspartic acid (RGD) tripeptide could be used cell recognition molecule and 
adhesion ligand for targeting (Ruoslahti and Pierschbacher, 1987).  
RGD peptides ares integrin antagonist whichlinks to integrin αvβ3, which plays a significant 
role in tumour angiogenesis (Wang et al., 2013; Chakravarty et al., 2015; Cai and Conti, 
2013). Integrin αvβ3, is a receptor for the extracellular matrix proteins with the exposed 
RGD tripeptide sequence. Integrin αvβ3 receptor has been reported on several types of 
cancer cells, including pancreatic cancer and plays an important role in tumour growth and 
metastasis (Hwang and Varner, 2004).  The cell adhesion molecule, integrin ανβ3, is highly 
prevalent in tumour cells and much less prevalent on normal healthy tissue (Wu et al., 
2005). The ability to target the integrin αvβ3 receptor on cancer cells increases the efficacy 
of targeted therapy and reduces the side effects (Xiong et al., 2006). RGD and RGD 
derivatives have been extensively used in studies of adhesion, cell migration, apoptosis and 
growth by RGD-integrin interactions (Hwang and Varner, 2004).   
RGD analogues are used in antiangiogenics approaches (Haubner et al., 2001) in tumour 
targeting with radio nucleotides (Hagen et al., 2000), in tumour imaging (Pasqualini et al., 
2000) and or chemotherapeutic drugs (Arap et al., 1998). Subsequently, RGD and different 
136 
 
cyclic RGD (cRGDfK, cRGDyK, cRGDfC and iRGD) (Figure 56) have been developed and 
significantly studied (Sheldrake and Patterson, 2009), (Mas-Moruno et al., 2010), (Paolillo et 
al., 2009) and (Auzzas et al., 2010).  
 
Figure 56: Schematic representation of the most commonly employed RGD peptide 
sequences (Cheng and Yuanhui, 2018). 
In comparing linear RGD and cyclic RGD, The cyclic RGD has been shown to be more 
selective and stabile than linear RGD and has been widely used to increase binding to 
certain integrin (e.g. ανβ3). iRGD can undertake as both a cell penetrating peptide and an 
integrin-homing peptide to improve the drug delivery to the tumour microenvironment and 
increase tumour penetration (Duro-Castano et al., 2017). In recent years, RGD-modified 
polymers, liposomes and other nano vehicles have been used for cancer therapy including 
photodynamic therapy, gene therapy, combination therapy, photo thermal therapy and 
chemotherapy. Many studies have been carried out to use RGD-modified nano-vehicles for 
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transporting drugs. In comparison with efficiency of monotherapy, the mixture of multiple 
treatments helps more overcome drug resistance through different mechanisms (Mas -
Moruno et al., 2010).  
Cyclo (Arg–Gly–Asp–D-Phe–Cys) (c(RGDfC)) is the cyclic RGD peptide which can inhibite 
αvβ3 integrin. c(RGDfC) functionalised with an aminooxy functionality via a suitable linkage 
(Xiang-Guo et al., 2012). The c(RGDfc) peptide was made by solid phase synthesis and 
functionalised by aminooxy conjugation with various sugars include D-ribose, 2-FDG, 6-FDG 
and D-Glucose under acid conditions (Figure  57) (Xiang-Guo et al., 2012). 
 
Figure 57: Functionalisation of c(RGDfC) (Xiang-Guo et al., 2012). 
c(RGDfC)) can attach to ανβ3 integrin and connect on the surface of polymeric micelle as the 
targeting group. c(RGDfC)) increased endocytosis mediated by the ανβ3 integrin in the 
surface of tumour cells in micelle body. Shen and his group studied on three types of colon 
tumour-bearing models consist of subcutaneous implantation, in situ induction and in situ 
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surgery transplantation models, in BALB/c mice were created for in vivo tumour inhibition 
assesses. Targeting delivery system c(RGDfC)) displayed advanced tumour tissue 
accumulation and antitumor abilities in comparison with those of the non-targeting 
platform in all three different tumour models. Consequently, c(RGDfC)-decorated targeting 
drug delivery systems have extensive clinical application prospect (Shen et al., 2015). 
Ji et al. studied on RGD-conjugated albumin nanoparticles as a novel delivery vehicle in 
pancreatic cancer therapy in 2012 (Ji et al., 2012). According to their research, RGD peptide 
was conjugated to albumin nanoparticle to increase the intracel lular uptake of anticancer 
drug into the pancreatic cancer cells  (BxPC-3). In the cellular uptake reports, the fluorescent 
signal of RGD-conjugated bovine serum albumin nanoparticles (BSANPs) in BxPC3 cells was 
greater than alone BSANPs according fluorescence spectrophotometer results.  
The uptake of RGD-conjugated BSANPs by pancreatic cancer cells was constrained by an 
excess amount of free RGD peptide, indicating that the binding and/or uptake were 
intercedes by the αvβ3 receptor (Ji et al.2012). Moreover, the nanoparticles were initiated 
to be placed close to the nuclei by using laser scanning confocal microscopy. Furthermore, 
no major in vitro cytotoxicity was found as measured with MTT assay. Both in vitro and in 
vivo antitumor ability was increased by targeting gemcitabine-loaded nanoparticles to BxPC-
3 cells using RGD peptides. Consequently, the RGD-conjugated BSANPs hold high potential 
as an effective drug delivery system to deliver therapeutic agents to pancreatic cancer (Ji et 
al., 2012). 
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Aims and objectives 
In this Chapter the c(RGDfC) peptide will be conjugated onto the achieved optimum ratio of 
BNIPDSpm-HNP-PEG and the drug uptake will comprise between gemcitabine (described in 
Chapter 1) and different BNIPDSpm formulations.The drug optimum loading will assess by 
HPLC in order to characterising BNIPDSpm-HNP-PEG- c(RGDfC) peptide conjugation and also 
Drug uptake potentials will assess in human epithelial-like pancreatic carcinoma (PANC-1).  
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4.2. Materials and methods 
Materials used 
Table12. Materials used in RGD characterization and drug uptake 
Materials Suppliers 
Cyclo(-Arg-Gly-Asp-D-Phe-Cys) peptide Bachem Co., Switzerland 
HPLC Grade ethanol Fisher Scientific, UK 
Thiolated poly ethylene glycol (PEG-thiol) Sigma-Aldrich Co., UK 
PRMI culture medium Life technologies Co., UK 
Penicillin streptomycin Life technologies Co., UK 
Phosphate buffered saline Fisher Scientific, UK 
Foetal bovine serum Fisher Scientific, UK 
Trypsin-EDTA Life technologies Co., UK 
Highly purified water MillexQ system (UK) 
Acetonitrile Sigma-Aldrich Co., UK 
Bis(naphthalimidopropyl)spermine 
(BNIPDSpm) 
Synthesised by Keele nanopharmaceutics 
Research group 
BxPC-3 cell line (Passage number:10) LGC Standards Co., UK 
Gemcitabine Sigma-Aldrich Co., UK 
Octane sulfonic acid Sigma-Aldrich Co., UK 
Sodium acetate ACROS Organics Co., USA 
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Methods 
Peptide conjugation to HNP-BNIPDSpm-PEG thiol and characterisation of the new 
formulation 
HNPs (2.5 mL, 1 mg mL-1), 25mg BNIPDSpm (dissolved in 5 mL deionised water), 25 mg PEG-
thiol (1:10:10 HNP:BNIPDSpm: PEG Thiol) and 1 mg c(RGDfC) peptide were added together. 
The mixture was stirred for 3 h and then magnetically separated and highly washed for 3 
times with deionised water. The amount of the attached drug and conjugated peptide was 
identified by RP-HPLC (Prominence, DEGASSER, LC20AD, SHIMADZU). For drug conjugation 
quantification the method which was described in Chapter 3, section 3.2.2.3.5.1 was used. In 
order to determine the amount of conjugated peptide, RP-HPLC with a fluorescence 
detector at 250 nm (excitation) and 307 nm (emission) (Jasco, PU-980, Japan; column 
C18(2), 150×4.60 mm 5 micron, flow rate: 1 mLmin-1, injection volume: 20μL) was used. The 
different mobile phase was used for detecting c(RGDfC) peptide in HPLC (Jin et al., 2007). 
The mobile phase was contained 50:50 of two different solvents. First solvent was including 
0.09 % trifluoroacetic acid (TFA) and second solvent contained acetonitrile containing 9.91% 
H2O and 0.09 % TFA (Jin et al., 2007). Before injecting 1 mL of sample was diluted with 1 mL 
of acetonitrile and then 20μL of the mixture was transferred into the HPLC.  
The amount of the peptide conjugated was calculated after assessing the amount of 
attached drug from the amount of free drug in waste solution. All measurements were 
carried out for three times. 
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For finding optimum drug attached, 1:10:10 HNP:BNIPDSpm:PEG-Thiol which has highest 
percentage of drug loading in compare with the other ratios HNPs solutions (1 mg  mL-1) 
(described in Chapter 3 section 3.2.2.3.5.1) were mixed with the c(RGDfC) peptide in the 
ratio (HNP: c(RGDfC) peptide) 1:1, 1:5, 1:10 respectively. The solutions were stirred for 3 h 
at room temperature. Finally the solution was magnetically separated and highly washing 
with deionised water for three times. The particles were separated from the supernatant 
(waste solution) after drug conjugation by using a strong permanent magnet on the outside 
of a glass vial containing the formulation. The waste solution (1 mL in water) was diluted 
with 1 mL of DMSO and drug concentrations were analysed via HPLC. All measurements 
were run in triplicate and recorded as average values. 
Cellular uptake of formulations in vitro 
For cellular uptake, human primary pancreatic adenocarcinoma cells (BxPC-3) were cultured 
in Roswell Park Memorial Institute (RPMI) media, with 1 % penicillin/ streptomycin and 10 % 
foetal bovine serum. Cells were seeded 150000 cells/ well in their exponential growth phase 
into 6-well plates and incubated for 24 h at 37° C with 5 % CO2. The media was removed and 
3 mL of 25 μgmL-1 & 50 μgmL-1 gemcitabine, BNIPDSpm, HNP-BNIPDSpm, HNP-BNIPDSpm-
PEG Thiol and HNP-BNIPDSpm-PEG Thiol- c(RGDfC) peptide were replaced and incubated for 
1 h and 4 h. The medium was removed and each well was washed with 1 mL phosphate 
buffered saline (PBS) and removed again. Trypsin (185μL) was added into each well. The 
wells were incubated for 3 min to detach the cells from the monolayer and 815μLof fresh 
media was added to the each well. This solution (50μL) was added to 50μL blue trypan and 
mixed in an Eppendorf tubes. The number of dead, live and total cells were counted using 
an automated cell counter (Invitrogen countess®, UK).  
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Cells were aliquoted (100,000) and diluted in DMSO: water (1:1) (for samples containing 
bisnaphthalamide derivatives) or water (for samples containing gemcitabine). The 
concentration of the drugs in different samples was measured using reverse phase high 
performance liquid chromatography (HPLC). Gemcitabine characterizing was carried out 
with HPLC with UV detector (Perkin Elmer, Flexar Autosampler and column: SPHERISORB 
ODS 2 5μm, length 250 mm, internal diameter 4.6 mm). Gemcitabine mobile phase was 
contained 30% H2O and 70% acetonitrile (Losa et al. 2006). The standard solutions of 
gemcitabine were scanned in the range of 200-400 nm against mobile phase as a blank. 
Gemcitabine demonstrated maximum absorbance at 234 nm with flow rate of 1 mL (Losa et 
al., 2006).  
Characterisation of bisnaphthalamide by reverse phase HPLC (Prominence, Degasser, 
LC20AD, Shimadzu) was described in Chapter Three (Section 3.2.2.2). 
4.3. Results 
Conjugation of targeting peptide onto the optimal formulation 
HPLC peak indicate that c(RGDfC) peptide was conjugated on the HNP successfully. Also 
amount of drug and targeting peptide were analysed by RP-HPLC. A calibration was carried 
out in rang of 0.03 – 0.96 μgmL-1 (R2 = 0.9999) (Figure 58).   
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Figure 58: Calibration graph of RGD peptide.  
The c(RGDfC) peptide sharp peak was observed at around 17 min at the concentration of 
0.683 μgmL-1 of c(RGDfC) (Figure 59). 
 
Figure 59:  Reverse phase HPLC analysis (with fluorescence detector) of 0.183 μgmL-1 
c(RGDfC). 
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The drug had sharp peak which observed between 9-10 min and same as the peak which 
described in Chapter 3 in Figure 39 (section 3.2.2.3.5.1). 
The concentration of the BNIPDSpm and c(RGDfC) peptide in BNIPDSpm-HNP-PEG-c(RGDfC) 
formulation was characterized and calculated by HPLC. The HPLC test result demonstrated 
that 4.113 ± 0.032 mg mL-1 of BNIPDSpm and 0.204 ± 0.011 mg mL-1 of c(RGDfC) peptide 
were conjugated in BNIPDSpm-HNP-PEG-c(RGDfC) formulation. Consequently 51 % of the 
initial amount of peptide was able to conjugate to the surface of HNPs. 
Different ratios c(RGDfC) peptide were added to the optimum ratio HNP-Drug-PEG Thiol 
(1:10:10 respectively). These ratios were including 1:10:10:1 HNP:BNIPDSpm:PEG-
Thiol:c(RGDfC), 1:10:10:5 HNP:BNIPDSpm:PEG-Thiol:c(RGDfC) and 1:10:10:10 
HNP:BNIPDSpm:PEG-Thiol:c(RGDfC). The drug conjugation was according to the Figure 60. 
 
Figure 60: Drug conjugations in different ratios of c(RGDfC).   
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According to the Figure 60, increasing ratios of c(RGDfC) did not have effect in drug 
conjugation. In ratio of 1:10:10:1 HNP:BNIPDSpm:PEG-Thiol: c(RGDfC), 95.03% ± 3.25  of 
drug was attached into the HNP. Almost same result was observed in different ratios of RGD 
as well.  Table 13 was demonstrated that 23.75 mg ± 3.25 of the drug (out of 25 mg) was 
attached into the HNP (2.5 mL, 1mg mL-1) (Table 13) (p < 0.05).  
Table 13: Drug loading with different ratios of c(RGDfC). Experiments were performed three 
times, and data were expressed as mean ± standard errors (n=3, ave ± SD). 
Different Ratios (mg.mL-1 ) Drug conjugated (out of 25 mg) 
1:10:10:1 HNP:BNIPDSpm:PEG-Thiol:RGD 23.75 ± 3.25 
1:10:10:5 HNP:BNIPDSpm:PEG-Thiol:RGD 23.11 ± 2.45 
1:10:10:10 HNP:BNIPDSpm:PEG-Thiol:RGD 23.59 ± 4.01 
 
Drug uptake investigations on BxPC-3 Cell line 
Drug uptake was investigated and compared between control anticancer drug 
(gemcitabine), BNIPDSpm and novel hybrid formulations  at different concentrations and 
times. The amount of accumulated free drug was quantified by RP-HPLC. A calibration      
was run using gemcitabine solutions, dissolved in H2O with the concentration of                
18.75 - 300μgmL-1 (R2 = 0.999) (Figure 61)  
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Figure 61: Calibration graph of Gemcitabine in HPLC. 
Drug uptake was investigated as a control anticancer drug at 25 μgmL-1 and 50 μgmL-1 
concentrations for 1 h and 4 h for gemcitabine (Figure 62). The amount of accumulated free 
drug was quantified by RP-HPLC.  
 
Figure 62: Drug uptake with Gemcitabine at 25 μgmL-1 and 50 μgmL-1 concentrations for 1 h 
and 4 h (n=3, ave ±SD).   
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Figure 62 demonstrates time and concentration are two important factors in increasing level 
of drug up taking. The drug uptake for 25 μgmL-1 gemcitabine on BxPC-3 cells was 91pg per 
cell after 1h (p < 0.05). The drug uptake on BxPC-3 cells was increased slightly to 95pg per 
cell for 50 μgmL-1 gemcitabine at same time (p < 0.05). After 4h incubation with 25μgmL-1 
and 50 μgmL-1 of gemcitabine with BxPC-3 cells, amount of 105pg per cell and 134pg per cell 
of drug was taken up by the cells, respectively (p < 0.05). 
BNIPDSpm (free drug), BNIPDSpm-HNP, BNIPDSpm-HNP-PEG and BNIPDSpm-HNP-PEG-RGD 
were incubated on BxPC-3 cells at 25 μgmL-1 and 50μgmL-1 concentrations for 1 h and 4 h 
(Figure 63).  
 
Figure 63: Drug uptake with BNIPDSpm and its formulations at 25 μgmL-1 and 50 μgmL-1 
concentrations for 1 h and 4 h (n=3, ave ±SD) (p < 0.05). 
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and 7pg per cell of the free drug was taken by cell after 4 h. Also at 50μgmL -1, 5pg per cell 
and 9pg per cell of free drug were taken on BxPC-3 Cell line after 1 h and 4 h respectively (p 
< 0.05). As BNIPDSpm formulations (with four amine groups in drug`s chemical structure) 
were more positive (discussed in Chapter Three), they were taken up more by BxPC-3 cells 
which might be related with the charge-charge interactions of positive formulation with the 
negative cell membrane. The test results demonstrate that by increasing time the drug 
uptake will increase significantly and also raising concentration can increase the drug uptake 
as well. BNIPDSpm-HNP drug uptake was significantly higher result in compare with 
BNIPDSpm (p < 0.05).  
The test result was demonstrated that during first hour around 31pg and 41pg of drug was 
taken by cells at 25 μgmL-1 and 50 μgmL-1. On the other hand, 62pg per cell and 84pg per 
cell of the drug attached by BxPC-3 Cells at 25 μgmL-1 and 50 μgmL-1 after 4h (p < 0.05).  At 
25 μgmL-1 HNP-BNIPDSpm-PEG, after 1 h incubation, 55 pg of BNIPDSpm was taken up from 
free drug and after 4h incubation 82 pg per cell of the drug was attached by the cells. At    
50 μgmL-1 HNP-BNIPDSpm-PEG, after 1 h incubation, 65 pg per cell of BNIPDSpm was taken 
up from free drug and after 4 h incubation 104 pg per cell of the drug was attached by the 
cells. The HNP-BNIPDSpm-PEG test result was higher than free drug and HNP-BNIPDSpm but 
lower than Gemcitabine drug up taken (p < 0.05).  
Consequently the target formulation had the highest drug uptake in compare with free drug 
and the formulations although the test result was slightly lower than Gemcitabine. The 
target formulation test result was demonstrated that during first hour around 67 pg per cell 
and 71 pg per cell of drug was taken by cells at 25 μgmL-1 and 50 μgmL-1. On the other hand, 
87 pg per cell and 108pg per cell of the drug attached by BxPC-3 Cells at 25 μgmL-1 and 50 
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μgmL-1 after 4 h (p < 0.05). As discussed before, free BNIPDSpm enters to cells through cell 
membrane pores/channels which is not energy dependant, but particles internalise by 
endocytosis, thus slower proliferation resulted in a bit less uptake of hybrid formulations 
compared to the Gemcitabine (p >0.05).  
4.4. Discussion 
αvβ3 integrin receptor which has been effective with different types of cancer including 
breast, ovarian, prostate, melanoma, glioblastoma, cervical, colon and pancreatic cancer 
(Demircioglu and Hodivala-Dilke, 2016). ανβ3 integrin receptor is a selective target with high 
potential for diagnosis and therapy of cancer (Demircioglu and Hodivala-Dilke, 2016). RGD 
peptide has high potential to act as a tumour-targeting moiety for decreasing adverse 
effects and enhancing anti-tumour activity (Verrier et al., 2012).  
Expansion of novel RGD peptides against integrin αvβ3 with greater affinity, better 
specificity, and improved stability represents a new trend in this field (Verrier et al., 2012). 
Novel RGDs such as cRGDfK, cRGDyK, cRGDfC and iRG were investigated to expand the anti-
tumor activity (Sheldrake and Patterson, 2009; Paolillo et al., 2009; Auzzas et al., 2010).  
Zuo and colleagues conjugated iRGD peptide (CRGDK/RGPD/EC) to the surface of super 
paramagnetic iron oxide nanoparticles (SPIONs) to enhance labelling of PANC-1 cells in 
cancer imaging. They suggested that SPIONs with iRGD peptide can raise the uptake and 
labelling rate of PANC-1 (Zuo et al., 2014). 
The concentration of the BNIPDSpm and c(RGDfC) peptide in BNIPDSpm-HNP-PEG-c(RGDfC) 
formulation was characterized and calculated by HPLC. c(RGDfC) peptide was successfully 
conjugated to the surface of BNIPDSpm-HNP-PEG (PEGylatedbformulation was used in order 
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to increase biocompatibility) and the amount of attached BNIPDSpm and peptide were 
analysed by RP-HPLC.  The HPLC test result demonstrated that 4.113 ± 0.032 mg mL-1 of 
BNIPDSpm and 0.102 ± 0.011 mg mL-1 of c(RGDfC) peptide were conjugated in BNIPDSpm-
HNP-PEG-c(RGDfC) formulation. Consequently 51 % of the initial amount of peptide was 
able to conjugate to the surface of HNPs. For RGD optimum drug conjugation, 1:10:10 
HNP:BNIPDSpm:PEG-Thiol which has highest percentage of drug loading were mixed with 
the c(RGDfC) peptide in the ratio (HNP: c(RGDfC) peptide) 1:1, 1:5, 1:10 respectively. In ratio 
of 1:10:10:1 HNP:BNIPDSpm:PEG-Thiol:c(RGDfC), we observed the maximum drug 
conjugation (95.03% ± 3.25  of drug was attached into the HNP). Almost same result was 
observed in different ratios of RGD as well.    
Drug uptake of gemcitabine, BNIPDSpm and HNP formulations were investigated and 
compared at 25 μgmL-1 and 50 μgmL-1 concentrations for 1 h and 4 h for BxPC-3. The 
amount of accumulated free drug was quantified by RP-HPLC. Drug uptake study of 
BNIPDSpm on BxPC-3 cells showed that hybrid formulations were taken up significantly 
higher than free drug (p < 0.05) (Figure 63). The drug uptake for 25 μgmL-1 gemcitabine on 
BxPC-3 cells was 91pg per cell after 1h. The drug uptake on BxPC-3 cells was increased 
slightly to 95pg per cell for 50 μgmL-1 gemcitabine at same time. After 4h incubation with 
25μgmL-1 and 50 μgmL-1 of gemcitabine with BxPC-3 cells, amount of 105pg per cell and 
134pg per cell of drug was taken up by the cells, respectively (p < 0.05). The test results 
demonstrated that the drug uptake for free drug and its formulations was BNIPDSpm<HNP-
BNIPDSpm<HNP-BNIPDSpm-PEG<HNP-BNIPDSpm-PEG-RGD.  
The best result was for the target formulations which has the highest drug uptake after 4 h. 
The target formulation test result was demonstrated that during first hour around 67pg per 
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cell and 71pg per cell of drug was taken by cells at 25μgmL -1 and 50μgmL-1. On the other 
hand, 87pg per cell and 108pg per cell of the drug attached by BxPC-3 Cells at 25 μgmL-1 and 
50 μgmL-1 after 4 h (p < 0.05). 
The test results demonstrated that the drug uptake for HNP-BNIPDSpm-PEG-RGD was 
significantly greater than free drug in different concentrations and times (p < 0.05) . It can 
prove that the target peptide play important role for efficient delivery of the drug into 
cancer cells. The RGD formulation was also higher than HNP-BNIPDSpm and BNIPDSpm-PEG 
However the HNP formulation with RGD was not significantly higher than HNP-BNIPDSpm-
PEG. It might be because this is a monolayer cell culture and not representative of 3D in vivo 
physiology. As the matter of fact in monolayer cell culture many challenges remain, 
including the mechanical microenvironment, the tissue-tissue interface and the 
spatiotemporal distributions of oxygen, nutrients, and metabolic wastes. These challenges 
may lead to affect in RGD formulation for uptaking drug in the cancer cells  (Duval et al., 
2017). 
The presence of targeting peptide within the formulations resulted in comparable uptake 
rate to gemcitabine. Gemcitabine has not significant increase in compare with target 
formulation, however previous researches was shown that the cytotoxicity of Gemcitabine 
was more than BNIPDSpm and its formulations (Malekigorji et al., 2017). In next Chapter the 
cytotoxicity of free drug and its formulation and also Gemcitabine will compare together. 
4.5. Conclusion 
The target peptide successfully conjugated in the novel drug formulations. In vitro drug 
uptake study also validated that hybrid formulations internalise and accumulate inside 
153 
 
pancreatic cancer cells significantly higher than free drugs. The target formulations had the 
highest drug uptake after 1 h and 4 h in from free drug and its formulations. 
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Chapter Five 
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characterisation of 
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formulations 
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5.1. Introduction 
Cytotoxic drugs  
Cytotoxic drugs or cytostatic (also cytotoxic chemotherapy) are drugs  which are used to 
destroy cancerous cells. Cytotoxic prevent the prolific cancer cell division and are commonly 
used either before or after surgery depending on the stage of the cancer. Cytotoxic drugs 
also reduce instances of metastases and can stop cancer progression or remove total cancer 
in patients. Using types of cytotoxic drugs depend on type of tumour, its mechanism, rate of 
development and ratio of cells in the distribution stage (Joensuu et al., 2013).  
Cytotoxic drugs are transported in the bloodstream throughout the body, which often poses 
a problem for the already sick patients which require them. Although cytotoxic drugs are 
valuable for cancer treatment, they are highly toxic and therefore kill healthy cells as well as 
their cancerous targets.  
As a result almost all chemotherapie possess very unpleasant side effects which patients 
must endure including hair loss, damage to the mouth and pharynx mucosa, bone marrow 
depletion, fatigue, diarrhoea and nausea. For instance, in their effect on bone marrow, the 
cytoxicity can lead to a drop in white blood cell, blood platelet and haemoglobin counts. 
Damage to the bone marrow enhances the risks of infection and communicable disease 
(Joensuu et al., 2013).  
The other disadvantages of chemotherapy also include swelling, changes to fingernails and 
toenails, symptoms affecting the mucous membranes of the eyes , muscle pain, 
hypersensitivity, constipation, premature menopause symptoms in women due to 
oestrogen deficiency and numbness in the hands and soles of the feet (Joensuu et al., 2013). 
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There are numerous techniques which have been studied in order to increase the efficacy of 
anticancer agents such as enhancing the solubility or uptake rate of drugs by cancer cells, 
mitochondria targeted drugs delivery (Modica-Napolitano and Weissig, 2015) and targeted 
delivery to tumour (Jeanbart et al., 2014). However, many of these methods failed to 
increase the site specific delivery of chemotherapeutic agents. The main reason is most of 
new compounds detected are insufficiently soluble in aqueous media or lack the ability for 
preferential uptake in cancerous cells (Lindenberg et al., 2004). 
In pancreatic cancer the first line treatment in the UK is with gemcitabine, or gemcitabine in 
combination with capecitabine.  Gemcitabine side effects include flu-like symptoms (muscle 
pain, fever, headache, chills, and fatigue), Fever (within 6-12 hours of first dose), fatigue, 
nausea (mild), vomiting, poor appetite, skin rash, low blood counts (Kasuya et al., 2012). 
Moreover, the resistance of pancreatic ductal adenocarcinoma (PDAC) cells to the 
chemotherapeutic agents remains a significant obstruction to effective chemotherapy 
(Chakraborty and Rahman, 2012).  
Recent studies have demonstrated that the epithelial and stromal compartments interact to 
enhance the aggressive nature of this cancer (Rasheed et al., 2012). Consequently, it is 
important to improve anticancer therapies targeting the stroma and epithelial cells, which 
may play a key role in clinical outcome development for cancer treatment (Rasheed et al., 
2012). In this chapter cytotoxicity of new formulations were determined in vitro as it is 
important to confirm the biocompatibility before introducing to in vivo environments.  
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Cytotoxicity assay 
MTT assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is extensively applied 
for cell viability and cytotoxicity assays (Lamprecht et al., 2000). The enzymatic reduction of 
3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to MTT-formazan has 
been catalyzed by mitochondrial succinate dehydrogenase (Figure 64) (Carmichael et al., 
1987).  
 
Figure 64: MTT to formazan mechanism (Carmichael et al., 1987). 
The MTT assay is a colorimetric reaction.  The mono layers cell can be counted in different 
plates such as 35 mm dishes or multi well plates. The test is according to the treating cells in 
their exponential growth phase to the MTT solution (Lamprecht et al., 2000). The assay 
relies on the reduction of MTT, a yellow water-soluble tetrazolium dye, primarily by the 
mitochondrial dehydrogenases, to purple coloured formazan crystals. The formazan product 
is analysed spectrophotometrically (550 nm) after dissolution in DMSO, the spectra of 
nanoparticle-treated and untreated cells giving validate of the extent of cytotoxicity (Lu et 
al., 2012). It’s been studied that 4 h is the optimal time for cells to be incubated with MTT. 
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After 4 h, the accurate viability determination by dissolving the formazan crystal in dimethyl 
sulfoxide (DMSO), following calculating the absorbance formazan solutions by a microplate 
reader. Consequently, the percentage of cell viability can be analysed and half maximal 
inhibitory concentration (IC50) can be identified (Carmichael et al., 1987). 
Trypan blue assay 
Trypan blue exclusion (TB) is a test used to distinguish the number of viable cells existing in 
a cell population compared with those which are dead (Tennant, 1964). The viable cells are 
displayed refractive, small and rounded while dead cells are presented dark blue, swollen 
and large (Tennant, 1964). In the TB test, a cell suspension should mix with same amount 
trypan blue and then visually tested to identify whether cells take up or exclude the dye. 
The solution move into the plate and cells can be measured by an automated cell counter or 
by a microscope. The IC50 value can be identify regarding the number of control cells 
(Tennant, 1964). 
Aims and objectives 
In this chapter the toxicity of BNIPDSpm, HNP-BNIPDSpm, HNP-BNIPDSpm-PEG and HNP-
BNIPDSpm-PEG-RGD and Gemcitabine were characterised using MTT and Trypan Blue 
assays. In vitro testing is an essential step in order to determine whether the novel 
formulations tested were better than existing drug therapies.  
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5.2. Materials and methods 
Materials used for this chapter 
Table14. Materials used for toxicity assay. 
Materials Suppliers 
Cyclo(-Arg-Gly-Asp-D-Phe-Cys) peptide Bachem Co., Switzerland 
3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich Co., UK 
Thiolated poly ethylene glycol (PEG-thiol) Sigma-Aldrich Co., UK 
RPMI culture medium Life technologies Co., UK 
Penicillin streptomycin Life technologies Co., UK 
Phosphate buffered saline Fisher Scientific, UK 
Foetal bovine serum Fisher Scientific, UK 
Trypsin-EDTA 0.05 % Life technologies Co., UK 
Highly purified water MillexQ system (UK) 
Bis(naphthalimidopropyl)spermine 
(BNIPDSpm) 
Synthesised by Keele nanopharmaceutics 
Research group 
BxPC-3 cell line LGC Standards Co., UK 
Gemcitabine Sigma-Aldrich Co., UK 
Dimethyl sulfoxide Sigma-Aldrich Co., UK 
phosphate buffered saline (PBS) Sigma-Aldrich Co., UK 
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Methods 
Cell culture and sub culturing 
BxPC-3 cells were cultured in Roswell Park Memorial Institute (culture medium)  (RPMI cell 
culture medium) supplemented with 1 % penicillin streptomycin and 10 % foetal bovine 
serum.  BxPC-3 cells grown in RPMI were incubated in an ESCO CO2 Incubator at 5% CO2 at 
37 °C for 3-4 days. The BxPC-3 cells were monitored under microscope to monitor cell 
growth; cells were allowed to grow to 70% confluency before being sub cultured.  The 
media was removed and 10mL phosphate buffered saline (PBS) added to the flask. The PBS 
was subsequently removed and 2.5mL trypsin added to the cells and the flasks where 
incubated for 5 min. Trypsin can separate the cells from the flask, once the cells were 
detached, 7.5mL RPMI was added to the flasks for further cell growth.  
Cytotoxicity Assay 
Cytotoxicity of free drugs, hybrid nanoparticles (HNP) naked and new formulations was 
investigated by using two different cytotoxicity assays: MTT and Blue trypan.  
MTT assay procedure 
BxPC-s cells (100μL, 15000 cells/ well) in exponential growth phases were seeded into 96 
well flat bottomed plate and incubated for 24 h at 37 °C with 5 % CO2. After 24 h, the media 
was replaced with various concentrations of gemcitabine, BNIPDSpm, naked HNPs, 
BNIPDSpm-HNP, BNIPDSpm-HNP-PEG Thiol and BNIPDSpm-HNP-PEG-RGD diluted in cellular 
growth medium. In 96 wells, Serial dilution solutions were made from these stock solutions 
(1x10-1 - 1x10-5 mg mL-1) using media as the diluent (Table 15).   
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Table15. Preparation of Excipient Solutions for MTT assay. 
Drug concentration  
(mg mL-1) 
Volume of 20 mg mL-1 drug 
stock solution (μL) 
Total volume of media (ml) 
0.1 22.5 4.5 
0.05 11.5 4.5 
0.025 5.6 4.5 
0.01 2.25 4.5 
0.005 1.125 4.5 
*0.001 90 4.5 
*0.0001 9 4.5 
*0.00001 1 4.5 
 
* Sample was made from 0.05 mg mL-1 concentration as a stock solution and the same 
concentrations of drug discussed in Table 14 were prepared. Furthermore, the 
concentrations made for naked HNP presents the concentration of iron oxide in hybrid 
formulations (HNP-drug). 
A 20 mg mL-1 of each free drug solution was prepared using 50:50 of sterile water: DMSO as 
the diluent to form a stock solution. MTT well plates have 12 rows which including eight 
dilutions (0.1 - 1×10-5 mg mL-1) were made using media as the diluent, Media which is 
positive control and deionised water which is negative control. Several 96 well plates were 
carried out with same MTT method. Samples were incubated for 24 h, 48 h and 72 h to 
check the effect of time on the cell viability. 
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After incubating the cells in different times (24 h, 48 h and 72 h) the drug solutions were 
removed and washed with fresh media to remove any excess drug. Fresh media was 
replaced into the wells (100μL). 3-[4, 5-dimethylthiazole-2-yl]-2, 5-diphenyl tetrazolium 
(MTT, 50μL, 5 mg mL-1 in PBS) was added to the wells and plate was incubated (37 °C with 5 
% CO2) for 4 h. After 4 h, the MTT solution was removed from the wells and 100μL of DMSO 
was replaced to dissolve the purple formazan crystals trapped in cells. The light absorbance 
of the resultant purple colour was identified at 570 nm by the using a microplate reader 
(Tecan, infinite 200 pro, GmbH 5082, Australia). All assays were carried out in triplicate. 
Percentage of cell viability and IC50 was calculated according to the microplate reader result 
for samples, negative and positive controls data. Percentage of cell viability and IC50 was 
calculated according to below equation.  
% Cell Viability = 
𝐴𝑏𝑠 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒−𝐴𝑏𝑠 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
𝐴𝑏𝑠 𝑜𝑓 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −𝐴𝑏𝑠 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
 x 100 
 
Trypan blue cytotoxicity test 
BxPC-3 cells (1 mL, 50000 cells/ well) in exponential growth phase was placed and seeded 
into 12 well flat bottomed plates. The plates were incubated for 24 h at 37°C with 5 % CO2. 
The samples such as drug, HNPs and novel formulations were placed in the plates with 
different concentrations with same method which described for MTT assay. The plates were 
incubated for 24 h, 48 h, and 72 h to check the effect of time on toxicity of different 
samples.  Then the media was soaked from plates and cells were washed 3 times with PBS. 
The cells were trypsinised and re-suspended in fresh media. The sample and trypan blue 
solution were mixed together with ratio of 1:1 (50μL: 50μL) and the mixture was placed in 
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an automated cell counter (Invitrogen Countess®, UK) to count the variable cells. Percentage 
of cell viability and IC50 was calculated according to below equation. 
% Cell Viability = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠 
 x 100 
 
In vitro thermo-responsive cytotoxicity assay 
Thermal responsive cytotoxicity assay was carried out on 96 wells plate for MTT assay and 
12 well flat bottomed plates for trypan blue test on BxPC-3 cells. The cells were seeded in 
free drug, HNPs and new formulations with same methods as described before and pre-
incubated for 4 h at 37°C in a humidified atmosphere of 95% air and 5% CO 2. After this time, 
96-well (MTT) and 12-well (blue trypan) plates were removed and placed into a pre-warmed 
incubator type Memmert IN-30 and heated at 44°C (to mimic the heat generated by the SPR 
of laser irradiated HNP silver coatings) and 60°C respectively for half an hour. After 0.5 h the 
plates were incubated again for 24 h, 48 h and 72 h respectively. Calculation cell viability 
was calculated as described in MTT and blue trypan sections. The % cell viability and IC50 
was identified for all the plates and the results were compared to the non-activated plates 
in order to investigate the effect of temperature and time on cell cytotoxicity. 
5.3. Results 
MTT and Trypan blue Cytotoxicity of drugs, naked HNP and novel formulations 
MTT and trypan blue assays were carried out to check and compare free drugs, naked HNP 
and new formulations toxicity. Cell viability of BxPC-3 incubated with unloaded HNPs were 
identified by the MTT cytotoxicity test and trypan blue exclusion assay in 24 h, 48 h and 72 h 
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(Figure 65 A and B). The concentrations illustrate in the graph for HNP are exactly same as 
the concentration of hybrid formulations but definitely without drug (the concentrations of 
Fe in HNP and hybrid formulations are the same).  There was no significant difference 
between the MTT and trypan blue test results (p>0.05). In (1.0 × 10-5 - 0.005 mg mL-1)         
the cell viability was around 98% in MTT and 96% in trypan blue (p > 0.05). Between            
0.05mg mL-1 – 0.01 mg mL-1 slight decreased was observed and the cell viability around 91% 
in MTT and Trypan blue tests. Consequently at 0.1 mg mL-1, the cell viability was  87% and 
85% in MTT and Trypan Blue respectively (p > 0.05) However, this is much more 
concentrated than would ever be expected to be managed in the drug formulation to a 
patient in the clinic (Cortajarena et al. 2014). The test results were demonstrated that 
increasing time did not have significant effect on HNP cell viability. After 48 h the test results 
were almost same as 24 h and. The cell viability was decreased for 14%-18% at highest 
concentration in MTT and Trypan blue respectively (p > 0.05). After 72 h, the cell viability 
was around 84% and 80% in MTT and Trypan blue respectively. The cell viability decreased 
for 16%-20% in highest concentration and after 72 h. (p > 0.05) (Figure 65A and 65B).   
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Figure 65: Cell viability of BxPC-3 exposed to HNPs and measured with MTT (A) and Trypan 
blue (B) tests in 24 h, 48 h and 72 h (n=3,±SD). 
The cell viability of BxPC-3 cells incubated with BNIPDSpm (free drug) measured using the 
MTT cytotoxicity test and trypan blue exclusion assay in 24 h, 48 h and 7 2h (Figure 66A and 
66B). In 1.0 × 10-5 mg mL-1 to 0.005 mg mL-1, the cell viability was decreased for around 6% - 
8% in MTT and Trypan blue respectively after 24 h. Also at this concentration, the cell 
viability was decreased around 12% - 13% in MTT and Trypan blue respectively after 48 h 
and around 14% - 17% in MTT and Trypan blue respectively after 72 h. The significant 
decrease was observed between 0.05mg mL-1 to 0.1mg mL-1 in MTT and trypan blue in 24 h, 
48 h and 72 h (p < 0.05). In 0.1 mg mL-1 concentration, 31% and 21% of cells were alieved in 
MTT and Trypan Blue respectively after 24 h (p < 0.05). The test results were demonstrated 
that increasing time slightly decreased the cell viability of BxPC-3. After 48 h, the cell 
viability was decreased for 73% - 85% at highest concentration in MTT and Trypan blue 
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respectively (p > 0.05). The cell viability decreased for 77% - 90% in highest concentration 
and after 72 h. (p > 0.05) (Figure 66A and 66B).   
 
 
Figure 66:  Cell viability of BxPC-3 exposed to BNIPDSpm in different times for MTT (A) and 
Trypan blue (B) (n=3, ±SD). 
The cytotoxic effect of hybrid formulations, BNIPDSpm and Gemcitabine (IC50) was tested 
and compared together with MTT cytotoxicity test and trypan blue exclusion assay on BxPC-
3 cells for 24 h, 48 h and 72 h by GraphPad Prism 6 software (Figure 67). The IC50 achieved 
within the concentrations tested from 1.0 × 10-5 mg mL-1 to 0.1mg mL-1. Gemcitabine IC50 
was calculated over 100μgmL-1 with MTT cytotoxicity test and trypan blue exclusion assay 
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on BxPC-3 cells for all different times (24 h, 48 h and 72 h). Therefore, no IC50 was noticeable 
using both the MTT assay and trypan blue cytotoxicity test for gemcitabine after 24 h, 48 h 
and 72 h. The MTT test results demonstrated, the IC50 for BNIPDSpm was 17.31±0.72μgmL
-1, 
17.11 ± 0.11μgmL-1 and 16.48 ± 0.91 μgmL-1 after 24 h, 48 h and 72 h respectively. Moreover 
the trypan blue test results demonstrated the IC50 for BNIPDSpm was 24.57 ± 0.91 μgmL
-1, 
23.97 ± 1.06μgmL-1 and 23.41 ± 0.02μgmL-1 after 24 h, 48 h and 72 h respectively. The IC50 of 
the free drugs was around 10, 13 and 14 times greater than HNP-BNIPDSpm, HNP-
BNIPDSpm-PEG and HNP-BNIPDSpm-PEG-RGD respectively after 24 h and these differences 
were increased significantly with increasing time (p < 0.05). This specifies that hybrid 
formulation was able to enhance the therapeutic effect of the drug compared with the free 
BNIPDSpm. MTT assay was demonstrated that, IC50 value of HNP-BNIPDSpm-PEG was 
0.83μgmL-1, 0.92μgmL-1 and 0.93 μgmL-1 lower than HNP-BNIPDSpm in 24 h, 48 h and 72 h 
respectively. Moreover in trypan blue IC50 value of HNP-BNIPDSpm-PEG was 1.16μgmL-1, 
1.17 μgmL-1 and 0.97 μgmL-1 lower than HNP-BNIPDSpm in 24 h, 48 h and 72 h respectively. 
The target formulation had the lowest IC50 value in compare with free drugs and non-
targeted formulations. The MTT test results demonstrated, the IC50 for HNP-BNIPDSpm-PEG-
RGD was 1.18 ± 0.02 μgmL-1, 0.99 ± 0.55 μgmL-1 and 0.79 ± 0.48 μgmL-1 after 24 h, 48 h and 
72 h respectively. Moreover the trypan blue test results demonstrated the IC 50 for target 
formulation was 1.62 ± 0.15 μgmL-1, 1.32 ± 0.17 μgmL-1 and 1.11 ± 0.33 μgmL-1 after 24 h, 48 
h and 72 h respectively (p > 0.05).These results confirm that the hybrid formulations have 
significantly higher efficacy compared with free drugs (p < 0.05) (Figure 67). 
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Figure 67: IC50 value of drugs and hybrid formulations on BxPC-3 cells obtained by MTT 
cytotoxicity test and trypan blue exclusion assay after 24 h, 48 h and 72 h (p < 0.05) (n=3, 
ave ± SD). IC50 achieved within the concentrations tested (0.1 – 1.0 × 10
-5 mg mL-1) and for 
Gemcitabine IC50 achieved over 100 μgmL
-1 by GraphPad Prism 6 software. * denotes 
significant decrease in IC50 from hybrid formulations compared with drug alone. 
In vitro thermo-responsive cytotoxicity assay 
The cytotoxicity assay for free drug, HNP and new formulations were carried out to assess 
the effect of time and temperature on cell toxicity. In this case MTT and trypan blue tests 
(triple times for each test) were carried to check and compare the test results in 37 oC, 44 oC 
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and 60 oC at 24 h, 48 h and 72 h. The test results were demonstrated that the MTT and 
trypan blue results were almost same as each other. In this case the average data’s of MTT 
and trypan blue were used for identifying thermos responsive cytotoxicity assay. Figure 68A, 
68B and 68C demonstrated the effect of temperature on HNP, BNIPDSpm, HNP-BNIPDSpm, 
HNP-BNIPDSpm-PEG and HNP-BNIPDSpm-PEG-RGD at 24 h, 48 h and 72 h respectively. Test 
results were demonstrated that time and temperatures are two main factors in cytotoxicity 
assay however in general, the result indicated that increasing the temperature and time had 
no significant impact on cytotoxicity of HNPs in compare with free drug and the other 
formulations (p > 0.05). After 24 h the cell viability of highest concentration of HNPs           
(0.1mg mL-1) decreased for 87%, 85% and 76% in 37 oC, 44 oC and 60 oC respectively. The cell 
viability in same concentration of HNPs was 86%, 81% and 71% in 37 oC, 44 oC and 60 oC 
after 48h respectively. At 72 h, the cell viability in same concentration of HNPs was 84%, 
78% and 67 % in 37 oC, 44 oC and 60 oC respectively. The test results demonstrated that time 
and temperature has significant effect on free drug and the new formulations. In 
comparison, after 24h the cell viability of highest concentration of BNIPDSpm (0.1 mg mL-1) 
decreased for 21%, 10% and 9% in 37 oC, 44 oC and 60 oC respectively. The cell viability in 
same concentration of HNPs was 17%, 9% and 5% in 37 oC, 44 oC and 60 oC after 48h 
respectively. In 72, the cell viability in same concentration of HNPs was 9%, 3% and 1 % in   
37 oC, 44 oC and 60 oC respectively (p < 0.05) (Figure 68 A, 68B and 68C). 
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Figure 68: In vitro thermo-responsive cytotoxicity test on BxPC-3 cell line at (A) 24 h, (B) 48 h 
and (C) 72 h (n=3,±SD). 
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According Figure 68A, 68B and 68C cytotoxicity of hybrid formulations on BxPC-3 cells 
considerably increased upon the time and temperature increase. The target formulation 
indicated the highest cytotoxicity on BxPC-3 cells. The viability of BxPC-3 cells treated with 
BNIPDSpm-HNP-PEG-RGD at 25 oC, 44 oC and 60 oC were 1 %, 0 % in 0.1 mg mL-1 and 0 % 
from 0.05mg mL-1 after 24 h, respectively (Figure 68A). The viability of BxPC-3 cells treated 
with BNIPDSpm-HNP-PEG-RGD at 25 oC, 44 oC and 60 oC were 0 % in 0.1mg mL-1, 0 % from 
0.05 mg mL-1 and 0 % from 0.025 mg mL-1 after 48 h, respectively (Figure 68 B). Finally, the 
viability of BxPC-3 cells treated with BNIPDSpm-HNP-PEG-RGD at 25 oC, 44 oC and 60 oC 
were 0 % from 0.05 mg mL-1, 0 % from 0.025 mg mL-1 and 0 % from0.01mg mL-1 after 72 h, 
respectively (p > 0.05) (Figure 68C). 
Further reduction in cell viability and IC50 was achieved upon the treating of BxPC-3 with 
BNIPDSpm in comparison with new formulations in different times and temperatures. Cell 
viability of BxPC-3 treated with new formulations was considerably smaller than free drug in 
different time and temperatures (Table 16). The cell viability and IC50 test results  illustrated 
that on BxPC-3 cells, Cytotoxicity of HNP-BNIPDSpm-PEG-RGD> HNP-BNIPDSpm-PEG> HNP-
BNIPDSpm > BNIPDSpm. The IC50 of free drug was almost 10, 14 and 15 times bigger than 
HNP-BNIPDSpm, HNP-BNIPDSpm-PEG and HNP-BNIPDSpm-PEG-RGD respectively (P < 0.05) 
(Table 16).  
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Table16. IC50 of hybrid formulations at different temperature and time in comparison with 
free BNIPDSpm on BxPC-3 cell line (n=3, ± SD). 
 
Time 
(h) 
Incubation 
Temperature 
(oC) 
 
BNIPDSpm 
(μgmL-1) 
 
HNP-BNIPDSpm 
(μgmL-1) 
HNP-BNIPDSpm-
PEG 
(μgmL-1) 
HNP-BNIPDSpm- 
PEG – RGD 
(μgmL-1) 
 
24 
37 20.94 ± 0.72 2.47 ± 1.21 1.47 ± 1.67 1.41 ± 0.11 
44 19.67 ± 0.37 2.02 ± 0.99 1.20 ± 0.64 1.32 ± 0.92 
60 17.29 ± 0.81 1.39 ± 0.05 0.91 ± 2.59 0.86 ± 1.21 
 
48 
37 20.54 ± 1.03 2.34 ± 0.94 1.31 ± 0.07 1.25 ± 0.63 
44 19.01 ± 1.21 1.91 ± 2.67 1.16 ± 0.77 1.07 ± 0.85 
60 16.99 ± 0.54 1.01 ± 0.57 0.59 ± 0.68 0.46 ± 1.92 
 
72 
37 19.94 ± 0.15 2.01 ± 0.09 1.18 ± 0.41 0.95 ± 0.03 
44 18.64 ± 1.11 1.83 ± 0.69 1.01 ± 0.29 0.79 ± 1.22 
60 16.05 ± 3.83 0.79 ± 0.81 0.25 ± 1.21 0.08 ± 0.73 
 
The temperature and time have significant effect on cytotoxicity of free drug and hybrid 
formulations. Although the lowest IC50 and cell viability of hybrid formulations on BXPC3 cell 
line was occurred in 60 oC, The cell viability of BXPC3 cell in expose of 0.1mg mL-1 naked 
HNPs was decreased to 76%, 71% and 67% at 24h, 48h and 72h respectively. In comparison, 
in 44 oC had lower effect of HNPs on BXPC3 cell line. In this temperature, the cell viability of 
BXPC3 cell in expose of 0.1mg mL-1 naked HNPs was decreased to 85%, 81% and 78% at 24 
h, 48 h and 72 h respectively. 
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5.4. Discussion 
Pancreatic ductal adenocarcinoma (PDAC) is related with poor survival as often diagnosed 
when they have metastasised. Radiotherapy and chemotherapy of PDAC is still largely 
consisting of classical cytotoxic chemotherapy agents (Zuo et al., 2014). The PDAC 
chemotherapy drugs side effects are including Flu-like symptoms (muscle pain, fever, 
headache, chills, and fatigue), Fever (within 6-12 hours of first dose), fatigue, nausea (mild), 
vomiting, poor appetite, skin rash, low blood counts (Kasuya et al., 2012). It is essential to 
improve anticancer therapies targeting the stroma and epithelial cells, which may play a key 
role in clinical outcome development for cancer treatment (Rasheed et al., 2012). General 
toxicity tests, such as MTT cytotoxicity assay and trypan blue exclusion cytotoxicity test are 
require to identify the biological activity of drugs and formulations, which can be carried out 
on many cell types. 
Brana et al. reported bisnaphthalimides as powerful chemotherapeutic agents (Brana et al., 
1980). Bisnaphthalimide derivatives are detected to have considerable anti-tumour activity 
in both human cancerous cells and murine (Brana et al., 2001). Existence of planar aromatic 
moieties in these molecules can insert within the DNA by entry via the major groove (Sami 
et al., 2000). In this research, MTT and trypan blue assays were carried out to check and 
compare free drugs, naked HNP and new formulations toxicity. Cell viability of BxPC -3 
incubated with unloaded HNPs were identified by the MTT cytotoxicity test and trypan blue 
exclusion assay in 24h, 48h and 72h (Figure 65 A and B). There were not significant different 
between MTT and trypan blue test results. In 0.1 mg mL-1 HNP concentration 87% and 85% 
of cells were alieved in MTT and Trypan Blue respectively (p > 0.05) However This is much 
more concentrated than would ever be expected to be managed in the drug formulation to 
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a patient in the clinic (Cortajarena et al., 2014). Barnett and colleagues reported that there 
was no significant cytotoxic effect for cells incubated with the high concentration of HNPs 
(100μg mL-1) with both BxPC-3 and differentiated U937 cells for up to 1 week (Barnett et al., 
2013a). In this research, test results were demonstrated that increasing time did not have 
significant effect on HNP cell viability. The cell viability decreased for 16%-20% in highest 
concentration and after 72 h. (p > 0.05). In comparison, the BXPC3 cell viability in expose of 
free drug (BNIPDSpm) was decreased for 77% - 90% in highest concentration and after 72h 
(p < 0.05). 
Gemcitabine IC50 was calculated over 100μgmL
-1 with MTT cytotoxicity test and trypan blue 
exclusion assay on BxPC-3 cells for all different times (24 h, 48 h and 72 h). Therefore, no 
IC50 was noticeable using both the MTT assay and trypan blue cytotoxicity test for 
gemcitabine after 24 h, 48 h and 72h. The MTT test results demonstrated, the IC50 for 
BNIPDSpm was 17.31 ± 0.72 μgmL-1, 17.11 ± 0.11 μgmL-1 and 16.48 ± 0.91 μgmL-1 after 24 h, 
48 h and 72 h respectively. Moreover, the trypan blue test results demonstrated the IC50 for 
BNIPDSpm was 24.57 ± 0.91 μgmL-1, 23.97 ± 1.06 μgmL-1 and 23.41 ± 0.02 μgmL-1 after 24 h, 
48 h and 72 h respectively. The IC50 of the free drugs was around 10, 13 and 14 times 
greater than HNP-BNIPDSpm, HNP-BNIPDSpm-PEG and HNP-BNIPDSpm-PEG-RGD 
respectively after 24 h and these differences were increased significantly with increasing 
time (p < 0.05). 
The cytotoxicity assay for free drug, HNP and new formulations were carried out to assess 
the effect of time and temperature on cell toxicity. In this case MTT and trypan blue tests 
(triple times for each test) were carried to check and compare the test results in 37 oC, 44 oC 
and 60 oC at 24h, 48h and 72h. Test results were demonstrated that time and temperatures 
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are two main factors in cytotoxicity assay however in general, the result indicated that 
increasing the temperature and time had no significant impact on cytotoxicity of HNPs in 
compare with free drug and the other formulations (p > 0.05). After 72h, the BXPC3 cell 
viability expose 100 μgmL-1 HNP was 84%, 78% and 67 % in 37 oC, 44 oC and 60 oC 
respectively. The cell viability and IC50 test results  illustrated that on BxPC-3 cells, 
Cytotoxicity of HNP-BNIPDSpm-PEG-RGD> HNP-BNIPDSpm-PEG> HNP-BNIPDSpm > 
BNIPDSpm. The IC50 of free drug was almost 10, 14 and 15 times biger than HNP-BNIPDSpm, 
HNP-BNIPDSpm-PEG and HNP-BNIPDSpm-PEG-RGD respectively. 
In previous studies, the cytotoxicity iron oxide-gold HNPs, BNIPDSpm-HNP-PEG and also 
BNIPDSpm-HNP-PEG-c(RGDfC) were compared with different bisnaphthalamide based drugs 
such as BNIPDSpm and gemcitabine (Malekigorji et al., 2017). According their research, in 
the highest concentration of HNPs (100 μgmL-1) 19-23 % decrease in viability was occurred 
after 24 h incubation. In comparison, at 0.1 mg mL-1, the cell viability of iron oxide-silver 
HNPs was 13% and 15% in MTT and Trypan Blue respectively. Although silver is more toxic 
than gold, our test results represented that the silver not effecting it and that this 
formulation may have benefits over hers such as antimicrobial nature as very recent studies 
have shown that bacteria in pancreatic tumour hinders therapy (McAllister et al., 2019).  
Although our HNP cytotoxicity tests represented lower toxicity results than iron oxide-gold 
HNPs, almost same results were observed between target formulations. Previous research 
demonstrated that after 24h incubation of BxPC-3 cells with BNIPDSpm-HNP-PEG-c(RGDfC), 
the IC50 was 1.15 μgmL-1 by MTT cytotoxicity test (Malekigorji et al., 2017). In this research, 
the IC50 for RGD was 1.18μgmL
-1 after 24 h by MTT cytotoxicity test. The previous studies 
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demonstrated that silver nanoparticles play important role in increasing cancer drugs 
activities (Gavamukulya et al. 2019). 
It is assumed (in relation to the drug release studies) that by increasing the particles 
temperature (accumulated inside the pancreatic cancer cells) via laser irradiation, drug will 
be released from HNP inside the cells; thus the hybrid formulations are able to kill 
pancreatic cancer cells in a more efficient way. In 44 oC had lower effect of HNPs on BXPC3 
cell line than 60 oC. In this temperature, the cell viability of BXPC3 cell in expose of         
0.1mg mL-1 naked HNPs was decreased for 15%, 19% and 22% at 24 h, 48 h and 72 h 
respectively. In comparison, the viability of BxPC-3 cells treated with target formulation 
(BNIPDSpm-HNP-PEG-RGD) in 44 oC was 0% after 24h (p > 0.05). 
5.5. Conclusion 
This study demonstrates the potential ability of BNIPDSpm novel formulations to 
accumulate and kill pancreatic cancer cells in compare with free drugs such as Gemcitabine 
and BNIPDSpm. However there was not significant toxicity effect with naked HNP pancreatic 
cancer cells. Test results has shown that increasing time and temperature are two main 
factors for increasing killing pancreatic cancer cells by new HNP formulations. Further 
research has to be performed in vitro and in vivo to fully exploit the properties of these 
nanoparticles for image guided thermally triggered drug delivery. 
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Chapter Six 
General conclusions  
 
 
178 
 
Hybrid iron oxide-silver core-shell nanostructures (HNPs) were successfully designed, 
synthesised and characterised. For the synthesis of HNPs, iron oxide nanoparticles were 
synthesised and coated with PEI. Colloidal silver seeds were synthesised and attached 
electrostatically onto the Fe3o4-PEI forming Fe3O4-PEI-AgNPseed. After this, acidic silver was 
reduced onto the surface forming to complete coating of the HNPs. These particles were 
characterised by different techniques such as their magnetic properties, particle size, zeta 
potential, inductively coupled plasma (ICP), ultraviolet light (UV) and transmission electron 
microscopy (TEM). The colour was changed in each stage of iron oxide coating which can 
indicate the status of each step. In each step of synthesising the sample was characterised 
by photon correlation spectroscopy and zeta potential measurement. The surface charge 
constantly shifted between positive and negative between the iron oxide, silver and PEI 
during coating. PEI caused to shift surface charge to positive as the presence primary amine 
groups in the structure. The changing zeta surface charge demonstrates that the coating 
was successful. The particle sizes were measured in each step for checking nanoparticle size 
and confirming that the particle was not aggregated. The particle size was shift to smaller 
size as the coatings in each step reduced the aggregation of the particles. The ICP data 
demonstrates that iron oxide core was successfully coated with silver forming the HNPs with 
a ratio between Fe and Ag of 3:1. The TEM images indicated that the silver seeds were 
successfully anchored onto the surface of the Fe3O4-PEI and also that subsequent coating 
had been achieved. TEM image of Silver nanoparticles were indicated the size of 5nm. The 
TEM images demonstrated that AgNPs were not aggregated after 6 weeks from 
synthesising. TEM image of the fully coated Fe3O4-PEI coated with Ag seeds displayed 
unique shape and different from the iron oxide core and the size was 85 nm. According to 
the UV data there was no plasmon resonance appears for Fe3O4 and Fe3O4-PEI which was 
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expected. Ag seeds have λmax of 400 nm. The Fe3O4-PEI-Ag seeds indicated λmax shift to 450 
nm which might be due to the interaction between solute and solvent or Ag shell and PEI 
polymer. Finally, the λmax of 490 nm was observed for HNP. Ideally a laser around 490 nm 
may result in better heating of the particles – however caution is advised as this sits below 
the biological near infrared window whereby tissue is not damaged.  
Silver-iron oxide HNPs demonstrates greater thermal capability in lower concentrations 
(25μgmL-1) in comparison with gold-iron oxide HNPs which have been previously reported in 
the literature (Malekigorji et al., 2017). The laser results demonstrate that there are 
significant changes between times, concentration between different HNPs in compare with 
the control. At concentrations of 25μgmL-1, ΔT was 7 °C ± 0.35 and at 50μgmL-1, ΔT was 11 
°C ± 0.56 at 37 °C in 30 s. The Laser data demonstrates high increasing temperature in first 5 
sec followed by a more discrete rise up to 15 s, after which a plateau was observed.  
The heat dissipation analysis away from the laser culmination point was measured and 
analysed for different times. The heat dissipation results clearly demonstrated that there is 
not differ between 2 points in any concentrations or times. At 25 μgmL-1 and 50 μgmL-1, the 
heat dissipation changes were not significant for 0 - 2 mm but the changes were dropped 
significantly from 2 mm to 10 mm. The SPR optimal wavelength of the particles was 500 nm 
and our HNPs observed heat generation up to 11 °C at 50 μgmL-1 and dissipation up to 10 
mm away from radiation site for 25μgmL-1 (0 s and 10 s). Consequently lower concentration 
would be more suitable for these purposes. Not only the heating generation was not 
significant different with higher concentration, but the heating effect was not occurred or 
with a small increase (1 oC) after 10 mm for 25 μgmL-1. It can decrease possibility of 
surrounding tissues damage.  
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HNPs were coated using thiolated poly (ethylene glycol) (PEG-thiol) to increase 
biocompatibility. The presence of and BNIPDSpm and PEG-Thiol in HNP was characterised by 
photon correlation spectrometer, Fourier transforms infrared spectroscopy (FTIR) and High 
performance liquid chromatography (HPLC). The surface charge results demonstrated that 
the ‘naked’ HNPs possessed a negative surface charge (-3.05 ± 0.29 mV) before conjugating 
with the drug. The surface charge shifted to positive (+32.51 ± 0.35 mV) after drug 
conjugation as BNIPDSpm possessed 4 amine groups. The surface charge for BNIPDSpm-
HNP-PEG was positive but lower than BNIPDSpm-HNP (+18.77± 0.41 mV), indicating further 
modification of PEG.  
FTIR were carried out for HNP, BNIPDSpm-HNP and BNIPDSpm-HNP-PEG to approve the 
conjugation of drugs onto the HNPs. The presences of peaks for C-H (3442 cm-1), N-H 
stretching (2930 cm-1) and N-H bending (1651 cm-1) proved the presence of PEI in HNP. The 
FTIR Bands demonstrated the presence of aromatic in-plane C-H bending, aromatic C=C 
stretching, C=O (Stretching) bands and C-H (stretching) which presented the existence of 
BNIPDSpm-HNP and BNIPDSpm-HNP-PEG respectively. On the other hands, bigger Peak 
observed at 1341 cm−1 (C–H bending; −CH2 and −CH3) confirm the presence of bound PEG 
within BNIPDSpm -HNP- PEG formulation. 
The ability of BNIPDSpm and BNIPDSpm-PEG to conjugate onto the surface of the silver 
HNPs, optimum drug releasing and physical and chemical drug stability were carried out by 
HPLC and ICP. HPLC results demonstrated that the ratio of 1:10 HNP:BNIPDSpm have 
highest percentage of drug conjugation. In this ratio, the percentage of drug conjugation 
was 90.88 %± 1.03 which means that 1 mg mL-1 HNP (Fe) conjugated 9 mg mL-1 of the drug 
in optimum ratio. Moreover the ratio of 1:10:10 HNP:BNIPDSpm:PEG-Thiol has highest 
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percentage of drug loading in compare with the other ratios. In this ratio, the percentag e of 
drug conjugation was 94.21 %± 0.83 which mean 1mg mL-1 HNP (Fe) was conjugated 9.42 
mg mL-1 of the drug in optimum ratio. 
HPLC results were shown that formulation state and temperature are two important factors 
in the physical stability of HNP. The results were shown that solid state is more stable than 
liquid state. It might be due to the presence of water in in aqueous formulations, which can 
raise the risk of drug release from the nano-carriers. Moreover decreasing temperature can 
increase the stability.  
The HPLC results demonstrated that increasing temperature will increase drug realising. In 
this case in 60 ˚C, the drug was released in deionised water at 59.22% ± 0.66 over 72 h for 
BNIPDSpm-HNP and also 78.31% ± 0.91 for BNIPDSpm-HNP-PEG over 72 h. Moreover 
reducing pH considerably increased the release rate of drug from both formulations as 
electrostatic interactions can be broken faster in lower pH. In fact, lower pH was broken the 
electrostatic interactions in NPs and can separate the drug from NPs amine groups. The 
HPLC data’s were shown that in first 4 h the drug release rate were significantly higher than 
after that. In BNIPDSpm-HNP-PEG the drug completely released after 75 h at 60 oC. The drug 
release in BNIPDSpm-HNP and BNIPDSpm-HNP-PEG were analysed in in culture media at 
pH= 7.5, pH=4.6 and pH=3.6 at 20 oC, 37 oC and 44 oC and 50 oC up to 312 h to mimic 
cytoplasm (pHi =7.42), endosome and lysosome environment in pancreatic cancer cells, 
respectively. The drug release was increased with increasing temperature and decreasing 
pH because the electrostatic interactions in NPs were broken and can separate the drug 
from NPs amine groups. Moreover, drug release in BNIPDSpm-HNP-PEG was significantly 
higher than BNIPDSpm-HNP in culture media. 
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We assessed the drug release in various pH in 44 oC and 37 oC (achieved by laser irradiation). 
In this case, the release pattern of the formulations inside the pancreatic cancer cells, 
before and after laser irradiation can be predicted. In body temperature, 64% ± 1.92 of drug 
was release for BNIPDSpm-HNP-PEG at pH=3.6 before 312 h. Moreover, in 44 oC, 100% of 
drug was release in BNIPDSpm-HNP-PEG at pH=3.6 before 168 h. Therefore, it is assumed 
that after accumulation of the NPs in endosome and lysosome, the low environmental pH 
and increasing the temperature through laser irradiation, will result in quick drug release 
from the particles. Then the free drug can enter cells` nucleus and interact with DNA for 
anticancer effect. 
The HNP and HNP-PEG physical stability was assessed in cell culture media during 4 weeks at 
pH=7.2 and pH=4.6. At pH 7.2 a maximum of 0.032% ± 0.52 of the iron concentration was 
observed in the media for the HNP and 0.030% ± 1.35 of Iron were released for HNP-PEG in 
same situation. The graph demonstrated that the results for HNP was slightly more than 
HNP-PEG as the matter of fact the HNP-PEG was more stable than HNP however the results 
was not significantly different. At pH 4.6, particle degradation was bigger than pH 7.2. At pH 
4.6 an initial burst release of iron (0.034% ± 1.25) was observed in the first 24 h for HNP 
followed by a slow incline over the duration to a maximum of 0.065%± 1.37 and 0.066%± 
0.77 for HNP and HNP- PEG respectively. 
HPLC peak represented that the c(RGDfC) peptide conjugation to the HNP successfully and 
present and amount of drug and targeting peptide were analysed by RP-HPLC. In ratio of 
1:10:10:1 HNP:BNIPDSpm:PEG-Thiol: c(RGDfC), 95.03% ± 3.25  of drug was attached into the 
HNP. Almost same result was observed in different ratios of RGD as well.  
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HPLC results demonstrate increasing time and concentration are two important factors in 
increasing level of drug up taking. The target formulation had the highest drug uptake in 
compare with free drug and HNP-BNIPDSpm and HNP-BNIPDSpm-PEG formulations. Free 
BNIPDSpm enters to cells through cell membrane pores/channels which are not energy 
dependant, but particles internalise by endocytosis, thus slower proliferation resulted in a 
bit less uptake of hybrid formulations compared to the Gemcitabine. However MTT 
cytotoxicity test and trypan blue exclusion assay on BxPC-3 cells for gemcitabine 
demonstrated that gemcitabine cytotoxicity is significantly higher than BNIPDSpm and new 
formulations. 
MTT and trypan blue assays were carried out to check and compare free drugs, naked HNP 
and new formulations toxicity. The BXPC-3 cell viability in expose of 0.1 mg mL-1 naked HNP 
concentration was decreased to 16% and 20% of in MTT and Trypan Blue respectively after 
72h. In comparison, the BXPC-3 cell viability in expose of free drug (BNIPDSpm) was  
decreased for 77% - 90% at concentration 0.1 mg mL-1 and after 72h. The IC50 of the free 
drugs was around 10, 13 and 14 times greater than HNP-BNIPDSpm, HNP-BNIPDSpm-PEG 
and HNP-BNIPDSpm-PEG-RGD respectively after 24h and these differences were increased 
with increasing time. 
MTT and trypan blue tests were carried to check and compare the test results in 37 oC, 44 oC 
and 60 oC at 24 h, 48 h and 72 h. Test results were demonstrated that increasing time and 
temperatures are two main factors in increasing cytotoxicity however, the result indicated 
that increasing the temperature and time had no significant impact on cytotoxicity of naked 
HNPs in compare with free drug and the other formulations. The cell viability and IC 50 test 
results  illustrated that on BxPC-3 cells, Cytotoxicity of HNP-BNIPDSpm-PEG-RGD> HNP-
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BNIPDSpm-PEG> HNP-BNIPDSpm > BNIPDSpm. The IC50 of free drug was almost 10, 14 and 
15 times biger than HNP-BNIPDSpm, HNP-BNIPDSpm-PEG and HNP-BNIPDSpm-PEG-RGD 
respectively. 
In conclusion, the HNPs conjugated with BNIPDSpm and have been presented for pancreatic 
cancer therapy. BNIPDSpm novel formulations have high potential to act as thermo-
responsive drug carriers and could help to increase killing pancreatic cancer cells. The data 
indicated that the presence of PEG and RGD targeting peptide increase the ability of the 
BNIPDSpm-HNP to act as biocompatible multimodal platforms with higher affinity to 
pancreatic cancer cells as an anticancer formulation. 
The aim of the thesis was preparation and evaluation of novel HNPs based silver nano 
structure in order to produce thermos-responsive drug carriers for pancreatic cancer 
therapy. Further work is required in order to fully defined the biological activity and safety 
of these systems first in vitro in terms of cellular uptake, cellular stress, degradation etc and 
in vivo particularly related to target ability, accumulation, clearance and off target effects.  
Using our novel HNP in carbon nanotubes sensors structures in the future may help in the 
rapid detection and distinction of bacterial pathogens, early availability of information of 
their antimicrobial susceptibility underpin the necessity for the continued development of 
novel bacterial sensors. Moreover using our novel HNP in carbon nano tubes structures can 
led to preventing bacteria growing and development, therapeutic, and diagnostic functions. 
In particular, nano-carbons become high potential sensors against bacterial pathogens 
which have thermos-responsive drug carriers’ ability for destroying them.   
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By considering the high potential of our HNP which has studied in this research, It also 
would be advantageous idea to study laser effect on our novel HNP in pancreatic tumour 
and explore reduced growth in xenograft mice over longer time periods to confirm the 
potential of the novel formulation for pharmaceutical therapies.  
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